0001628280-22-008842 | 20-F | XBRL Viewer

Print Document View Excel Document

Cover page	12 Months Ended
Cover page	Dec. 31, 2021 shares
Entity Information [Line Items]
Document Type	20-F
Document Registration Statement	false
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-39777
Entity Registrant Name	NANOBIOTIX S.A.
Entity Incorporation, State or Country Code	I0
Entity Address, Address Line One	60 rue de Wattignies
Entity Address, Postal Zip Code	75012
Entity Address, City or Town	Paris
Entity Address, Country	FR
Title of 12(b) Security	Ordinary shares, nominal value €0.03 per share
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding	34,825,872
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Accounting Standard	International Financial Reporting Standards
Entity Shell Company	false
Entity Central Index Key	0001760854
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Amendment Flag	false
No Trading Symbol Flag	true
Business Contact
Entity Information [Line Items]
Entity Address, Address Line One	60 rue de Wattignies
Entity Address, Postal Zip Code	75012
Entity Address, City or Town	Paris
Entity Address, Country	FR
Contact Personnel Name	Mr. Bart van Rhijn
City Area Code	33
Local Phone Number	(0)1 40 26 04 70
Contact Personnel Fax Number	33 (0)1 40 26 04 44
American depositary shares, each representing one ordinary share, nominal value €0.03 per share
Entity Information [Line Items]
Title of 12(b) Security	American depositary shares, each representing one ordinary share, nominal value €0.03 per share
Trading Symbol	NBTX
Security Exchange Name	NASDAQ

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2021
Auditor Information [Abstract]
Auditor Name	ERNST & YOUNG et Autres
Auditor Firm ID	1704
Auditor Location	Paris-La Défense, France

STATEMENTS OF CONSOLIDATED FINANCIAL POSITION - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Non-current assets
Intangible assets	€ 4	€ 21
Property, plant and equipment	8,186	8,256
Non-current financial assets	519	505
Total non-current assets	8,709	8,782
Current assets
Trade receivables	0	62
Other current assets	9,139	6,035
Cash and cash equivalents	83,921	119,151
Total current assets	93,060	125,248
TOTAL ASSETS	101,769	134,030
Shareholders’ equity
Share capital	1,045	1,033
Premiums related to share capital	255,767	255,735
Accumulated other comprehensive income	643	555
Treasury shares	(202)	(196)
Reserve	(183,459)	(153,069)
Net loss for the period	(47,003)	(33,590)
Total shareholders’ equity	26,790	70,468
Non-current liabilities
Non-current provisions	318	414
Non-current financial liabilities	37,816	44,107
Total non-current liabilities	38,134	44,522
Current liabilities
Current provisions	110	40
Current financial liabilities	8,204	4,872
Trade payables and other payables	6,482	7,106
Other current liabilities	5,531	7,022
Deferred revenues and contract liabilities	16,518	0
Total current liabilities	36,845	19,041
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	€ 101,769	€ 134,030

STATEMENTS OF CONSOLIDATED OPERATIONS - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues and other income
Revenues	€ 10	€ 50	€ 68
Other income	2,637	2,462	2,473
Total revenues and other income	2,647	2,512	2,541
Research and development expenses	(30,378)	(24,330)	(30,411)
Selling, general and administrative expenses	(19,434)	(14,611)	(18,909)
Other operating income and expenses	(5,414)	0	0
Total operating expenses	(55,226)	(38,941)	(49,320)
Operating income (loss)	(52,579)	(36,428)	(46,779)
Financial income	6,360	201	837
Financial expenses	(780)	2,646	(4,970)
Financial income (loss)	5,580	2,847	(4,133)
Income tax	(5)	(9)	(3)
Net loss for the period	€ (47,003)	€ (33,590)	€ (50,915)
Basic loss per share (in euro per share)	€ (1.35)	€ (1.38)	€ (2.35)
Diluted loss per share (in euro per share)	€ (1.35)	€ (1.38)	€ (2.35)

STATEMENTS OF CONSOLIDATED COMPREHENSIVE LOSS - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of comprehensive income [abstract]
Net loss for the period	€ (47,003)	€ (33,590)	€ (50,915)
Actuarial gains and losses on retirement benefit obligations (IAS 19)	182	(4)	88
Tax impact	0	0	0
Other comprehensive loss that will not be reclassified subsequently to income or loss	182	(4)	88
Currency translation adjustment	(94)	125	(36)
Tax impact	0	0	0
Other comprehensive income that may be reclassified subsequently to income or loss	(94)	125	(36)
Total comprehensive loss	€ (46,915)	€ (33,469)	€ (50,863)

- Definition

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 18
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2021-01-01
-Paragraph 24
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2021-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2021-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 28
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2021-03-24

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2021-01-01
-Paragraph 39L
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard
-URIDate 2021-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 23
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard
-URIDate 2021-03-24

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2023-01-01
-Name IFRS
-Number 17
-IssueDate 2021-01-01
-Paragraph 113
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2021-03-24

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2021-03-24

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 106
-Subparagraph d
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2021-03-24

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 81A
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2021-03-24

+ Details

STATEMENTS OF CONSOLIDATED CHANGES IN SHAREHOLDERS’ EQUITY - EUR (€)	Total	Share capital Ordinary shares	Premiums related to share capital	Accumulated other comprehensive income (loss)	Treasury shares	Reserve	Net loss for the period
Number of shares outstanding at beginning of period (in shares) at Dec. 31, 2018		19,633,373
Equity at beginning of period at Dec. 31, 2018	€ 14,243,000	€ 589,000	€ 122,799,000	€ 381,000	€ (124,000)	€ (79,057,000)	€ (30,345,000)
Net loss for the period	(50,915,000)						(50,915,000)
Currency translation adjustments	(36,000)			(36,000)
Actuarial gains and losses (IAS 19)	88,000			88,000
Total comprehensive loss	(50,863,000)			52,000			(50,915,000)
Allocation of prior period loss	0					(30,345,000)	30,345,000
Capital increase, net (in shares)		2,566,666
Capital increase, net	28,079,000	€ 77,000	28,002,000
BSPCE exercise (in shares)		215,000
BSPCE exercise	1,306,000	€ 6,000	1,300,000
Subscription of warrants	21,000		8,000			13,000
Share based payment	4,320,000					4,320,000
Treasury shares	(45,000)				(45,000)
U.S. Initial public offering costs offset	1,030,000		1,030,000
Number of shares outstanding at end of period (in shares) at Dec. 31, 2019		22,415,039
Equity at end of period at Dec. 31, 2019	(1,908,000)	€ 672,451.17	153,139,000	433,000	(169,000)	(105,070,000)	(50,915,000)
Net loss for the period	(33,590,000)						(33,590,000)
Currency translation adjustments	125,000			125,000
Actuarial gains and losses (IAS 19)	(4,000)			(4,000)
Total comprehensive loss	(33,469,000)			121,000			(33,590,000)
Allocation of prior period loss	0					(50,915,000)	50,915,000
Capital increase, net (in shares)		12,017,083
Capital increase, net	102,942,000	€ 361,000	102,591,000			(10,000)
Subscription of warrants	5,000		5,000
Share based payment	2,924,000					2,924,000
Treasury shares	(27,000)				€ (27,000)
U.S. Initial public offering costs offset	(10,700,000)
Number of shares outstanding at end of period (in shares) at Dec. 31, 2020		34,432,122			12,970
Equity at end of period at Dec. 31, 2020	70,468,000	€ 1,032,963.66	255,735,000	555,000	€ (196,000)	(153,070,000)	(33,590,000)
Net loss for the period	(47,003,000)						(47,003,000)
Currency translation adjustments	(94,000)			(94,000)
Actuarial gains and losses (IAS 19)	182,000			182,000
Total comprehensive loss	(46,915,000)			88,000			(47,003,000)
Allocation of prior period loss	0					(33,590,000)	33,590,000
Capital increase, net (in shares)		393,750
Capital increase, net	0	€ 12,000				(12,000)
Subscription of warrants	43,000		32,000			11,000
Share based payment	3,201,000					3,201,000
Treasury shares	(6,000)				€ (6,000)
Number of shares outstanding at end of period (in shares) at Dec. 31, 2021		34,825,872			15,456
Equity at end of period at Dec. 31, 2021	€ 26,790,000	€ 1,044,776.16	€ 255,767,000	€ 643,000	€ (202,000)	€ (183,460,000)	€ (47,003,000)

STATEMENTS OF CONSOLIDATED CASH FLOWS - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows used in operating activities
Net loss for the period	€ (47,003)	€ (33,590)	€ (50,915)
Elimination of other non-cash, non-operating income and expenses
Depreciation and amortization	1,560	1,754	1,767
Provisions	152	(48)	164
Expenses related to share-based payments	3,201	2,924	4,320
Cost of net debt	2,224	2,115	1,940
Loss on disposals	0	0	45
U.S. Initial public offering 2018 costs reversal	0	0	201
Impact of deferred income related to financial liabilities discounting effect	(1,554)	(6,463)	2,833
Other charges with no impact on cash	8	7	(5)
Cash flows used in operations, before tax and changes in working capital	(41,412)	(33,300)	(39,647)
(Increase) / Decrease in trade receivables	62	(51)	(85)
Decrease in Research tax credit receivable	1,927	5,688	0
Increase in other receivables	(5,034)	(721)	(4,640)
Increase / (Decrease) in trade and other payables	(281)	(995)	2,057
Increase / (Decrease) in other current liabilities	(1,652)	1,840	1,146
Increase in deferred income and contract liabilities	16,518	0	0
Changes in operating working capital	11,540	5,762	(1,522)
Net cash flows used in operating activities	(29,872)	(27,538)	(41,169)
Cash flows from (used in) investing activities
Acquisitions of intangible assets	(5)	(11)	(353)
Acquisitions of property, plant and equipment	(228)	(96)	(1,091)
Addition in non-current financial assets	(9)	(4)	(16)
Net cash flows from (used in) investing activities	(242)	(112)	(1,459)
Cash flows from financing activities
Capital increases	0	113,650	29,517
Warrants subscription	43	5	1,327
Transaction costs	(349)	(10,359)	(1,438)
Increase in loans and conditional advances	0	10,350	14,000
Loans repayments	(2,833)	(250)	(500)
Payment of lease liabilities	(909)	(928)	(1,067)
Interest paid	(1,132)	(700)	(350)
Net cash flows from financing activities	(5,180)	111,769	41,489
Effect of exchange rates changes on cash	64	(63)	29
Net increase (decrease) in cash and cash equivalents	(35,230)	84,056	(1,109)
Net cash and cash equivalents at beginning of period	119,151	35,094	36,203
Net cash and cash equivalents at end of period	€ 83,921	€ 119,151	€ 35,094

Company information	12 Months Ended
Company information	Dec. 31, 2021
Disclosure Of Information Related To The Company [Abstract]
Company information	Company information Presentation of the Company Nanobiotix S.A. was incorporated in 2003 as a spin-off from the State University of New York (SUNY) in Buffalo. Nanobiotix S.A. (together with its subsidiaries, the “Company”), is headquartered in Paris, France. The Company is a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment, as well as the utility and efficacy of radiotherapy. Its lead product candidate, NBTXR3, is an aqueous suspension of functionalized crystalline metallic nanoparticles approximately 50 nanometers (50 billionths of a meter) in diameter, designed for injection directly into a malignant tumor. When exposed to ionizing radiation, NBTXR3 amplifies the localized, intratumor killing effect of that radiation. NBTXR3 is designed to enhance the overall efficacy of radiotherapy without resulting in additional side effects on the surrounding healthy tissues. Alongside the Company’s core NBTXR3 development program, the Company is also pursuing a development program to explore the use of radiotherapy-activated NBTXR3 in combination with immune checkpoint inhibitors across several solid tumor indications. The Company is listed on the Euronext regulated market in Paris (under the ticker symbol “NANO”; Code ISIN: FR0011341205, Bloomberg code: NANO:FP) and on the Nasdaq Global Select Market (under the ticker symbol “NBTX”). Significant events of the period Nanobiotix and PharmaEngine mutually agree to terminate their collaboration In March 2021, in light of disagreements over a number of issues with respect to the development of NBTXR3 in the Asia-Pacific region, Nanobiotix and PharmaEngine mutually agreed to terminate the licensing and collaboration agreement entered into in August 2012. Accordingly, on March 4, 2021, Nanobiotix and PharmaEngine entered into a termination and release agreement (the “Termination Agreement”). Under the Termination Agreement, Nanobiotix retained all rights to the development and commercialization of NBTXR3 in the Asia-Pacific region. Nanobiotix agreed to make total termination payments to PharmaEngine of up to $12.5 million in the aggregate as described below. PharmaEngine was eligible for and received in March 2021 a $2.5 million payment following the announcement of Nanobiotix’s collaboration with LianBio for the Asia-Pacific region. In May 2021, PharmaEngine received an additional $4.0 million in conjunction with the completion of various administrative steps in connection with the winding-up of the collaboration. PharmaEngine will be eligible to receive an additional $1.0 million in administrative fees and a final payment of an additional $5.0 million upon a second regulatory approval of an NBTXR3-containing product in any jurisdiction of the world for any indication. PharmaEngine is entitled to receive a low-single digit tiered royalty based on net sales of NBTXR3 in the Asia-Pacific region for a 10-year period commencing on the corresponding first date of sales in the region. As of December 31, 2021, these future payments were not accrued because the triggering events have not occurred. As part of the Termination Agreement, PharmaEngine re-assigned to Nanobiotix rights for the development, manufacture, commercialization and exploitation of NBTXR3 in the Asia-Pacific region, as well as all development data, regulatory materials, and all regulatory approvals that are in the name of PharmaEngine or its affiliates. Consequently, NBTXR3 clinical trials conducted by PharmaEngine in Asia are in the process of being concluded or terminated. Nanobiotix and PharmaEngine also agreed to a mutual release of all claims against the other party and its respective affiliates. Nanobiotix partners with LianBio for the development and commercialization of NBTXR3 in several oncology indications and in combination with several anti-cancer therapies, in China and other Asian markets In May 2021, Nanobiotix entered into a partnership with LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets, to develop and commercialize Nanobiotix’s lead product candidate, NBTXR3 into Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. LianBio will collaborate in the development of NBTXR3 in Asia Pacific, and contribute to patient enrollment in five future global registrational studies across several tumor types and therapeutic combinations including immunotherapy. LianBio will also support the expansion of global phase III registrational study in head and neck cancer into Greater China with longer term strategic alignment across multiple tumor indications and therapeutic combinations. Under the terms of the agreement, the Company received a $20 million upfront payment and is entitled to receive up to an aggregate of $220 million in potential contingent, development and commercialization milestone payments. The Company will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. LianBio will fund all development and commercialization expenses in the collaboration territory, and the Company will continue to fund all development and commercialization expenses in all other geographies. Nanobiotix announces the appointment of Dr. Gary Phillips as Chairman of the Supervisory Board In May 2021, Dr. Gary Phillips was appointed Chairman of the Company's supervisory board of the Company (“the “Supervisory Board”). Dr Phillips succeeded Laurent Condomine, who retired from the Supervisory Board after 11 years of leadership. Nanobiotix announces the appointment of Bart Van Rhijn as Chief Financial Officer and member of the executive board of the Company to support its international expansion On June 1, 2021, the Company announced the appointment of Bart Van Rhijn, MBA, as Chief Financial Officer and member of the executive board of the Company (the “Executive Board”). Mr. Van Rhijn brings proven capabilities in global financial management, business development and pharmaceutical commercialization as the Company prepares for the planned launch of its second clinical registration study for NBTXR3 in head and neck cancer (NANORAY-312), continued development in immunotherapy, and planned expansion across solid tumor types and therapeutic combinations. He succeeded Philippe Mauberna, who stepped down from his roles as Chief Financial Officer and Executive Board member after 8 years of service to the Company.

General Information, Statement of Compliance and Basis of Presentation	12 Months Ended
	Dec. 31, 2021
General Information, Statement of Compliance and Basis of Presentation [Abstract]
General Information, Statement of Compliance and Basis of Presentation	General Information, Statement of Compliance and Basis of Presentation General principles The statement of consolidated financial position as of December 31, 2021 and 2020 and the statements of consolidated operations, the statements of consolidated comprehensive loss, the consolidated changes in shareholders’ equity and statements of consolidated cash flows for the years ended December 31, 2021, 2020 and 2019 were prepared under management’s supervision and were approved by the Executive Board of the Company (the “Executive Board”) and reviewed by the Supervisory Board of the Company (the “Supervisory Board”) on March 30, 2022. All amounts presented in the consolidated financial statements are presented in thousands of euros, unless stated otherwise. Some figures have been rounded. Accordingly, the totals in some tables may not be the exact sums of component items. The preparation of the consolidated financial statements in accordance with International Financial Reporting Standards (‘‘IFRS’’) requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements (see Note 3.2 for additional information). The consolidated financial statements have been prepared using the historical cost measurement basis, with the exception of financial assets and liabilities, which are measured at fair value. The consolidated financial statements were prepared on a going concern basis. The Executive Board determined it is appropriate to apply a going concern assumption because the Company’s historical losses are due to the innovative nature of the products it is developing, which necessitates a research and development phase spanning several years. With cash and cash equivalents of €83,921 thousand as of December 31, 2021, as compared to €119,151 thousand as of December 31, 2020, the Company believes it has sufficient resources to continue operating for at least twelve months following the consolidated financial statements’ publication. Statement of Compliance and Basis of Presentation The consolidated financial statements have been prepared in accordance with IFRS, International Accounting Standards (“IAS”) as issued by the International Accounting Standards Board (“IASB”) as well as interpretations issued by the IFRS Interpretations Committee (“IFRS-IC”) and the Standard Interpretations Committee (the “SIC”), which application is mandatory as of December 31, 2021. The consolidated financial statements are also compliant with IFRS as adopted by the European Union. Those are available on the European Commission website: https://ec.europa.eu/info/law/international-accounting-standards-regulation-ec-no-1606-2002 The accounting principles used to prepare the consolidated financial statements for the fiscal year ended December 31, 2021 are identical to those used for the previous year except for the standards listed below that required adoption in 2021. Application of New or Amended Standards and Interpretations The Company adopted the following standards, amendments and interpretations, whose application was mandatory for periods beginning on or after January 1, 2021: •Amendments to IAS 39, IFRS 9, IFRS 7 and IFRS 16 related to the interest rate benchmark reform - Phase 2; and •Amendments to IFRS 16 - Covid-19 Related rent concession. The application of these standards had no impact on the consolidated financial statements of the Company. Application of New or Amended Standards and Interpretations early adopted by the Company The Company elected to early adopt no new standards, amendments and interpretations which application was not yet mandatory for the year ended December 31, 2021. Application of New or Amended Standards and Interpretations not yet applied by the Company The application of the following new standards, amendments and interpretations was not yet mandatory for the year ended December 31, 2021 : •IFRS 17 - Insurance contracts and related amendments. No impact expected on the financial statements. •Amendment to IAS 1 - Classification of Liabilities as Current or Non-Current, Disclosure of significant accounting policies, and Update of Practice Statement 2 "Making materiality”. No significant impact expected on the financial statements. •Amendment to IAS 37 - Onerous Contracts - Cost of Fulfilling a Contract. No significant impact expected on the financial statements. •Amendment to IFRS 3 - Conceptual framework. No significant impact expected on the financial statements. •Amendment to IAS 8 - Definition of an accounting estimate. No significant impact expected on the financial statements. •Amendments to IAS 16 - Property, Plant and Equipment: Proceeds before Intended Use. No significant impact expected on the financial statements.

Consolidation principles and methods	12 Months Ended
Consolidation principles and methods	Dec. 31, 2021
Significant Accounting Policies [Abstract]
Consolidation principles and methods	Consolidation principles and methods 3.1 Basis of consolidation Accounting policy In accordance with IFRS 10 – Consolidated Financial Statements, an entity is consolidated when it is controlled by the Company. The Company has decision-making authority over the financial and operating policies of all its subsidiaries and holds greater than 50% of the voting rights of each subsidiary. Accordingly, each of the Company’s subsidiaries has been fully consolidated from the date on which the Company obtained control over it. A subsidiary would be deconsolidated as of the date on which the Company no longer exercises control. All intra-Company balances, transactions, unrealized gains and losses resulting from intra-Company transactions and all intra-Company dividends are eliminated in full. The accounting methods of the Company’s subsidiaries are aligned with those of the Company. The consolidated financial statements are presented in euros, which is the reporting currency and the functional currency of the parent company, Nanobiotix S.A. The financial statements of consolidated foreign subsidiaries whose functional currency is not the euro are translated into euros for statement of financial position items at the closing exchange rate at the date of the statement of financial position and for the statement of operations, statement of comprehensive loss and statement of cash flow items at the average rate for the period presented, except where this method cannot be applied due to significant exchange rate fluctuations during the applicable period. The dollar to euro exchange rate used in the consolidated financial statements to convert the financial statements of the U.S. subsidiary were $1.1326 as of December 31, 2021 and an average of $1.1835 for the year ended December 31, 2021 (source: Banque de France) compared with $1.2271 and $1.1413, for 2020 and $1.1234 and $1.1196 for 2019, respectively. The resulting currency translation adjustments are recorded in other comprehensive income (loss) as a cumulative currency translation adjustment. Consolidated entities As of December 31, 2021, the Company involves one parent entity, “Nanobiotix S.A.,” and five wholly owned subsidiaries: •Nanobiotix Corp., incorporated in the State of Delaware in the United States in September 2014; •Nanobiotix Germany GmbH, incorporated in Germany in October 2017; •Nanobiotix Spain S.L.U., incorporated in Spain in December 2017; •Curadigm S.A.S., incorporated on July 3, 2019 and located in France; and •Curadigm Corp., a wholly-owned subsidiary of Curadigm S.A.S., incorporated in the State of Delaware on January 7, 2020 and headquartered in Boston, Massachusetts. The consolidated financial statements as of and for the year ended December 31, 2021 include the operations of each of these subsidiaries from the date of their incorporation. Accordingly, the consolidated financial statements as of and for the year ended December 31, 2020 include the operations of each of these subsidiaries from the date of their incorporation. The consolidated financial statements as of and for the year ended December 31, 2019 include the operations of each of these subsidiaries from the date of their incorporation, excluding Curadigm Corp which was created in 2020. 3.2 Use of judgement, estimates and assumptions The preparation of consolidated financial statements in accordance with IFRS requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. The estimates and judgments used by management are based on historical information and on other factors, including expectations about future events considered to be reasonable given the circumstances. These estimates may be revised where the circumstances on which they are based change. Consequently, actual results may vary significantly from these estimates under different assumptions or conditions. The main items affected by the use of estimates are share-based payments, deferred tax assets, clinical trials accruals, revenue recognition and the fair value of financial instruments. Measurement of share-based payments The Company measures the fair value of stock options (OSA), founders’ warrants (BSPCE), warrants (BSA) and free shares (AGA) granted to employees, members of the Supervisory Board and consultants based on actuarial models. These actuarial models require that the Company use certain calculation assumptions with respect to characteristics of the grants (e.g., vesting terms) and market data (e.g., expected share volatility) (see Note 17). Deferred tax assets Deferred taxes are recognized for temporary differences arising from the difference between the tax basis and the accounting basis of the Company’s assets and liabilities that appear in its financial statements. The primary temporary differences are related to the tax losses that can be carried forward or backward, depending on the jurisdiction. Enacted tax rates are used to measure deferred taxes (see Note 19). The deferred tax assets are recorded in the accounts only to the extent that it is probable that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow income projections judged to be sufficiently reliable to be made, the Company has not recognized deferred tax assets in relation to tax losses carryforwards in the Statements of Consolidated Financial Position. Clinical trial accruals Clinical trial expenses, although not yet billed in full, are estimated for each study and a provision accrual is recognized accordingly. See Note 13.1 for information regarding the clinical trial accruals as of December 31, 2021 and 2020. Revenue recognition In order to determine the amount and timing of revenue under the contract with LianBio, the Company is required to use significant judgments, mainly with respect to identifying performance obligations of the Company and determining the timing of satisfaction of support services provided to LianBio. See Note 15 for additional detail regarding the Company’s accounting policies for its additional sources of revenue. Fair value of financial assets and liabilities The fair value measurement of the loan granted by European Investment Bank (“EIB”) requires the Company to assess the amount of additional interest (“royalties”, as defined by the royalty agreement with EIB) that will be due according to the loan agreement during a royalty calculation period commencing on January 1, 2021. The royalties due during this period will be determined and calculated based on the number of tranches that have been withdrawn and will be indexed to the Company’s annual sales turnover. For the purpose of measuring the fair value of the EIB loan, the Company forecasts the sales that it expects to generate during the royalty period, taking into consideration the operational assumptions such as market release dates of the products, growth and penetration rate in each market. (see notes 4.2 and 12 for details about this loan and the accounting treatment applied).

Significant transactions	12 Months Ended
Significant transactions	Dec. 31, 2021
Disclosure of transactions between related parties [abstract]
Significant transactions	Significant transactions 4.1 LianBio In May 2021, Nanobiotix announced a partnership with LianBio Oncology Limited a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets, to develop and commercialize NBTXR3 into Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. LianBio will collaborate in the development of NBTXR3 in Asia Pacific, and contribute to patient enrollment in five future global registrational studies across several tumor types and therapeutic combinations. LianBio will also support the expansion of the global phase III registrational study in head and neck cancer into Greater China, while supporting longer term strategic alignment across multiple tumor indications and therapeutic combinations. As of December 31, 2021, a non-refundable upfront payment of $20 million has been collected by the Company at the signature of the LianBio Agreement. The Company is entitled to receive up to an aggregate of $220 million in potential contingent, development and commercialization milestone payments. Nanobiotix will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. See Note 15 Revenues and other income for further details on this new partnership. 4.2 PharmaEngine In August 2012, the Company entered into an Exclusive License and Collaboration Agreement (as amended in 2014, the ‘‘License and Collaboration Agreement’’) with PharmaEngine, a biopharmaceutical company specializing in the development of new drugs for the treatment of cancer in Asia. Under the terms of the License and Collaboration Agreement, PharmaEngine will receive the exclusive right to further develop NBTXR3 to obtain regulatory approval, leverage the data generated by the Company’s development activities and commercialize NBTXR3 in multiple countries throughout the Asia-Pacific region. Under the same Agreement, PharmaEngine is responsible for developing (non-clinical and clinical research) and commercializing NBTXR3 throughout the contractual territory and making certain development and minimum commercial milestone payments to the Company. Key provisions of the License and Collaboration Agreement include: •An exclusive perpetual license granted to PharmaEngine, with the right to sublicense the Company’s technology in order to exploit or have NBTXR3 exploited and use the Company’s trademark in connection with the exploitation of NBTXR3 in the contractual territory (with exploitation including among others developing, obtaining and maintaining regulatory approval, commercializing, distributing, promoting and marketing); •The Company’s commitment to furnish PharmaEngine with know-how necessary and useful to develop and commercialize NBTXR3 in the contractual territory, know-how meaning any results of experimentation and pre-clinical, clinical and non-clinical trial data by providing PharmaEngine with access to an electronic data platform; and •The Company’s commitment to supplying or having supplied PharmaEngine with all quantities of NBTXR3 required and used by PharmaEngine for clinical testing and subsequent commercialization if and when regulatory approvals are obtained. In return, PharmaEngine commits to use commercially reasonable efforts to develop NBTXR3 in the contractual territory at PharmaEngine’s cost. Under the License and Collaboration Agreement, the Company has received and/or is entitled to receive: •A $1.0 million up-front payment on signature of the contract, fully received in 2012; •Payments upon the achievement of development milestones, including key stages of product development, first filing for regulatory approval, and first regulatory approval in the contractual territory; •Payments upon the achievement of commercial milestones based on specified sales thresholds; •Up to double-digit royalties based on net product sales in the Asia-Pacific region; and •Payments for the supply of NBTXR3. Potential development and commercial milestone payments, including those paid to date, amount to an aggregate of up to $56 million. The Company and PharmaEngine amended the agreement in October 2014, as part of which PharmaEngine agreed: •To join the global pivotal clinical trial of NBTXR3 for the treatment of Soft Tissue Sarcoma initiated by the Company in the Asia-Pacific area, with each party committing itself to share clinical trial results in order to increase the tested population and to accelerate growth and value creation; •To pay the first development milestone ($1 million, received by the Company in 2014) and share external clinical research organization costs charged to the Company in proportion to its contribution in recruiting the patient population included in the clinical trial; and •To pay the development milestone ($1 million, received by the Company in 2016) related to the launch of the first Phase II of the pivotal study. As of December 31, 2020, $3.0 million has been received since the signature of the License and Collaboration Agreement. The next potential milestone payment under the agreement will become payable only if PharmaEngine files a commercialization authorization of NBTXR3 in their region. In November 2020, Nanobiotix notified PharmaEngine of a material breach of the terms of the License and Collaboration agreement. While both Nanobiotix and PharmaEngine believe in the potential of NBTXR3 to improve treatment outcomes for patients with cancer, the parties have had disagreements regarding the optimal strategy for development in the Asia-Pacific region. As such, after discussion between the two parties, Nanobiotix and PharmaEngine have mutually agreed to discontinue the collaboration. This agreement to terminate the License and Collaboration agreement represents a full resolution of outstanding disagreements over a number of issues with respect to the development of NBTXR3 in the Asia-Pacific region. See Note 15 for additional detail regarding the accounting policy applied to the License and Collaboration Agreement. In March 2021, the Company and PharmaEngine mutually agreed to terminate the License and Collaboration agreement. As of December 31, 2021, the Company paid a cumulative amount of $6.5 million to PharmaEngine in accordance with the termination agreement signed between the parties. PharmaEngine will receive additional payments of $1 million upon receipt by the Company of certain clinical study reports and of $5 million upon the second regulatory approval of NBTXR3 in any jurisdiction of the world for any indication. The Company has also agreed to pay royalties to PharmaEngine at low single-digit royalty rates with respect to sales of NBTXR3 in the Asia-Pacific region for a 10-year period beginning at the date of the first sales in the region. These future payments were not accrued because the triggering events have not occurred. 4.3 Financing Agreement with the European Investment Bank (“EIB”) In July 2018, the Company signed a non-dilutive financing agreement with the EIB to borrow up to €40 million in order to fund its research, development and innovation activities related to NBTXR3 in various therapeutic indications, subject to achieving a set of agreed-upon performance criteria. This financing is divided in three tranches: •a first tranche of €16 million, received in October 2018, subject to a 6% fixed rate and that will be fully repaid in 2023 at the latest; •a second tranche of €14 million, received in March 2019, subject to a 5% fixed rate, with repayments beginning in 2021 and continuing into 2024; and, •a last tranche of €10 million, subject to a 4% fixed interest rate, that will be fully repaid after a period of five years, which begins within one year of obtaining it. The Company has not yet met the criteria to request this tranche. The deadline for requesting this third tranche, initially scheduled as of July 26, 2020, was delayed by 12 months to July 31, 2021. As the conditions have not been met by July 31, 2021, the Company will not request the final tranche of the EIB loan. In connection with this financing agreement, the Company also entered into a royalty agreement with EIB pursuant to which the Company is required, during a six-year royalty calculation period commencing on January 1, 2021, to pay (on each June 30 with respect to the preceding year within the calculation period) royalties to EIB. The amount of royalties payable is calculable based on low single-digit royalty rates, which vary according to the number of tranches that have been drawn, and indexed on the Company’s annual sales turnover. The €14 million second tranche, which was received in March 2019, was disbursed on the basis of achieving the following criteria: •Determination of the recommended dose at 22% of the tumor volume for head and neck cancers treatment following the end of the Phase I clinical trial with NBTXR3; and •Positive evaluation of the clinical benefit/risk ratio of NBTXR3 in the Phase II/III clinical trial in soft tissue sarcomas by the clinical expert mandated by the French notified body covering medical devices, GMED. See Note 22 for discussion of royalties that may be due in the case of early repayment or change of control after repayment of the loan. 4.4 Collaboration Agreement with the University of Texas MD Anderson Cancer Center In January 2019, the Company and the University of Texas MD Anderson Cancer Center, world prominent center of research, education, prevention and care for cancer patients announced a large-scale research collaboration. The collaboration will support multiple new Phase I/II clinical trials involving around 340 patients with Nanobiotix’s product NBTXR3 for use in treating several cancer types –, including head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers. As part of the funding for this collaboration, Nanobiotix is committed to pay approximately $11 million for those clinical trials during the collaboration, and made an initial $1.0 million payment at the commencement of the collaboration and a second $1.0 million payment on February 3, 2020. Additional payments were made in the six months following patients enrollment, with the balance payable upon enrollment of the final patient for all studies. Nanobiotix may also be required to pay an additional one-time milestone payment upon (i) grant of the first regulatory approval by the Food and Drug Administration in the United States and (ii) the date on which a specified number of patients have been enrolled in the clinical trials. The milestone payment increases on an annual basis ranging from $2.2 million to $16.4 million. As of December 31, 2021 and 2020, the Company recognized prepaid expenses for €1.0 million and €1.6 million respectively. Expenses will be recorded during the course of the collaboration in the statement of consolidated operations based on the patients enrolled during the relevant period. See Note 8.2 for further details on other current assets.

Intangible assets

12 Months Ended

Dec. 31, 2021

Intangible assets other than goodwill [abstract]

Intangible assets

Accounting policies

In accordance with IAS 38 – Intangible Assets, intangible assets are carried at their acquisition cost.

Research and Development costs

Research costs are recorded in expenses in the period during which they are incurred. Under IAS 38 – Intangible Assets, development costs may only be capitalized as intangible assets if the following criteria are met:

•it is technically feasible to complete the development of the intangible asset so that it will be available for use or sale;

•the Company intends to complete the development of the intangible asset and use or sell it;

•the Company has the ability to use or sell the intangible asset;

•it is probable that the intangible asset will generate future economic benefits;

•adequate technical, financial and other resources are available to complete the development of the intangible asset; and

•the Company is able to reliably measure the expenditures attributable to the development of the intangible asset.

The Company believes that because of the risks and uncertainties related to the grant of regulatory approval for the commercialization of its product candidates, the technical feasibility of completing its development projects will only be demonstrated when requisite approvals are obtained for the commercialization of products. Accordingly, pursuant to IAS 38, the Company has recognized all of its research and development costs incurred as an expense in 2021 and prior periods.

Patents

Costs incurred by the Company in connection with the filing of patent applications are recognized as an expense until such time as the relevant patents are obtained, in line with the treatment of research and development costs. Once the patents are obtained from relevant authorities, their related patent costs are amortized on a straight-line basis over the patent protection period. The useful life of the patents is reassessed each year, according to IAS 36.

Software

The costs of acquiring software licenses are recognized as assets on the basis of the costs incurred to acquire and implement the software to which the license relates. These costs are amortized on a straight-line basis over the life of the license.

Recoverable amount of intangible assets

Intangible assets with a definite useful life are tested for impairment when there are events or changes in circumstances that indicate that the asset might be impaired. Impairment tests involve comparing the carrying amount of an intangible asset with its recoverable amount. The recoverable amount of an asset is the higher of (i) its fair value less costs to sell and (ii) its value in use. If the recoverable amount of any asset is below its carrying amount, an impairment loss is recognized to reduce the carrying amount to the recoverable amount.

Detail of intangible assets

The change in intangible assets breaks down as follows:


(in thousands of euros)	As of As of January 1, 2021	Increases	Decreases	Transfer	Currency translation	As of December 31, 2021
Patents	65	—	—	—	—	65
Software	651	5	—	—	—	657
Intangible assets in progress	—	—	—	—	—	—
Gross book value of intangible assets	717	5	—	—	—	722
Patents	(65)	—	—	—	—	(65)
Software	(630)	(22)	—	—	—	(652)
Accumulated depreciation of intangible assets (1)	(695)	(22)	—	—	—	(717)
Net book value of intangible assets	21	(17)	—	—	—	4

(1)Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses


(in thousands of euros)	As of January 1, 2020	Increases	Decreases	Transfer	Currency translation	As of December 31, 2020
Patents	65	—	—	—	—	65
Software	584	11	(5)	61	—	651
Intangible assets in progress	61	—	—	(61)	—	—
Gross book value of intangible assets	710	11	(5)	—	—	717
Patents	(65)	—	—	—	—	(65)
Software	(483)	(152)	5	(0)	(0)	(630)
Accumulated depreciation of intangible assets (1)	(548)	(152)	5	—	—	(695)
Net book value of intangible assets	163	(141)	—	(0)	(0)	21

(1)Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses

Property, plant and equipment

12 Months Ended

Dec. 31, 2021

Property, plant and equipment [abstract]

Property, plant and equipment

Accounting policies

Property, plant and equipment are recorded at their acquisition cost. Major renovations and improvements necessary to bring an asset to the working condition for its use as intended by the Company’s management are capitalized. The cost of repairs, maintenance and other renovation work is expensed as incurred.

Property, plant and equipment are depreciated on a straight-line basis according to the estimated useful life of the relevant assets.

The depreciation periods used are as follows:

•General fixtures and fittings, building work: 5 to 10 years;

•Technical installations, equipment and industrial tooling: 3 to 10 years; and

•Office and IT equipment and furniture: 1 to 10 years.

Recoverable amount of property, plant and equipment

Property, plant and equipment with a definite useful life are tested for impairment when there are events or changes in circumstances that indicate that the asset might be impaired. An impairment loss is recognized for the excess of the carrying amount of the asset over its recoverable amount. The recoverable amount of an asset is equal to the higher of (i) its fair value less costs to sell and (ii) its value in use.

Detail of property, plant and equipment

The change in property, plant and equipment is as follows:


(in thousands of euros)	As of January 1, 2021	Increases	Decreases	Transfer	Currency translation	As of December 31, 2021
Fixtures, fittings and installations	3,313	5	—	—	—	3,318
Right of use – Buildings	7,171	1,362	(139)	—	—	8,393
Technical equipment	2,061	73	—	1	—	2,135
Office and IT equipment	988	53	(35)	—	4	1,010
Transport equipment	31	—	—	—	3	33
Right of use – Transport equipment	65	—	(38)	—	1	28
Tangible assets in progress	1	97	—	(0)	—	98
Prepayments on tangible assets	—	—	—	(0)	—	—
Gross book value of tangible assets	13,630	1,590	(212)	—	8	15,017
Fixtures, fittings and installations	(1,320)	(320)	—	—	—	(1,641)
Right of use – Buildings	(1,739)	(901)	30	—	—	(2,610)
Technical equipment	(1,466)	(178)	—	—	—	(1,644)
Office and IT equipment	(783)	(124)	34	—	(3)	(875)
Transport equipment	(31)	—	—	—	(3)	(33)
Right of use – Transport equipment	(36)	(12)	20	—	(1)	(28)
Accumulated depreciation of tangible assets(1)	(5,374)	(1,534)	84	—	(6)	(6,831)
Net book value of tangible assets	8,256	56	(129)	—	3	8,186

In 2021, the €1,362 thousand increase in Right of use – Buildings mainly relates to the extension of Villejuif leases for 4 years for €1,390 thousand reduced by approximately €25 thousand related to rent indexation impact.

The €139 thousand decrease in Right of use – Buildings relates to the termination of a lease contract in Faubourg Saint-Antoine in Paris, France.


(in thousands of euros)	As of January 1, 2020	Increases	Decreases	Other movements & transfer.	Currency translation	As of December 31, 2020
Fixtures, fittings and installations	3,297	16	—	—	—	3,313
Right of use – Buildings	6,766	418	(14)	—	—	7,171
Technical equipment	2,019	42	—	—	—	2,061
Office and IT equipment	957	37	(1)	—	(4)	988
Transport equipment	34	—	—	—	(3)	31
Right of use – Transport equipment	115	—	(41)	(5)	(4)	65
Tangible assets in progress	11	1	—	(11)	—	1
Prepayments on tangible assets	—	—	—	—	—	—
Gross book value of tangible assets	13,197	515	(57)	(15)	(11)	13,630
Fixtures, fittings and installations	(1,001)	(320)	—	—	—	(1,320)
Right of use – Buildings	(829)	(911)	—	2	—	(1,739)
Technical equipment	(1,272)	(194)	—	—	—	(1,466)
Office and IT equipment	(629)	(157)	1	—	2	(783)
Transport equipment	(34)	—	—	1	3	(31)
Right of use – Transport equipment	(45)	(35)	42	—	1	(36)
Accumulated depreciation of tangible assets(1)	(3,811)	(1,616)	43	4	6	(5,374)
Net book value of tangible assets	9,386	(1,101)	(14)	(12)	(4)	8,256

(1)Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses

In 2020, the €418 thousand increase in Right of use – Buildings mainly relates to:

•Two new lease contracts: one in Rue Oberkampf in Paris, France for €155 thousand, the other in Rue du Faubourg Saint-Antoine in Paris, France for €140 thousand,

•The termination of a lease contract by Curadigm SAS for €43 thousand;

•The addition of a parking for the Villejuif facility for €30 thousand, and

•The impact of an annual rent adjustment for the Wattignies and Villejuif leases based on the INSEE (National Institute of Statistics and Economic Studies) index for €35 and €15 thousand, respectively.

Non-current financial assets

12 Months Ended

Dec. 31, 2021

Disclosure of financial assets [abstract]

Non-current financial assets

Accounting policies

Non-current financial assets are recognized and measured in accordance with IFRS 9 – Financial Instruments.

No non-current financial assets are estimated at fair value through other comprehensive income (OCI).

Pursuant to IFRS 9 – Financial Instruments, financial assets are classified in three categories according to their nature and the intention of management:

•Financial assets at fair value through profit and loss;

•Financial assets at fair value through other comprehensive income; and

•Financial assets at amortized cost.

All regular way purchases and sales of financial assets are recognized at the settlement date.

Financial assets at fair value through profit or loss

This category includes marketable securities, cash and cash equivalents. They represent financial assets held for trading purposes, i.e., assets acquired by the Company to be sold in the short-term. They are measured at fair value and changes in fair value are recognized in the consolidated statements of operations as financial income or expense, as applicable.

Financial assets at amortized cost

This category includes other financial assets (non-current), trade receivables (current) and other receivables and related accounts (current). Other financial assets (non-current) include advances and security deposits and guarantees granted to third parties as well as term deposits and restricted cash, which are not considered as cash equivalents.

They are non-derivative financial assets with fixed or determinable payments that are not listed on an active market. They are initially recognized at fair value plus transaction costs that are directly attributable to the acquisition or issue of the financial asset, except trade receivables that are initially recognized at the transaction price as defined in IFRS 15.

After initial recognition, these financial assets are measured at amortized cost using the effective interest rate method when both of the following conditions are met:

•The financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows; and

•The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Gains and losses are recorded in the consolidated statements of operations when they are derecognized, subject to modification of contractual cash flows and/or impaired.

IFRS 9 – Financial Instruments requires an entity to recognize a loss allowance for expected credit losses on a financial asset at amortized cost at each Statement of Financial Position date. The amount of the loss allowance for expected credit losses equals: (i) the 12 - month expected credit losses or (ii) the full lifetime expected credit losses. The latter applies if credit risk has increased significantly since initial recognition of the financial instrument. An impairment is recognized, where applicable, on a case–by–case basis to take into account collection difficulties which are likely to occur based on information available at the time of preparation of the financial statements.

Disputed receivables are written-off when certain and precise evidence shows that recovery is impossible, and existing credit loss allowance are released.

Financial assets and liabilities are monitored for any indication of impairment. Under IFRS 9, the impairment model is based on the accounting on expected credit losses during the life of the financial assets. A financial asset is impaired if its credit risk, determined with both historic and prospective data, increased significantly since its initial booking. The loss will impact the net income (loss) recorded to the statement of operations.

Detail of non-current financial assets

The change in non-current financial assets breaks down as follows:


(in thousands of euros)	Liquidity contract - Cash account(1)	Other long-term investments pledged as collateral	Security deposits paid	Total
Net book value as of December 31, 2019	131	—	399	529
Additions	—	—	9	9
Decreases	(27)	—	(5)	(31)
Currency translation adjustments	—	—	(2)	(2)
Net book value as of December 31, 2020	105	—	401	505
Additions	—	—	9	9
Decreases	(6)	—	—	(6)
Transfer	—	—	8	8
Currency translation adjustments	—	—	3	3
Net book value as of December 31, 2021	98	—	421	519

(1)See note 10.2 Treasury shares

In 2021, non-current financial assets increased by €14 thousand compared to 2020. In 2020, non-current financial assets decreased by €24 thousand compared to 2019. In 2021, the security deposits paid increased by €20 thousand, mainly due to a €9 thousand deposit paid in connection with a new Nanobiotix Corp headquarters’ lease contract in Cambridge, Massachusetts, United States.

The decrease of the liquidity contract – cash account corresponds to treasury shares transactions whose counterpart is recorded as capital on the "treasury shares" line in the statement of change in shareholders’ equity.

Trade receivables and other current assets

12 Months Ended

Dec. 31, 2021

Subclassifications of assets, liabilities and equities [abstract]

Trade receivables and other current assets

Accounting policies for trade receivables and other current assets are described in Note 7.

8.1 Trade receivables

In 2020, trade receivables related mainly to invoices issued to PharmaEngine, in connection with the charging-back of shared external clinical research organization costs under the License and Collaboration Agreement as amended (see Note 4 for more detail on the License and Collaboration Agreement). This agreement terminated in March 31, 2021 and the related receivables have been settled.


	As of December 31,
(in thousands of euros)	2021	2020
Trade receivables	—	62
Trade receivables	—	62

Trade receivables break down as follows:


	As of December 31,
(in thousands of euros)	2021	2020
Due in 3 months or less	—	62
Due between 3 and 6 months	—	—
Due between 6 and 12 months	—	—
Due after more than 12 months	—	—
Trade receivables	—	62

8.2 Other current assets

Other current assets break down as follows:


	As of December 31,
(in thousands of euros)	2021	2020
Research tax credit receivable	2,490	1,927
VAT receivable	1,058	971
Prepaid expenses	2,213	2,217
Other receivables	3,378	920
Other current assets	9,139	6,035

As of December 31, 2021, prepaid expenses mainly relate to:

•research agreements related to the MD Anderson agreement (see Note 4.4 – Collaboration Agreement with the University of Texas MD Anderson Cancer Center) for €1.0 million, and

•insurance related to the Directors & Officers for €0.6 million.

As of December 31, 2020, prepaid expenses mainly relate to research agreements related to MD Anderson agreement (see Note 4.4 – Collaboration Agreement with the University of Texas MD Anderson Cancer Center) for €1.6 million.

Other receivables mainly comprised advances paid to suppliers in the amounts of €3,043 thousand as of December 31, 2021 as compared to €805 thousand as of December 31, 2020. This advance payment is mainly related to the new ICON contract signed in 2021 in conjunction with the launch of the 312 study.

Research tax credit

The Company receives a research tax credit (Crédit d’Impôt Recherche, or ‘‘CIR’’) from the French tax authorities. See Note 15 for additional details on the CIR research tax credit.

The research tax credit for 2021 was €2.5 million (€2.3 million for Nanobiotix S.A. and €218 thousand for Curadigm SAS), while the amount for 2020 was €1.9 million (€1.9 million for Nanobiotix S.A. and €69 thousand for Curadigm SAS).

The 2020 research tax credit was collected by the Company in November 2021, while the 2019 research tax credit was collected in July 2020.

The change in research tax credit receivables breaks down as follows:


(in thousands of euros)
Receivable as of December 31, 2019			5,688
Refund of 2018 research tax credit – Nanobiotix SA			(3,251)
Refund of 2019 research tax credit – Nanobiotix SA			(2,374)
Refund of 2019 research tax credit – Curadigm SAS			(64)
2020 research tax credit – Nanobiotix SA			1,858
2020 research tax credit – Curadigm SAS			69
Receivable as of December 31, 2020			1,927
Refund of 2020 research tax credit – Nanobiotix SA			(1,858)
Refund of 2020 research tax credit – Curadigm SAS			(69)
2021 research tax credit – Nanobiotix SA			2,272
2021 research tax credit – Curadigm SAS			218
Receivable as of December 31, 2021			2,490

Cash and cash equivalents

12 Months Ended

Dec. 31, 2021

Subclassifications of assets, liabilities and equities [abstract]

Cash and cash equivalents

Accounting policy

Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other reasons. They are easily converted into known amounts of cash and are subject to an insignificant risk of changes in value. Cash and cash equivalents consist of liquid assets that are available immediately and term deposits.

Cash equivalents are measured at amortized cost.

Detail of cash and cash equivalents

Cash and cash equivalent break down as follows:


(in thousands of euros)	As of December 31, 2021	As of December 31, 2020
Cash and bank accounts	83,921	119,151
Net cash and cash equivalents	83,921	119,151

As of December 31, 2021, cash and bank accounts decreased by €35,230 thousand as compared with December 31, 2020 mainly due to:

•the non-refundable upfront payment from LianBio in June 2021 of €16.5 million ($20.0 million);

•the payments made to PharmaEngine for a total of €5.4 million in 2021 pursuant to the PharmaEngine Termination Agreement;

•the debt reimbursement related to the EIB loan for €3.0 million and to the Bpifrance loan for €0.5 million; and

•other cash flows used in operating activities.

Share Capital

12 Months Ended

Dec. 31, 2021

Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]

Share Capital

10.1 Capital issued

Accounting policies

Ordinary shares are classified in shareholders’ equity. The cost of equity transactions that are directly attributable to the issue of new shares or options is recognized in shareholders’ equity as a deduction from the proceeds of the issue.

Detail of share capital transactions


(in thousands or number of shares)	Nature of transaction	Share Capital	Premiums related to share capital	Number of shares
December 31, 2019		672	153,139	22,415,039
March 6, 2020	Capital increase	9	0	316,083
June 24, 2020	Subscription of 2020 warrants	—	1	—
June 26, 2020	Subscription of 2020 warrants	—	1	—
June 29, 2020	Subscription of 2020 warrants	—	2	—
June 30, 2020	Subscription of 2020 warrants	—	1	—
July 27, 2020	Capital increase	—	—	6,000
July 28, 2020	Private placement Capital increase	99	20,030	3,300,000
July 28, 2020	Private placement Capital increase transaction costs	—	(1,387)	—
December 16, 2020	U.S. Initial public offering initial deal € - Nasdaq (€11.14)	56	20,609	1,855,000
December 16, 2020	U.S. Initial public offering initial deal $ - Nasdaq ($13.50)	163	60,494	5,445,000
December 18, 2020	U.S. Initial public offering green shoe $ - Nasdaq ($13.50)	33	12,165	1,095,000
December 18, 2020	U.S. Initial public offering costs	—	(9,322)	—
December 31, 2020		1,033	255,735	34,432,122
March 31, 2021	Capital increase AGA 2018-1	1	—	24,500
March 31, 2021	Capital increase AGA 2019-1	11	—	369,250
April 20, 2021	Warrants attribution	—	(11)	—
May 31, 2021	Warrants subscription (BSA 2021)	—	43	—
December 31, 2021		1,045	255,767	34,825,872

As of December 31, 2021, the share capital was €1,044,776.16 divided into 34,825,872 fully paid in ordinary shares each with a par value of €0.03, as compared with the 2020 share capital of €1,032,963.66 divided into 34,432,122 fully paid in ordinary shares, each with a par value of €0.03 and the 2019 share capital of €672,451.17 divided into 22,415,039 fully paid in ordinary shares each with a par value of €0.03.

In 2021, the increase in share capital is inherent to the definitive acquisition of free shares warrants related to the AGA 2018-1 and AGA 2019-1 plans.

In 2020, the increase in share capital is mainly related to the U.S. initial public offering, which closed in December 2020. In the global offering, a total of 8,395,000 ordinary shares was issued, as follows:

•5,445,000 ordinary shares in the form of ADSs were issued in the United States at $13.50 per ADS;

•1,855,000 ordinary shares were issued through a concurrent offering in certain jurisdictions outside of the United States to certain investors at €11.14 per ordinary share; and,

•the underwriters for the global offering exercised in full their option to purchase 1,095,000 additional ADSs at the same public offering price of $13.50 per ADS.

As of December 31, 2020, €10.7 million of transaction costs had been recorded, €9.3 million of which were related to the initial public offering in the United States, and are recognized as a reduction to premiums related to share capital. Those transaction costs were almost paid in full as of December 31, 2020. The remaining €349 thousand were paid in 2021.

10.2 Treasury shares

On December 31, 2021, the Company held 15,456 treasury shares under a liquidity contract compared to 12,970 treasury shares as of December 31, 2020. This liquidity contract complies with the general regulations of, and market practices accepted by, the French Financial Markets Authority (“AMF”), entered into following the Company’s French initial public offering in 2012. These shares were deducted from IFRS equity in the amount of €202 thousand and €196 thousand as of December 31, 2021 and 2020, respectively.

10.3 Founders’ warrants, warrants, stock options and free shares

Accounting policies

Accounting policies for share-based payments are described in Note 17.

Detail of change in founders’ warrants, warrants, stock options and free shares

As of December 31, 2021 and 2020, the Company had the following type of equity plans in place: founders’ warrant (BSPCE) plans, warrant (BSA) plans, stock option (OSA) plans and free shares (AGA) plans.

The following tables summarize activity in these plans during the years ended December 31, 2021 and 2020.

Founders’ warrants (BSPCE)


Type	Grant date	Exercise price (in euros)	Outstanding at January 1, 2021	Issued	Exercised	Forfeited	Outstanding at December 31, 2021	Number of shares issuable
BSPCE 2012-2	December 18, 2012	6.63	100,000	—	—	—	100,000	100,000
BSPCE 08-2013	August 28, 2013	5.92	50,000	—	—	—	50,000	50,000
BSPCE 09-2014	September 16, 2014	18.68	86,150	—	—	—	86,150	86,150
BSPCE 2015-1	February 10, 2015	18.57	68,450	—	—	—	68,450	68,450
BSPCE 2015-3	June 10, 2015	20.28	30,700	—	—	(350)	30,350	30,350
BSPCE 2016	February 2, 2016	14.46	202,617	—	—	(1,776)	200,841	200,841
BSPCE 2017	January 7, 2017	15.93	180,850	—	—	(1,350)	179,500	179,500
Total			718,767	—	—	(3,476)	715,291	715,291


Type	Grant date	Exercise price (in euros)	Outstanding at January 1, 2020	Issued	Exercised	Forfeited	Outstanding at December 31, 2020	Number of shares issuable
BSPCE 2012-2	December 18, 2012	6.63	100,000	—	—	—	100,000	100,000
BSPCE 08-2013	August 28, 2013	5.92	50,000	—	—	—	50,000	50,000
BSPCE 09-2014	September 16, 2014	18.68	92,100	—	—	(5,950)	86,150	86,150
BSPCE 2015-1	February 10, 2015	18.57	70,950	—	—	(2,500)	68,450	68,450
BSPCE 2015-3	June 10, 2015	20.28	38,400	—	—	(7,700)	30,700	30,700
BSPCE 2016	February 2, 2016	14.46	212,969	—	—	(10,352)	202,617	202,617
BSPCE 2017	January 7, 2017	15.93	187,166	—	—	(6,316)	180,850	180,850
Total			751,585	—	—	(32,818)	718,767	718,767

By way of exception, the Executive Board decided to lift, for three former employees and for two former members of the Executive Board, the continued service condition, and, where applicable for a former Executive Board member, the performance conditions to which the exercise of certain BSPCEs was subject, notwithstanding the termination of their employment agreement and/or corporate office.

The impact of share-based payments on income is detailed in Note 17.

The probability of meeting the performance conditions for the 2016 BSPCE, BSA and OSA performance plans was reassessed as of December 31, 2021. As a consequence, no new instrument became issuable.

Warrant Plans (BSA)


Type	Grant date	Exercise price (in euros)	Outstanding at January 1, 2021	Issued	Exercised	Forfeited	Outstanding at December 31, 2021	Number of shares issuable
BSA 04-12	May 4, 2012	6.00	30,000	—	—	—	30,000	30,000
BSA 2013	April 10, 2013	6.37	6,000	—	—	—	6,000	6,000
BSA 2014	September 16, 2014	17.67	10,000	—	—	—	10,000	10,000
BSA 2015-1	February 10, 2015	17.67	21,000	—	—	—	21,000	21,000
BSA 2015-2(a)	June 25, 2015	19.54	64,000	—	—	—	64,000	64,000
BSA 2015-2(b)	June 25, 2015	19.54	—	—	—	—	—	—
BSA 2016	February 2, 2016	13.74	36,208	—	—	(36,208)	—	—
BSA 2016-2	November 3, 2016	15.01	8,000	—	—	(8,000)	—	—
BSA 2017	January 7, 2017	15.76	18,000	—	—	—	18,000	18,000
BSA 2018-1	March 6, 2018	13.55	28,000	—	—	—	28,000	28,000
BSA 2018-2	July 27, 2018	16.102	5,820	—	—	—	5,820	5,820
BSA 2019-1	March 29, 2019	11.66	18,000	—	—	—	18,000	18,000
BSA 2020	March 17, 2020	6.59	18,000	—	—	—	18,000	18,000
BSA 2021 (a)	April 21, 2021	13.47	—	48,103	—	(33,672)	14,431	14,431
BSA 2021 (b)	April 21, 2021	13.64	—	30,000	—	—	30,000	30,000
Total			263,028	78,103	—	(77,880)	263,251	263,251


Type	Grant date	Exercise price (in euros)	Outstanding at January 1, 2020	Issued	Exercised	Forfeited	Outstanding at December 31, 2020	Number of shares issuable
BSA 04-12	May 4, 2012	6.00	30,000	—	—	—	30,000	30,000
BSA 2013	April 10, 2013	6.37	6,000	—	—	—	6,000	6,000
BSA 2014	September 16, 2014	17.67	10,000	—	—	—	10,000	10,000
BSA 2015-1	February 10, 2015	17.67	21,000	—	—	—	21,000	21,000
BSA 2015-2(a)	June 25, 2015	19.54	64,000	—	—	—	64,000	64,000
BSA 2015-2(b)	June 25, 2015	19.54	6,000	—	—	(6,000)	—	—
BSA 2016	February 2, 2016	13.74	36,208	—	—	—	36,208	36,208
BSA 2016-2	November 3, 2016	15.01	8,000	—	—	—	8,000	8,000
BSA 2017	January 7, 2017	15.76	18,000	—	—	—	18,000	18,000
BSA 2018-1	March 6, 2018	13.55	28,000	—	—	—	28,000	28,000
BSA 2018-2	July 27, 2018	16.102	5,820	—	—	—	5,820	5,820
BSA 2019-1	March 29, 2019	11.660	18,000	—	—	—	18,000	18,000
BSA 2020	March 17, 2020	6.59	—	18,000	—	—	18,000	18,000
Total			251,028	18,000	—	(6,000)	263,028	263,028

At a meeting on April 20, 2021, the Executive Board, acting pursuant to the delegation granted by the Company’s shareholders' meeting held on November 30, 2020 granted 48,103 warrants to members and observers of the Supervisory Board, each entitling its holder to subscribe one ordinary share, each with a par value of €0.03 and at a price of €13.47 (share premium included). The designated warrants included 18,103 warrants that were issued in replacement of certain 2016 ordinary warrants that became null on February 2, 2021. The subscription period was open from the date of the meeting of the Executive Board until September 30, 2021, inclusive. As of December 31, 2021, 14,431 warrants have been subscribed by their beneficiaries.

The warrants can be exercised at any time during a 10-year period, subject to the satisfaction of the following conditions:

•the subscription by the relevant beneficiary of his/her warrant;

•the relevant holder has attended at least 75% of the Supervisory Board meetings held during the twelve months preceding the exercise of the warrants or, as the case may be, the date the holder ceases to be part of the Group; and

•the recommended dose for two out of the three patient cohorts enrolled in the study 1100 has been determined in order to define the next steps of the immuno-oncology development plan.

It is being specified that (i) the Executive Board, with the prior approval of the Supervisory Board, shall acknowledge the satisfaction of such condition and (ii) such condition shall automatically be waived in the event of a change of control.

At the same meeting, the Executive Board, acting pursuant to the above mentioned delegation, also granted 30,000 warrants to a consultant of the Company, each warrant giving its holder the right to subscribe one ordinary share, each with a par value of €0.03 and at a price of €13.64 (share premium included) at any time during a 10-year period subject to (i) the subscription by such consultant of the warrants and (ii) the drafting by such consultant of a Chemistry, Manufacturing, Control (CMC) risk assessment report. The corresponding subscription period has been fixed from the date of the meeting of the Executive Board until July 20, 2021 inclusive. As of December 31, 2021, no warrants have been subscribed by the beneficiary. In addition, as of December 31, 2021 the report is not prepared yet. Therefore, the warrants are not vested yet.

At a meeting on March 17, 2020, the Executive Board, acting pursuant to the delegation granted by the thirty-fourth resolution of the annual shareholders' meeting dated April 11, 2019 and following the approval granted by the Supervisory Board on March 13, 2020, granted 18,000 warrants to members of the Supervisory Board, each entitling the holder to subscribe to a defined number of ordinary shares with a par value of €0.03, at a price of €6.59. The holders subscribed to the warrants prior to the end of the subscription period on September 30, 2020.

Stock Option Plans (OSA)


Type	Grant date	Exercise price (in euros)	Outstanding at January 1, 2021	Issued	Exercised	Forfeited	Outstanding at December 31, 2021	Number of shares issuable
OSA 2016-1	February 2, 2016	13.05	400	—	—	—	400	400
OSA 2016-2	November 3, 2016	14.26	4,000	—	—	—	4,000	4,000
OSA 2017	January 7, 2017	14.97	500	—	—	—	500	500
OSA 2018	March 6, 2018	12.87	52,000	—	—	—	52,000	52,000
OSA 2019-1	March 29, 2019	11.08	28,750	—	—	(500)	28,250	28,250
OSA LLY 2019	October 24, 2019	6.41	500,000	—	—	—	500,000	500,000
OSA 2020	March 11, 2020	6.25	400,709	—	—	(13,253)	387,456	387,456
OSA 2021-04	April 20, 2021	13.74	—	571,200	—	(80,000)	491,200	491,200
OSA 2021-06	June 21, 2021	12.99	—	120,000	—	—	120,000	120,000
Total			986,359	691,200	—	(93,753)	1,583,806	1,583,806


Type	Grant date	Exercise price (in euros)	Outstanding at January 1, 2020	Issued	Exercised	Forfeited	Outstanding at December 31, 2020	Number of shares issuable
OSA 2016-1	February 2, 2016	13.05	400	—	—	—	400	400
OSA 2016-2	November 3, 2016	14.26	4,000	—	—	—	4,000	4,000
OSA 2017	January 7, 2017	14.97	500	—	—	—	500	500
OSA 2018	March 6, 2018	12.87	54,000	—	—	(2,000)	52,000	52,000
OSA 2019-1	March 29, 2019	11.08	30,250	—	—	(1,500)	28,750	28,750
OSA LLY 2019	October 24, 2019	6.41	500,000	—	—	—	500,000	500,000
OSA 2020	March 11, 2020	6.25	—	407,972	—	(7,263)	400,709	400,709
Total			589,150	407,972	—	(10,763)	986,359	986,359

At a meeting on April 20, 2021, the Executive Board, acting pursuant to delegations granted by the Company’s shareholders’ meeting held on November 30, 2020, granted to certain employees of the Group and members of the Executive Board 571,200 stock options (including 143,200 stock options and 428,000 performance stock options), each giving its holder the right to subscribe one ordinary share, each with a par value of €0.03 and at a price of €13.74 (share premium included). Such stock options are governed by the 2020 stock option plan adopted by the Executive Board on February 9, 2021 and approved by the Company’s annual shareholders’ meeting held on April 28, 2021 (the “2020 Stock Option Plan”).

The ordinary stock options are exercisable as follows:

•up to one-third of the ordinary stock options as from April 20, 2022;

•an additional one-third of the ordinary stock options as from April 20, 2023,

•the balance, i.e., one-third of the ordinary stock options as from April 20, 2024, subject to, for each increment, a continued service condition, and in any case,

•no later than 10 years after the date of grant, it being specified that stock options which have not been exercised by the end of this 10-year period will be forfeited by law.

The performance stock options may be exercised under the following conditions:

•10% of the stock options may be exercised when the market price of the Company’s shares on the regulated market of Euronext in Paris reaches €24.00,

•an additional 10% of the stock options may be exercised when the market price of the Company's shares on the regulated market of Euronext in Paris reaches €30.00,

•an additional 40% of the stock options may be exercised when the market price of the Company’s shares on the regulated market of Euronext in Paris reaches €40.00,

•an additional 40% of the stock options may be exercised when the market price of the Company's shares on the regulated market of Euronext in Paris reaches €60.00, and

•at the latest within 10 years of the date of grant, it being specified that stock options which have not been exercised by the end of this 10-year period will be forfeited by law.

It being specified that (i) among such performance stock options that may be exercised, and subject to, for each increment, a continued service condition, their holders may only exercise (x) up to 10% of such performance stock options as from April 20, 2022, (y) an additional 30% of such performance stock options as from April 20, 2023, and (z) the balance, i.e., 60% of such performance stock options as from April 20, 2024, and (ii) such additional vesting condition shall be automatically waived in the event of a change of control.

The number of ordinary and performance stock options that may be exercised under the above exercise schedules would always be rounded down to the nearest whole number.

At a meeting on June 21, 2021, the Executive Board, acting pursuant to the delegation granted by the shareholders’ meeting held on November 30, 2020 granted 60,000 ordinary stock options to Mr. Bart Van Rhijn following his entry into the Company and his appointment as a Member of the Executive Board. Such stock options are governed by the 2020 Stock Option Plan. Acting pursuant to a delegation granted by the Company’s annual shareholders’ meeting held on April 28, 2021, it also decided to adopt the 2021 stock option plan and to grant to Mr. Bart Van Rhijn 60,000 performance stock options governed by such plan. Each of such 120,000 stock options (whether ordinary and performance) gives it holders the right to subscribe one ordinary share, each with a par value of €0.03 and at a price of €12.99 (share premium included).

The exercise conditions of the 143,200 ordinary stock options and 428,000 performance stock options granted on April 20, 2021 described above shall apply mutatis mutandis to these 60,000 ordinary stock options and 60,000 performance stock options respectively, save for the anniversary date which shall be June 30 rather than April 20. In addition, in accordance with French regulation, the exercise of the above stock options (whether ordinary and performance) are subject to an additional performance condition as soon as they are granted to a member of the Executive Board: determination of the recommended dose for two of the three patient cohorts enrolled in the NBTXR3-1100 clinical study, in order to be able to define the next stage of the development plan in immuno-oncology.

At a meeting on March 11, 2020, the Executive Board adopted the 2019 Stock Option Plan and, acting pursuant to the authorization granted by the thirty-second resolution of the annual shareholders' meeting dated April 11, 2019, granted 407,972 stock options (the “OSA 2020”), 300,000 of which to members of the Executive Board and Mr. Alain Dostie and the remaining 107,972 to employees of the Company, under such 2019 Stock Option Plan. Each OSA 2020 entitles its holder to subscribe one ordinary share of the Company with a par value of €0.03, at an exercise price of €6.25 (issue premium included).

The OSA 2020 may be exercised as follows:

•up to one-third of the OSA 2020 as from March 11, 2021;

•an additional one-third of the OSA 2020 as from March 11, 2022; and

•the balance, i.e., one-third of the OSA 2020 as from March 11, 2023, subject to, for each increment, a continued service condition.

In addition, the Executive Board decided that the exercise of the OSA 2020 granted to members of the Executive Board and Mr. Alain Dostie would also be subject to the achievement of positive results in the 1100 study in 2020.

The satisfaction of this performance condition was acknowledged by the Executive Board, with the approval of the supervisory board, on March 17, 2021.

By way of exception, the Executive Board decided to lift the continued service condition of the OSA 2020 for two former Executive Board members as well as to accelerate, as from June 30, 2021, the vesting of the OSA 2020 one

of these former executive board members holds, enabling him to exercise all of them, in the context of his departure from the Company.

Free share plans (AGA)


Type	Grant date	Exercise price (in euros)	Outstanding at January 1, 2021	Issued	Definitively acquired	Forfeited	Outstanding at December 31, 2021	Number of shares exercisable
AGA 2018-1	March 6, 2018	n.a.	24,500	—	(24,500)	—	—	—
AGA 2018-2	July 27, 2018	n.a.	—	—	—	—	—	—
AGA 2019-1	March 29, 2019	n.a.	372,000	—	(369,250)	(2,750)	—	—
AGA 2020	March 11, 2020	n.a.	50,000	—	—	—	50,000	50,000
AGA 2021	April 20, 2021	n.a.	—	362,515	—	(2,003)	360,512	360,512
Total			446,500	362,515	(393,750)	(4,753)	410,512	410,512


Type	Grant date	Exercise price (in euros)	Outstanding at January 1, 2020	Issued	Definitively acquired	Forfeited	Outstanding at December 31, 2020	Number of shares exercisable
AGA 2018-1	March 6, 2018	n.a.	355,250	—	(316,083)	(14,667)	24,500	24,500
AGA 2018-2	July 27, 2018	n.a.	6,000	—	(6,000)	—	—	—
AGA 2019-1	March 29, 2019	n.a.	385,000	—	—	(13,000)	372,000	372,000
AGA 2020	March 11, 2020	n.a.	—	50,000	—	—	50,000	50,000
Total			746,250	50,000	(322,083)	(27,667)	446,500	446,500

At a meeting on April 20, 2021, the Executive Board, acting pursuant to the authorization granted by Company’s shareholders’ meeting on November 30, 2020, granted 362,515 free shares, each with a par value of €0.03 to certain employees of the Group and members of the Executive Board. Such free shares will be subject to a one-year holding period starting at the end of the two-year acquisition period, i.e. starting on April 20, 2023. Such free shares are governed by the 2020 free share plan adopted by the Executive Board on February 9, 2021.

Furthermore, the final vesting of the free shares granted to members of the Executive Board is conditioned upon the determination of the recommended dose for two out of the three patient cohorts enrolled in the NBTXR3-1100 clinical study in order to define the next steps of the development plan in immuno-oncology.

At a meeting on March 11, 2020, the Executive Board, acting pursuant to the authorization granted by the thirty-third resolution of the annual shareholders’ meeting dated April 11, 2019, granted 50,000 free shares (the “AGA 2020”) with a par value of €0.03 to Ms. Anne-Juliette Hermant, a member of the Executive Board.

In addition to the acquisition and holding conditions detailed below, the acquisition of the AGA 2020 granted to Ms. Hermant is conditioned upon the achievement of positive results in Study 1100 in 2020. The satisfaction of this performance condition was acknowledged by the Executive Board, with the approval of the Supervisory Board, on March 17, 2021.

Free share vesting conditions

The AGA 2020 and AGA 2021 are subject to, for French tax residents, a two-year acquisition period and a one-year holding period, and, for foreign tax residents, a three-year acquisition period. The free shares granted by the Company are definitively acquired at the end of the acquisition period as set by the Executive Board. At the end of such period, the beneficiary is the owner of the shares. However, during the holding period (as set by the Executive Board), if any, the shares may not be sold, transferred or pledged.

Unless otherwise decided by the supervisory and executive boards of the Company, the AGA 2020 and the AGA 2021 are subject to continued service during the acquisition period (i.e., for the AGA 2020, until March 11, 2022 and for AGE 2021, until April 20, 2023), it being specified that, failing such continued service, the beneficiary definitively and irrevocably loses his or her right to acquire the relevant AGA 2020 or AGA 2021.

Unless otherwise decided by the supervisory and executive boards of the Company, in the event of disability or death of a beneficiary before the end of the acquisition period, the relevant free shares shall be definitely acquired at, respectively, the date of disability or the date of the request of allocation made by his or her beneficiary in the framework of the inheritance, provided that such request is made within six months from the date of death.

At a meeting on March 17, 2021, the Executive Board acknowledged the definitive acquisition of 24,500 free shares granted on March 6, 2018 following a three-year acquisition period, thus acknowledging the related share capital increase of €735.

At a meeting on April 1, 2021, the Executive Board acknowledged the definitive acquisition of 369,250 free shares granted on March 29, 2019 following a two-year acquisition period, thus acknowledging the related share capital increase of €11,077.50.

At a meeting on September 22, 2020, the Executive Board acknowledged the definitive acquisition of 6,000 free shares granted on July 27, 2018 following a two-year acquisition period, thus acknowledging the related share capital increase of €180.

In accordance with the terms of the free shares, the Executive Board decided to lift, for seven Company’s employees and a former Executive Board member, the continued service condition to which the definitive acquisition of their free shares is subject, notwithstanding the termination of their employment agreement or corporate office. The impact of share-based payments on income is discussed in Note 17. As of December 31, 2021, the assumptions related to the estimated vesting of the founders’ warrants, the warrants and performance stock-options have been updated (see Note 17).

Provisions

12 Months Ended

Dec. 31, 2021

Provisions [abstract]

Provisions

Accounting policies

Provisions for contingencies and charges

Provisions for contingencies and charges reflect obligations resulting from various disputes and risks which due dates and amounts are uncertain, that the Company may face as part of its normal business activities.

A provision is recognized when the Company has a present obligation (legal or constructive) as a result of a past event, where it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

The amount recorded in provisions is a best estimate of the outflow of resources that will be required to settle the obligation, discounted, if required, at year-end.

Provisions for retirement obligations

Company employees receive the retirement benefits provided for by law in France:

•Lump-sum retirement benefit paid by the Company to employees upon retirement (defined benefit plan); and

•Pension benefits paid by social security agencies, which are financed through employer and employee contributions (State defined contribution plan).

The cost of retirement benefits payable under defined benefit plans is estimated using the projected credit unit cost method.

Based on this method, the cost of retirement is recorded in income such that the amount is distributed uniformly over the term of the employee’s career. Past service cost related to non-vested benefits is recognized as an expense (increase in the benefits granted) or as income (reduction in the benefits granted) when the plan amendment or curtailment occurs. Actuarial gains and losses are recognized directly and in full in other comprehensive income (loss) under equity.

Retirement benefit obligations are measured at the present value of future estimated payments by reference to market yields on high quality corporate bonds with a maturity equivalent to that estimated for the plan. The Company uses experts to carry out an annual valuation of the plans. The Company's payments to defined contribution plans are recognized as expenses in each period to which they relate.

As of December 31, 2021 and 2020, the Company updated the parameters for calculating the lump-sum retirement benefit plan to take recent changes into account. The salary increase rate, staff turnover and discount rate were all updated (see Note 11.2 for further details on assumptions used).


(in thousands of euros)	As of January 1, 2021	Increases	Decreases	As of December 31, 2021
Lump-sum retirement benefits	414	—	(97)	318
Non-current provisions	414	—	(97)	318
Provisions for disputes	40	54	—	94
Provision for charges	—	16	—	16
Current provisions	40	70	—	110
Total provisions	454	70	(97)	428


(in thousands of euros)	As of January 1, 2020	Increases	Decreases(1)	As of December 31, 2020
Lump-sum retirement benefits	331	83	—	414
Non-current provisions	331	83	—	414
Provisions for disputes	—	40	—	40
Provision for charges	164	—	(164)	—
Current provisions	164	40	(164)	40
Total provisions	495	123	(164)	454

(1)See Statement of consolidated cash flows and Note 16.4 for the nature of these decreases

11.1 Current provisions

Provisions for disputes comprise employee disputes in progress. The increase during 2021 and 2020 of €54 thousand and €40 thousand, respectively, were due to a new employee dispute that occurred during the respective years.

In 2020, the reversal of provisions for charges of €164 thousand were related to termination costs accounted for in 2019 following an employee departure.

11.2 Non-current provisions

Commitments for retirement benefits


	As of December 31,
(in thousands of euros)	2021	2020
Provision as of beginning of period	414	331
Cost of services	84	76
Interests / discounting costs	1	3
Expense for the period	85	79
Gains or losses related to experience	(133)	(61)
Gains or losses related to change in demographic assumptions	(5)	3
Gains or losses related to change in financial assumptions	(43)	62
Actuarial gains or losses recognized in other comprehensive income	(182)	4
Provision as of end of period	318	414

The assumptions used to measure lump-sum retirement benefits are as follows:


Measurement date	December 31, 2021	December 31, 2020
Retirement assumptions	Management: Age 66 Non-management: Age 64	Management: Age 66 Non-management: Age 64
Social security contribution rate	42.01 %	44 %
Discount rate	0.98 %	0.33 %
Mortality tables	Regulatory table INSEE 2015 -2017	Regulatory table INSEE 2014 -2016
Salary increase rate (including inflation)	Executive: 3% Non-Executive: 2.5%	Executive: 3% Non-Executive: 2.5%
Staff turnover	Constant average rate of 5.86%	Constant average rate of 5.86%
Duration	20 years	17 years

The rights granted to Company employees are defined in the Collective Agreement for the Pharmaceutical industry (manufacturing and sales of pharmaceutical products).

The staff turnover rate was determined using a historical average over the 2015-2019 period.

The sensitivity to the discount rate and to the salary growth is as follows:


Discount rate	0.73%	0.98%	1.23%
Defined Benefit Obligation as of December 31, 2021 (in thousands of euros)	333	318	303

The company does not expect to pay a material amount of benefits for the five next years.

Financial liabilities

12 Months Ended

Dec. 31, 2021

Disclosure of financial liabilities [abstract]

Financial liabilities

Accounting policies

The Company receives assistance in the form of grants, conditional advances and interest-free loans.

Under IFRS, a repayable advance that does not require the payment of annual interest is considered to be an interest-free loan. The difference between the amount of the advance at historical cost and the advance discounted at the Company's average borrowing rate is considered to be a government grant. These grants are deferred over the estimated duration of the projects they finance.

The long-term (more than one year) portion of conditional advances is recognized in non-current financial liabilities and the short-term portion in current financial liabilities.

Non-repayable conditional loans are treated as government grants when there is reasonable assurance that the Company will comply with the conditions for non-repayment. Otherwise, they are classified in liabilities.

Government grants made available to offset expenses or losses already incurred, or as immediate financial assistance to the Company with no future related costs, are recognized in income in the period in which the grant is allocated.

Financial liabilities are recognized and measured in accordance with IFRS 9 – Financial Instruments. Financial liabilities, including trade and other payables are valued at amortized cost.

Financial liabilities at amortized cost

Loans and other financial liabilities are recognized and measured in accordance with IFRS 9 – Financial Instruments.

They are recognized at amortized cost, which is defined under IFRS 9 as the initial value of a financial asset or liability, after deduction of reimbursement of principal, increased or decreased by the accumulated amortization, calculated using the effective interest rate method.

Transaction costs directly attributable to the acquisition or issuance of financial liabilities are deducted from the financial liabilities. The costs are then amortized on an actuarial basis over the life of the liability using the effective interest rate, namely the rate that exactly discounts estimated future cash flows to the net carrying amount of the financial liability in order to determine its amortized cost.

Details of financial liabilities


	As of December 31,
(in thousands of euros)	2021	2020
Lease liabilities – Short term	1,126	1,197
Repayable BPI loan advances - Short term	800	500
PGE*	1,086	141
EIB Loan – Short term	5,192	3,033
Total current financial liabilities	8,204	4,872
Lease liabilities – Long term	5,393	4,991
Repayable BPI loan advances – Long term	2,259	2,975
PGE*	8,982	9,922
EIB loan – Long term	21,182	26,218
Total non-current financial liabilities	37,816	44,107
Total financial liabilities	46,020	48,979

(*)”PGE”or in French “Prêts garantis par l’Etat” are state-guaranteed loans

Bpifrance conditional advances

The Company receives repayable advances from Banque Publique d’Investissement (formerly known as OSEO Innovation). Some of these advances are interest-free and are fully repayable in the event of technical and/or commercial success. In 2018, the Company was informed that the initial date of reimbursement of the Bpifrance repayable advance was deferred for 18 months.

The other advances are bearing 1.56% interest. The amount to be reimbursed corresponds to the amount received to date, €2.1 million, increased by the interest amount (see Note 12.1).

In June 2020, Curadigm SAS obtained a €500 thousand conditional advance from Bpifrance, €350 thousand of which was received at the signature date while the remaining amount had been scheduled to be received by Curadigm at the end of the work, expected as of March 1, 2022 at the latest, but Curadigm SAS requested an extension of the work period to Bpifrance as a result of COVID-19 which - in case of Bpifrance’s approval - could result in collectibility of the remaining €150 thousand. As of December 31, 2021, the work had not been completed and the balance, therefore, has not been paid.

EIB loan

In July 2018, the Company obtained a fixed rate loan from the EIB. The loan could reach a maximum amount of €40 million, divided in three tranches. The first tranche, with a nominal value of €16 million, was received in October 2018 and will be repaid in full in 2023. The accumulated fixed-rate interest related to this tranche will be paid at the same time. The second tranche, with a nominal value of €14 million, was received in March 2019 and will be repaid between 2021 and 2024. The accumulated fixed-rate interest related to this second tranche will be paid twice a year together with the principal due.

The third tranche, which abides by specific conditions (NBTXR3 should obtain the European Commission trademark and reach the main performance criteria for the Phase III pivot, for head and neck cancer treatment), has not been requested by the Company. The deadline for requesting this third tranche, initially scheduled as of July 26, 2020, had been delayed by 12 months to July 31, 2021. As the conditions were not met by July 31, 2021, the Company will not be able to request the final tranche of the EIB loan.

Pursuant to the terms of the loan, the Company is also required, during a six-year royalty calculation period commencing on January 1, 2021, to pay (on each June 30 with respect to the preceding year within the calculation period) additional interest in the form of royalties, calculated according to the number of tranches that have been withdrawn and indexed on the annual sales turnover (see Note 4.2). Initially, the Company calculated estimated future royalties based on its forecast of future annual sales turnover, and this estimated amount was included in the amortized cost of the loan. When the Company revises its forecasts of estimated royalties, the carrying value of the liability is subsequently adjusted based on the revised estimate of future royalties, which is discounted at the original effective interest rate. The related impact on the carrying value of the liability is recorded as financial income or expense, as applicable. Due to the delay caused by COVID-19 in clinical trials and the revision of the related sales development plan, the sales forecasts were updated resulting in a change in estimate of the accrued royalties (see Note 12 of our consolidated financial statements for details about the impact of this sales forecast update). A 10%

increase of the estimated future net sales would result in an immaterial change of the EIB loan valuation recorded as of December 31, 2021.

PGE loan

The Company announced in June 2020 that it has received approval for financing from both HSBC and Bpifrance for €5 million each in the form of state-guaranteed loans (“Prêts Garantis par l’Etat”, or “PGE” in France); the €5 million from HSBC (the ‘‘HSBC PGE Loan’’) was received in June 2020. This loan is booked at amortized cost for a minimum of 12 months and allows the Company to delay the reimbursement of this 12 months loan by 1 to 5 years. The Company uses this option and the reimbursement date was delayed by 1 year and will start in September 2022. The effective interest rate amounts to 0.31%.

On July 10, 2020, the Company entered into the second €5 million PGE loan with Bpifrance (the ‘‘Bpifrance PGE Loan’’). The Bpifrance PGE loan has a six-year term and is 90% guaranteed by the French State. The Bpifrance PGE loan did not bear any interest for the first 12-month period but, following such 12-month period and for the subsequent 5 years, is bearing an interest rate of 2.25% per annum, inclusive of an annual State guarantee fee of 1.61% per annum. The principal and interest of the Bpifrance PGE loan will be reimbursed in 20 quarterly installments as from October 31, 2021 until July 26, 2026.

12.1 Conditional advance, bank loan and loans from government and public authorities

The table below shows the detail of liabilities recognized on the statements of financial position by type of conditional advances and loans from government and public authorities.

Conditional advances and loans from government and public authorities


(in thousands of euros)	Bpifrance advance	Interest-free Bpifrance loan	EIB Loan	Curadigm Bpifrance advance	Total
As of January 1, 2020	2,165	1,210	34,746	—	38,121
Principal received	—	—	—	350	350
Impact of discounting and accretion	19	14	(1,736)	(65)	(1,769)
Accumulated fixed interest expense accrual	32	—	1,731	—	1,763
Accumulated variable interest expense accrual	—	—	(4,789)	—	(4,789)
Repayment	—	(250)	(700)	—	(950)
As of December 31, 2020	2,216	974	29,251	285	32,727
Principal received	—	—	—	—	—
Impact of discounting and accretion	17	19	(5,817)	16	(5,765)
Accumulated fixed interest expense accrual	32	—	1,758	—	1,790
Accumulated variable interest expense accrual	—	—	4,214	—	4,214
Repayment	—	(500)	(3,033)	—	(3,533)
As of December 31, 2021	2,266	493	26,374	300	29,433

The impact of discounting and accretion of €5.8 million, in 2021 relates to impact from the “catch-up method” related to the variable compensation further to the royalty component in the EIB loan that is linked to future revenue expectations. When the Company revises its forecasts of estimated royalties, the carrying value of the liability is subsequently adjusted based on the revised estimate of future royalties, which is discounted at the original effective interest rate. The related impact on the carrying value of the liability is recorded as financial income or expense, as applicable. The rest of the catch up impact is presented on the line variable interest future payments.

The expected royalty payments to be made in the future, initially estimated as €17.2 million as of December 31, 2020 have been updated to €3.4 million as of December 31, 2021.

Bank loan


(in thousands of euros)	HSBC “PGE” (1)	Bpifrance “PGE” (1)	Total
As of January 1, 2020	—	—	—
Principal received	5,000	5,000	10,000
Impact of discounting and accretion	14	34	47
Accumulated fixed interest expense accrual (2)	7	10	17
As of December 31, 2020	5,020	5,044	10,064
Principal received	17	(14)	3
Impact of discounting and accretion	26	120	146
Accumulated fixed interest expense accrual (3)	(33)	(112)	(145)
As of December 31, 2021	5,030	5,038	10,068

(1)”PGE”or in French “Prêts garantis par l’Etat” are state-guaranteed loans

(2) In 2020 the fixed interest accrual refers to guarantee fee of 0.25% of the principal of the HSBC PGE loan and to a guarantee fee of 0.25% added to a fixed interest rate of 1.36% for the Bpifrance PGE loan, respectively.

(3) In 2021 the fixed interest accrual refers to guarantee fee of 0.25% of the principal of the HSBC PGE loan and to a guarantee fee of 0.25% added to a fixed interest rate of 1.36% for the Bpifrance PGE loan, respectively.

12.2 Lease liabilities

The table below shows the detail of changes in lease liabilities recognized on the statements of financial position over the periods disclosed:


(in thousands of euros)			Lease liabilities
As of January 1st, 2020			6,405
New lease contracts			521
Impact of discounting of the new lease contracts			(94)
Fixed interest expense			333
Repayment of lease			(928)
Early termination of lease contracts			(49)
As of December 31, 2020			6,188
Engagement			1,476
Impact of discounting and accretion			(110)
Accumulated fixed interest expense accrual			288
Repayment of lease			(1,195)
Early termination of lease contracts			(128)
As of December 31, 2021			6,519

12.3 Due dates of the financial liabilities

The due dates for repayment of the advances loans and lease liabilities at their nominal value and including fixed-rate interest are as follows:


	As of December 31, 2021
(in thousands of euros)	Less than 1 year	Between 1 and 3 years	Between 3 and 5 years	More than 5 years
Bpifrance	300	1,300	808	—
Interest-free Bpifrance loan	500	—	—	—
Curadigm interest-free Bpifrance advance	—	200	150	—
HSBC “PGE” (1)	661	2,572	1,904	—
Bpifrance “PGE” (1)	425	2,662	2,237	—
EIB fixed rate loan	5,192	28,762	—	—
Lease liabilities	1,126	2,252	2,247	1,714
Total	8,204	37,747	7,346	1,714

(1)”The Company will reimburse the two “PGE”or (“Prêts garantis par l’Etat” or state-guaranteed loans) over 5 years with a deferral of 1 year (last reimbursement being in 2026), for the reasons mentioned in the paragraph below.

The long-term debt obligations relate to the fixed rate interest and principal payable on repayable advances, the interest-free Bpifrance loan, EIB loan, PGE loans and the lease liabilities. These amounts do not include the discounting impact, but only reflect the committed amounts under those contracts as of December 31, 2021.

The outstanding balance of the EIB loan included in the table above was €33.9 million as of December 31, 2021, including €7.0 million of total fixed rate interest to be paid over the term of the loan, out of which €1.8 million was accrued as of December 31, 2021. The balance in the table above does not include €3.4 million of estimated variable rate interest, based on the consolidated forecasted sales expected to be generated by the Company during the six-year period beginning January 1, 2021 (see Notes 3.2, 4.3 and 12.1).

On April 07, 2021, the Company received the approval of HSBC on its debt rescheduling request. The HSBC PGE loan will be reimbursed at the same pace as the Bpifrance loan, starting on September 2022.

Trade payables and other current liabilities

12 Months Ended

Dec. 31, 2021

Subclassifications of assets, liabilities and equities [abstract]

Trade payables and other current liabilities

13.1 Trade and other payables

Accounting policies

Accounting policies for Trade and other payables are described in Note 12, ‘‘Financial Liabilities.’’

Accrued expenses

Taking into account the time lag between the time at which treatment costs are incurred in studies or clinical trials and the time at which such costs are invoiced, the Company estimates an amount of accrued expenses to record in the financial statements at each reporting date.

The treatment costs for patients were estimated for each study based on contracts signed with clinical research centers conducting the trials, taking into account the length of the treatment and the date of injection of each patient. The total amount estimated for each study has been reduced by the amount of invoices received at the closing date.

Details of trade and other payables


	As of December 31,
(in thousands of euros)	2021	2020
Accrued expenses - clinical trials	1,486	1,532
Trade payables & other accruals	4,996	5,574
Total trade and other payables	6,482	7,106

Trade payables are not discounted, as none of the amounts were due in more than one year.

Other trade payables include €447 thousand of costs relating to the ICON contract not yet paid, as of December 31, 2021.

13.2 Other current liabilities


	As of December 31,
(in thousands of euros)	2021	2020
Tax liabilities	258	283
Payroll tax and other payroll liabilities	4,820	6,248
Other payables	453	491
Other current liabilities	5,531	7,022

Payroll tax and other payroll liabilities consist primarily of payroll taxes, namely the employer costs to be paid on free shares, accrued bonuses, vacation days and related social charges.

Payroll tax and other payroll liabilities decreased by €1.4 million from €6.2 million as of December 31, 2020 to €4.8 million as of December 31, 2021 as a result of the decrease in social charges accrual related to free shares and to bonuses.

13.3 Deferred revenues and contract liabilities


	As of December 31,
(in thousands of euros)	2021	2020
Deferred revenues and contract liabilities	16,518	—
Deferred revenues and contract liabilities	16,518	—

Change in deferred revenues and contract liabilities as of December 31, 2021 consists of contract liabilities relating to the LianBio contract in the amount of €16.5 million, accounted for in accordance with IFRS 15. See Note 15 Revenues and other income for more details.

Financial instruments included in the statement of financial position and impact on income

12 Months Ended

Dec. 31, 2021

Disclosure of detailed information about financial instruments [abstract]

Financial instruments included in the statement of financial position and impact on income

Accounting policies

Accounting policies for financial instruments included in the statements of financial position and impact on income are described in Note 7, ‘‘Non-current financial assets’’, Note 8, ‘‘Trade receivables and other current assets’’, Note 9, ‘‘Cash and cash equivalents’’ and Note 12, ‘‘Financial liabilities.’’

Detail of financial instruments included in the statements of financial position and impact on income


	As of December 31, 2021
(in thousands of euros)	Book value on the statement of financial position	Financial assets carried at fair value through profit or loss	Assets and liabilities carried at amortized cost	Fair value(1)
Non-current financial assets
Non-current financial assets	519	97	421	519
Trade receivables	—	—	—	—
Cash and cash equivalents	83,921	—	83,921	83,921
Total assets	84,440	97	84,343	84,440
Financial liabilities
Non-current financial liabilities	38,733	—	38,733	38,733
Current financial liabilities	7,288	—	7,288	7,288
Trade payables and other payables	6,482	—	6,482	6,482
Total liabilities	52,503	—	52,503	52,503

(1)The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance and the EIB loan, recorded at amortized cost was assessed using unobservable “level 3” inputs, in the IFRS 13 classification for fair value.


	As of December 31, 2020
(in thousands of euros)	Book value on the statement of financial position	Financial assets carried at fair value through profit or loss	Assets and liabilities carried at amortized cost	Fair value (1)
Non-current financial assets
Non-current financial assets	505	104	401	505
Trade receivables	62	—	62	62
Cash and cash equivalents	119,151	—	119,151	119,151
Total assets	119,717	104	119,613	119,717
Financial liabilities
Non-current financial liabilities	44,107	—	44,107	44,107
Current financial liabilities	4,872	—	4,872	4,872
Trade payables and other payables	7,106	—	7,106	7,106
Total liabilities	56,085	—	56,085	56,085

(1)The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, recorded at amortized cost was assessed using unobservable “level 3” inputs, in the IFRS 13 classification for fair value.

Management of financial risks

The principal financial instruments held by the Company are instruments classified as cash and cash equivalents. These instruments are managed with the objective of enabling the Company to finance its business activities. The Company's policy is to not use financial instruments for speculative purposes. It does not use derivative financial instruments.

The principal financial risks faced by the Company are liquidity, foreign currency exchange, interest rate and credit risks.

Liquidity risk

Given the amount of cash and cash equivalents held by the Company as of December 31, 2021 (see Note 9), the Company does not believe that it is exposed to short-term liquidity risk.

Foreign Currency Exchange Risk

The functional currency of Nanobiotix S.A. is the euro. Exposure to foreign currency exchange risk is derived almost entirely from intragroup transactions between Nanobiotix S.A. and its U.S. subsidiaries, for which the functional currency is the U.S. dollar, as well as trade relations with customers and suppliers outside the euro zone.

At this stage of its development, the Company does not use hedging to protect its business against exchange rate fluctuations. However, a significant increase in its business activity outside the euro zone could lead to a greater exposure to foreign currency exchange risk. If this occurs, the Company may implement a suitable hedging policy for these risks.

The following table shows the impact of a 10% increase or decrease in the exchange rate between the euro and the U.S. dollar, calculated on the amounts of capital contributions and loans to the Company’s U.S. subsidiaries as of December 31, 2021, and 2020.


	For the year ended December 31, 2021
Impact	Net income		Equity
(in thousands of euros)	Increase	Decrease	Increase	Decrease
USD / Euro exchange rate	45	(45)	87	(87)
Total	45	(45)	87	(87)


	For the year ended December 31, 2020
Impact	Net income		Equity
(in thousands of euros)	Increase	Decrease	Increase	Decrease
USD / Euro exchange rate	5	(5)	124	(124)
Total	5	(5)	124	(124)

Credit risk

Credit risk arises from cash and cash equivalents, derivative instruments and deposits with banks and other financial institutions as well as from exposure to customer credit, in particular unpaid receivables and transaction commitments.

The credit risk related to cash and cash equivalents and to current financial instruments is not material given the quality of the relevant financial institutions. Customer credit risk is limited, due in part to low trade receivables as of December 31, 2021 and in part to its customers’ high credit rating for other receivables.

Interest rate risk

The Company's exposure to interest rate risk is primarily related to cash equivalents and investment securities, which consist of money market mutual funds (SICAVs). Changes in interest rates have a direct impact on the interest earned from these investments and the cash flows generated.

Fair value

The fair value of financial instruments traded on an active market is based on the market price on the reporting date. The market prices used for the financial assets held by the Company are the bid prices in the market on the measurement date.

The carrying value of receivables and current liabilities is assumed to approximate their fair value.

Revenues and other income

12 Months Ended

Dec. 31, 2021

Revenue [abstract]

Revenues and other income

Accounting policies

Revenue

Revenue is recognized in accordance with IFRS 15.

Under IFRS 15, revenue is recognized when the Company satisfies a performance obligation by transferring a distinct good or service (or a distinct bundle of goods and/or services) to a customer, i.e. when the customer obtains control of these goods or services. An asset is transferred when the customer obtains control of the asset (or service).

Given the wide spectrum of therapeutic research and development opportunities, aside from the fields that the Company intends to research and develop with its own scientific and financial resources, the Company has entered and expects to enter into license and collaboration agreements with third parties in certain specific fields that have generated or will generate revenue.

Therefore, each agreement has been and will be analyzed, on a case-by-case basis to determine whether the arrangement contains performance obligations to the other party and, if so, to identify the nature of these performance obligations in order to determine the appropriate accounting under IFRS 15 principles of the amounts that the Company has received or is entitled to receive from the other party e.g.:

•Development services performed by the Company to create or enhance an intellectual property controlled by the client, for which revenue is recognized over time, when services are rendered;

•A transfer of control of an existing intellectual property of the Company for which revenue is recognized at the time such control is transferred;

•A license:

◦If the license is assessed to be a right to access the Company’s intellectual property as it exists throughout the license period, revenue is recognized over the license period; or

◦If the license is a right to use the Company’s intellectual property as it exists (in term of forms and functionality), revenue is recognized when the other party is able to use and benefit from the license; or

•Product supply for which the revenue is recognized once the control over the delivered products is transferred.

Contingent revenue arising from successful milestones or sales-based royalties are not recognized before the related milestone has been reached or sale has occurred.

Application to the license and collaboration agreement with PharmaEngine

Under the License and Collaboration Agreement, the Company’s and PharmaEngine’s rights are clearly identified and, financial terms are defined in the contract. The contract has commercial substance (the Company’s cash flows have been affected by the terms of the contract) and the Company has collected and is entitled to collect in the future consideration in exchange for the goods and services transferred to PharmaEngine.

The Company identified three performance obligations in the License and Collaboration Agreement described under Note 4 above:

•the license of the right to use the Company’s patent and know-how;

•the support provided by the Company to PharmaEngine until the first regulatory approval is granted in PharmaEngine’s territory that the Company views as a series of distinct periods of access to information and experience that is satisfied over time; and

•the supply of NBTXR3 to PharmaEngine.

An upfront payment of $1.0 million was fully recognized as revenue when the license was transferred to PharmaEngine in 2012.

Development milestones constitute variable payments that are recognized over-time. As milestone payment timing was defined to reflect the efforts of both parties over time and were amended to reflect all changes in the contractual development plan, the Company concluded that the terms of variable payments reflect its efforts to satisfy the performance obligation related to each development phase and that no portion if any of such consideration that would relate to the license would impact the timing of recognition because of the highly probable collectability requirement. On this basis, the first milestone payment of $1 million (upon signature of the first amendment that allowed PharmaEngine to benefit from the results of the Company’s clinical studies for soft-tissue sarcoma indication) and the second milestone payment of $1 million (first patient’s injection with NBTXR3 in soft tissue sarcoma study in Asia) were received and recognized in 2014 and 2016, respectively. The next milestone will be

received following the first filing for regulatory approval for marketing NBTXR3 in PharmaEngine ’s territory, which had not occurred as of December 31, 2021.

Royalties are considered at market conditions and will be fully recognized once the subsequent sales occur.

In March 2021, the Company and PharmaEngine mutually agreed to terminate the license and collaboration agreement. See note 4 Significant Transactions.

Application of IFRS 15 to the license and collaboration agreement with LianBio

Under the clause 8.5 of the license and collaboration agreement between the Company and LianBio, LianBio has the final decision on development and marketing activities in its territory. Consequently, the agreement does not qualify as a partnership under IFRS 11, which requires joint control and unanimous approval of strategic decisions by both parties. The agreement falls within the scope of IFRS 15.

We identified the separate performance obligations of the contract under IFRS 15. The agreement includes the following obligations to LianBio:

•an exclusive license, under the Company's intellectual property, to develop and market the licensed products;

•the right to actively participate in global Phase III registration trials to obtain marketing approval in China;

•if a pivotal trial is initiated by the Company in another country, the right to obtain a license and the right to reference efficacy data from the study and regulatory filings and approvals;

•if a Phase I and Phase II trial is initiated by the Company, the right to obtain access to and a license to all clinical data and regulatory filings relating to such clinical trial; and

•the requirement to purchase products under license to the Company.

The Company's know-how as disclosed and made available to LianBio could not technically be used by LianBio, or by a third party, to manufacture the licensed products. The provision of additional know-how data and information by the Company is necessary to enable a third party to manufacture the licensed products. This information will only be provided if the Company, at any time following a change of control of the Company, fails to provide at least 80% of LianBio's forecasted need for licensed products in a given calendar year. The license cannot be separated because LianBio cannot benefit from the license alone (i.e. without the ongoing manufacturing service provided by the Company). On this basis, we concluded that the license and the manufacturing service are not distinct.

As the license is not separate, any services performed in connection with the clinical trials cannot be analyzed as a separate service provided by the Company to LianBio, because LianBio cannot benefit from the clinical trials alone.

LianBio has the exclusive right to purchase and sell the licensed products in its territory but has no enforceable obligation to make the purchases.

Accordingly, the agreement contains only one performance obligation: the manufacturing and the supply by Nanobiotix to LianBio of the licensed products.

In consideration for this exclusive right to purchase and sell the licensed products granted to LianBio, the Company received on June 15, 2021, a non-refundable upfront payment of $20 million and may receive up to $220 million in potential additional payments upon the achievement of certain development and commercialization milestones. The development milestones events refer to the effort provided by LianBio to register the licensed product as a drug and to enroll patients in the global phase III registrational study in head and neck within 18 months and the receipt of marketing authorization for the Licensed Product in the territory for any indication in the field. The Company is entitled to receive sales milestones payments, once the aggregate net sales of the Licensed product in the territory achieve graduated amounts.

No revenue is to be recognized when such a right is granted. The upfront payment and milestone payments are considered as advance payments for future deliverables. Therefore, no revenue will be recognized until the first sales of the licensed products occur. In accordance with paragraph 106 of IFRS 15, upon receipt of an upfront payment from LianBio, the Company shall recognize a contractual liability to the extent of the upfront payment. The Company shall derecognize this contractual liability (and recognize revenue) when it transfers the licensed products.

The upfront payment and milestone payments must be allocated to the sales of licensed products. Significant judgment will be required to determine how to allocate the upfront payments to the sales of licensed products.

Nanobiotix will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. The method of recognizing these revenues is also yet to be determined.

Grants

Due to its innovative approach to nanomedicine, the Company has received various grants and other assistance from the government of France and French public authorities since its creation. The funds are intended to finance its operations or specific recruitments. Grants are recognized in income as the corresponding expenses are incurred and independently of cash flows received.

Research tax credit

The French tax authorities grant a research tax credit (Crédit d’Impôt Recherche, or “CIR”), to companies in order to encourage them to conduct technical and scientific research. Companies demonstrating that they have incurred research expenditures that meet the required criteria (research expenses in France or, since January 1, 2005, other countries in the European Community or the European Economic Area that have signed a tax treaty with France containing an administrative assistance clause) receive a tax credit that can theoretically be compensated with the income tax due on the profits of the financial year during which the expenses have been incurred and the following three years. Any unused portion of the credit is then refunded by the French Treasury. If the Company can be qualified as small and medium-sized enterprises, in France the “PME”, it can request immediate refund of the remaining tax credit, without application of the three-year period).

The Company has received research tax credits since its creation. These amounts are recognized as "Other income" in the fiscal year in which the corresponding charges or expenses were incurred. The portion related to capitalized expenses is deducted from the amount of capitalized expenses on the statements of financial position and from the amortization charges for these expenses on the statements of operations.

Detail of revenues and other income

The following table summarizes the Company’s revenues and other income per category for the years ended December 31, 2021, 2020, and 2019.


	For the year ended December 31,
(in thousands of euros)	2021	2020	2019
Services	5	50	40
Other sales	5	—	28
Total revenues	10	50	68
Research tax credit	2,490	1,927	2,437
Subsidies	126	526	20
Other	21	10	17
Total other income	2,637	2,462	2,473
Total revenues and other income	2,647	2,512	2,541

The Company’s revenue of €10 thousand in 2021, €50 thousand in 2020 and €68 thousand in 2019 were derived mainly from the charging-back of shared external clinical research organization costs in connection with the development support provided by the Company to PharmaEngine as part of the 2014 amendment to the Company's License and Collaboration Agreement.

100% of the revenues recognized in 2021, 2020 and 2019 were derived from the arrangement with PharmaEngine (see Note 4.1).

In 2020, the Company’s other income, other than the research tax credit, mainly derives from French State subsidies of €312 thousand provided as part of the ‘‘partial unemployment measure,’’ a National plan allowing companies facing economic challenges during the COVID-19 crisis to receive from the French State approximately 84% of specific employees’ net salary, as well as the €350 thousand received by Curadigm in connection with the Bpifrance Deep Tech Funding, €187 thousand of which was recognized as revenue for the years ended December 31, 2020.

Operating expenses

12 Months Ended

Dec. 31, 2021

Analysis of income and expense [abstract]

Operating expenses

Accounting policies

Leases included in the practical expedients under the IFRS 16 standard and used by the Company (low value asset and short-term leases) are recognized in operating expenses. Payments made for these leases are expensed, net of any incentives, on a straight-line basis over the contract term (see Note 22).

Accounting policies for research and development expenses are described in Note 5.

16.1 Research and development expenses


	For the year ended December 31,
(in thousands of euros)	2021	2020	2019
Purchases, sub-contracting and other expenses	(19,562)	(12,734)	(16,804)
Payroll costs (including share-based payments)	(9,605)	(10,306)	(11,980)
Depreciation, amortization and provision expenses(1)	(1,211)	(1,290)	(1,627)
Total research and development expenses	(30,378)	(24,330)	(30,411)

(1)see note 16.4 Depreciation, amortization and provision expenses

Purchases, sub-contracting and other expenses increased by €6.9 million, or 54% for the year ended December 31, 2021 as compared with the same period in 2020. This reflects the increase of the clinical development activities, especially driven by the launch of our global Phase III clinical trial for elderly head and neck cancer patients ineligible for platinum-based (cisplatin) chemotherapy (NANORAY-312).

Payroll costs decreased by €774 thousand, or 8% for the year ended December 31, 2021 as compared with the same period in 2020. This variation is mainly due to a change in the mix and in the location of our research and development staff.

As of December 31, 2021, the Company’s workforce amounted to 75 research and development staff, including 9 additional positions created during the year ended December 31, 2021.

As of December 31, 2020, the Company’s workforce amounted to 66 research and development staff, including a decrease of fifteen positions created during the year ended December 31, 2020 and 81 research and development staff, including 2 additional positions created during the year ended December 31, 2019.

The impact of share-based payments (excluding employer’s contribution) on research and development expenses amounted to €677 thousand in 2021 as compared with €629 thousand in 2020 and €902 thousand in 2019.

16.2 Selling, General and Administrative (SG&A) expenses


	For the year ended December 31,
(in thousands of euros)	2021	2020	2019
Purchases, fees and other expenses	(9,638)	(6,482)	(9,435)
Payroll costs (including share-based payments)	(9,379)	(7,789)	(9,205)
Depreciation, amortization and provision expenses (1)	(417)	(340)	(270)
Total SG&A expenses	(19,434)	(14,611)	(18,909)

(1)see note 16.4 Depreciation, amortization and provision expenses

In 2021, purchases, fees and other expenses increased by €3,156 thousand, or 49% for the year ended December 31, 2021 as compared with the same period in 2020. This variation reflects two main impacts, first the legal expenses relating to partnership agreements as well as consulting fees, legal and compliance expenses as a result of being a U.S. public company. The second main impact relates to recruitment expenses.

In 2020, wages, salaries and payroll costs, together, amounted to €15.1 million as compared with €16.8 million in 2019. This is mainly due to a decrease in staff over the period because of the COVID 19 pandemic and to the reversal of a provision related to employer’s contribution following the exercise by beneficiaries of their right to free shares.

These increases in fees and other expenses were partially offset by the decrease in rental expenses following the application of IFRS 16 for the year ended December 31, 2019.

Payroll costs increased by €1.6 million or 21% in 2021, mainly due to a change in the mix and location changes of our staff in SG&A functions (more US based employees) and a one-time severance payment related to the departure of Philippe Mauberna, the prior CFO.

As of December 31, 2021, the Company’s workforce amounted to 25 staff in SG&A functions in comparison with a Company’s workforce of 24 staff in SG&A functions during the year ended December 31, 2020 and a Company’s workforce of 29 staff in SG&A functions, including 6 additional positions created during the year ended December 31, 2019.

The impact of share-based payments (excluding employer’s contribution) on SG&A expenses amounted to €2.5 million in 2021, as compared with €2.3 million in 2020 and €3.4 million in 2019.

16.3 Payroll costs


	For the year ended December 31,
(in thousands of euros)	2021	2020	2019
Wages and salaries	(11,391)	(11,141)	(11,876)
Payroll taxes	(4,308)	(3,953)	(4,913)
Share-based payments	(3,201)	(2,924)	(4,320)
Retirement benefit obligations	(84)	(76)	(76)
Total payroll costs	(18,984)	(18,094)	(21,185)
Average headcount	96	97	112
End-of-period headcount	100	90	110

As of December 31, 2021, the Company’s workforce totaled 100 employees, compared with 90 December 31, 2020 and 110 as of December 31, 2019.

In 2021, wages, salaries and payroll costs, together, amounted to €15.7 million as compared with €15.1 million in 2020. This is mainly due to the 10 additional positions created during the year ended December 31, 2021.

In 2019, wages and salaries and payroll taxes, together, reached €16.8 million due to the Company's growth and a related increase in the number of employees during the year ended December 31, 2019, together with the impact of its compensation policy.

In accordance with IFRS 2 – Share-based Payment, the share-based payment amount recognized in the statements of operations reflects the expense associated with rights vesting during the fiscal year under the Company's share-based compensation plans. The share-based payment expenses amounted to €3.2 million for the year ended December 31, 2021, as compared with €2.9 million as of December 31, 2020 and €4.3 million as of December 31, 2019 (see Note 17).

16.4 Depreciation, amortization and provision expenses

Depreciation, amortization and provision expenses by function are detailed as follows:


	For the year ended December 31, 2021
(in thousands of euros)	R&D	SG&A	Total
Amortization expense of intangible assets	(34)	(10)	(45)
Amortization expense of tangible assets	(1,109)	(406)	(1,515)
Provision for charges	(68)	—	(68)
Total depreciation, amortization and provision expenses	(1,211)	(416)	(1,628)


	For the year ended December 31, 2020
(in thousands of euros)	R&D	SG&A	Total
Amortization expense of intangible assets	(152)	(23)	(176)
Amortization expense of tangible assets	(1,250)	(329)	(1,579)
Utilization of provision for disputes	145	—	145
Provision for charges	—	(40)	(40)
Reversal of provision for disputes	—	19	19
Total depreciation, amortization and provision expenses	(1,257)	(373)	(1,630)


	For the year ended December 31, 2019
(in thousands of euros)	R&D	SG&A	Total
Amortization expense of intangible assets	(289)	(3)	(292)
Depreciation expense of property, plant and equipment	(1,208)	(270)	(1,478)
Utilization of provision for charges	—	55	55
Provision for charges	(112)	(52)	(164)
Total depreciation, amortization and provision expenses	(1,609)	(270)	(1,879)

16.5 OTHER OPERATING INCOME AND EXPENSES


	For the year ended December 31, 2021
(in thousands of euros)	2021	2020
Contract termination indemnity (PharmaEngine)	(5,414)	—
Total Other operating income and expenses	(5,414)	—

The Company has made payments for a cumulative amount of $6.5 million (€5.4 million converted at the exchange rate on the payment date) to PharmaEngine in accordance with the termination and release agreement signed between the parties. See Note 4.2 PharmaEngine.

Share-based payments

12 Months Ended

Dec. 31, 2021

Disclosure of terms and conditions of share-based payment arrangement [abstract]

Share-based payments

Accounting policy

The Company has adopted a number of compensation plans since its inception. As of December 31, 2021, the Company had nine (9) outstanding founders’ warrant plans, twelve (12) outstanding warrant plans, nine (9) stock option plans and two (2) outstanding free shares plans.

These share-based compensation plans are settled in equity instruments.

The Company has applied IFRS 2 – Share-based Payment to all equity instruments granted to employees since 2006.

As required by IFRS 2 – Share-based Payment, the cost of remuneration paid in the form of equity instruments is recognized as an expense, with a corresponding increase in shareholders’ equity for the vesting period during which the rights with respect to the equity instruments are earned.

The fair value of the equity instruments granted to employees is measured using the Black-Scholes or Monte Carlo model, as described below.

Detail of share-based payments

The Company has granted stock options (option sur actions, ‘‘OSA’’), warrants (bons de souscription d’actions, ‘‘BSA’’), founders’ warrants (bons de souscription de parts de créateur d’entreprise, ‘‘BSPCE’’) and free shares (attributions gratuites d’actions, ‘‘AGA’’) to corporate officers, employees and members of the Supervisory Board and consultants. In certain cases, exercise of the options and warrants is subject to performance conditions. The Company has no legal or contractual obligation to pay the options in cash.

The number of options and warrants outstanding on December 31, 2021 and their main characteristics, are detailed below:

Founders’ warrants


	Pre-2021 founders’ warrant plans
	BSPCE 2012-2	BSPCE 08-2013	BSPCE 09-2014	BSPCE 2015-1	BSPCE 2015-03
Type of underlying asset	New shares	New shares	New shares	New shares	New shares
Number of founder’s warrants granted	100,000	50,000	97,200	71,650	53,050
Date of shareholders' resolution approving the plan	05/04/2012	06/28/2013	06/18/2014	06/18/2014	06/18/2014
Grant date	12/18/2012	08/28/2013	09/16/2014	02/10/2015	06/10/2015
Contractual expiration date	12/18/2022	08/28/2023	09/16/2024	02/10/2025	06/10/2025
Grant price	—	—	—	—	—
Exercise price	€6.63	€5.92	€18.68	€18.57	€20.28
Number of founders’ warrants as of Number of founders’ warrants as of December 31, 2021	100,000	50,000	86,150	68,450	30,350
Number of founders’ warrants exercised	—	—	—	—	—
Including founders’ warrants exercised during the period	—	—	—	—	—
Number of founders’ warrants lapsed or cancelled	—	—	11,050	3,200	22,700
Including founders’ warrants lapsed or cancelled during the period	—	—	—	—	350


	Pre-2021 founders’ warrant plans
	BSPCE 2016 Ordinary	BSPCE 2016 Performance	BSPCE 2017 Ordinary	BSPCE 2017
Type of underlying asset	New shares	New shares	New shares	New shares
Number of founder’s warrants granted	126,400	129,250	117,650	80,000
Date of shareholders' resolution approving the plan	06/25/2015	06/25/2015	06/23/2016	06/23/2016
Grant date	02/02/2016	02/02/2016	01/07/2017	01/07/2017
Contractual expiration date	02/02/2026	02/02/2026	01/08/2027	01/07/2027
Grant price	—	—	—	—
Exercise price	€14.46	€14.46	€15.93	€15.93
Number of founders’ warrants as of December 31, 2021	100,567	100,274	99,500	80,000
Number of founders’ warrants exercised	333	—	—	—
Including founders’ warrants exercised during the period	—	—	—	—
Number of founders’ warrants lapsed or cancelled	25,500	28,976	18,150	—
Including founders’ warrants lapsed or cancelled during the period	350	1,426	1,350	—

Warrants


	Pre-2021 warrant plans
	BSA 04-2012	BSA 2013	BSA 2014	BSA 2015-1	BSA 2015-2 (a)	BSA 2015-2 (b)	BSA 2016 ordinary
Type of warrants	New shares	New shares	New shares	New shares	New shares	New shares	New shares
Number of warrants granted	52,500	10,000	14,000	26,000	64,000	6,000	18,103
Date of shareholders' resolution approving the plan	05/04/2012	05/04/2012	06/18/2014	06/18/2014	06/18/2014	06/25/2015	06/25/2015
Grant date	05/04/2012	04/10/2013	09/16/2014	02/10/2015	06/25/2015	06/25/2015	02/02/2016
Contractual expiration date	05/04/2022	04/10/2023	09/16/2024	02/10/2025	06/25/2025	06/25/2020	02/02/2021
Grant price	€0.60	€2.50	€4.87	€4.87	€5.00	€2.80	€1.67
Exercise price	€6.00	€6.37	€17.67	€17.67	€19.54	€19.54	€13.74
Number of warrants as of December 31, 2021	30,000	6,000	10,000	21,000	64,000	—	—
Number of warrants exercised	22,500	—	—	—	—	—	—
Including warrants exercised during the period	—	—	—	—	—	—	—
Number of warrants lapsed or cancelled	—	4,000	4,000	5,000	—	6,000	18,103
Including warrants lapsed or cancelled during the period	—	—	—	—	—	—	18,103


	Pre-2021 warrant plans
	BSA 2016 performance	BSA 2016-2	BSA 2017	BSA 2018-1	BSA 2018-2	BSA 2019-1	BSA 2020
Type of warrants	New shares	New shares	New shares	New shares	New shares	New shares	New shares
Number of warrants granted	18,105	8,000	18,000	28,000	5,820	18,000	18,000
Date of shareholders' resolution approving the plan	06/25/2015	06/23/2016	06/23/2016	06/14/2017	05/23/2018	05/23/2018	04/11/2019
Grant date	02/02/2016	11/03/2016	01/07/2017	03/06/2018	07/27/2018	03/29/2019	03/17/2020
Contractual expiration date	02/02/2021	11/03/2021	01/07/2022	03/06/2023	07/27/2028	03/29/2029	03/17/2030
Grant price	€1.67	€2.03	€2.26	€1.62	€2.36	€1.15	€0.29
Exercise price	€13.74	€15.01	€15.76	€13.55	€16.102	€11.66	€6.59
Number of warrants as of December 31, 2021	—	—	18,000	28,000	5,820	18,000	18,000
Number of warrants exercised	—	—	—	—	—	—	—
Including warrants exercised during the period	—	—	—	—	—	—	—
Number of warrants lapsed or cancelled	18,105	8,000	—	—	—	—	—
Including warrants lapsed or cancelled during the period	18,105	8,000	—	—	—	—	—


	2021 warrants
	BSA 2021 (a)	BSA 2021 (b)
Type of warrants	New shares	New shares
Number of warrants granted	48,103	30,000
Date of shareholders' resolution approving the plan	11/30/2020	11/30/2020
Grant date	04/20/2021	04/20/2021
Contractual expiration date	04/20/2031	04/20/2031
Grant price	€2.95	€0.68
Number of warrants as of Exercise price	€13.47	€13.64
Number of warrants as of December 31, 2021	14,431	30,000
Number of warrants exercised	—	—
Including warrants exercised during the period	—	—
Number of warrants lapsed or cancelled	33,672	—
Including warrants lapsed or cancelled during the period	33,672	—

Stock options


	Pre-2021 stock option plans
	OSA 2016-1 Performance	OSA 2016-2	OSA 2017 Ordinary	OSA 2018	OSA 2019-1	OSA LLY 2019	OSA 2020
Type of underlying asset	New shares	New shares	New shares	New shares	New shares	New shares	New shares
Number of options granted	6,400	4,000	3,500	62,000	37,500	500,000	407,972
Date of shareholders' resolution approving the plan	06/25/2015	06/23/2016	06/23/2016	06/14/2017	05/23/2018	04/11/2019	04/11/2019
Grant date	02/02/2016	11/03/2016	01/07/2017	03/06/2018	03/29/2019	10/24/2019	03/11/2020
Contractual expiration date	02/02/2026	11/03/2026	01/07/2027	03/06/2028	03/29/2029	10/24/2029	03/11/2030
Grant price	—	—	—	—	—	—	—
Exercise price	€13.05	€14.26	€14.97	€12.87	€11.08	€6.41	€6.25
Number of options as of December 31, 2021	400	4,000	500	52,000	28,250	500,000	387,456
Number of options exercised	—	—	—	—	—	—	—
Number of options as of Including options exercised during the period	—	—	—	—	—	—	—
Number of options lapsed or cancelled	6,000	—	3,000	10,000	9,250	—	13,253
Including options lapsed or cancelled during the period	—	—	—	—	500	—	13,253


	2021 stock option plans
	OSA 2021-04	OSA 2021-06
Type of underlying asset	New shares	New shares
Number of options granted	571,200	120,000
Date of shareholders' resolution approving the plan	11/30/2020	04/28/2021
Grant date	04/20/2021	06/21/2021
Contractual expiration date	04/20/2031	06/21/2031
Grant price	—	—
Exercise price	€13.74	€12.99
Number of options as of December 31, 2021	491,200	120,000
Number of options exercised	—	—
Number of options as of Including options exercised during the period	—	—
Number of options lapsed or cancelled	80,000	—
Including options lapsed or cancelled during the period	80,000	—

Free shares


	Pre-2021 free shares plan not yet vested				2021 free shares plan
	AGA 2018-1	AGA 2018-2	AGA 2019-1	AGA 2020	AGA 2021
Type of underlying assets	New shares	New shares	New shares	New shares	New shares
Number of free shares granted	396,250	6,000	438,250	50,000	362,515
Date of shareholders' resolution approving the plan	06/14/2017	05/23/2018	05/23/2018	04/11/2019	11/30/2020
Grant date	03/06/2018	07/27/2018	03/29/2019	03/11/2020	04/20/2021
Grant price	—	—	—	—	—
Exercise price	—	—	—	—	—
Number of free shares as of December 31, 2021	—	—	—	50,000	360,512
Number of free shares exercised	340,583	6,000	369,250	—	—
Including free shares exercised during the period	24,500	—	369,250	—	—
Number of free shares lapsed or cancelled	55,667	—	69,000	—	2,003
Including free shares lapsed or cancelled during the period	—	—	2,750	—	2,003


	BSPCE	BSA	OSA	AGA	Total
Total number of shares underlying grants outstanding as of December 31, 2021	715,291	263,251	1,583,806	410,512	2,972,860


	BSPCE	BSA	OSA	AGA	Total
Total number of shares underlying grants outstanding as of December 31, 2020	718,767	263,028	986,359	446,500	2,414,654


	BSPCE	BSA	OSA	AGA	Total
Total number of shares underlying grants outstanding as of December 31, 2019	751,585	251,028	589,150	746,250	2,338,013

The measurement methods used to estimate the fair value of stock options, warrants and free shares are described below:

•The share price on the grant date is equal to the exercise price, except for the BSA 2014 which exercise price was set at €40, taking into account both the average share price on the 20 days preceding the grant date and the expected development perspectives of the Company;

•The risk-free rate was determined based on the average life of the instruments; and

•Volatility was determined based on a sample of listed companies in the biotechnology sector on the grant date and for a period equal to the life of the warrant or option.

The performance conditions for all of the plans were assessed as follows:

•Performance conditions unrelated to the market were analyzed to determine the likely exercise date of the warrants and options and expense was recorded accordingly based on the probability these conditions would be met; and

•Market-related performance conditions were directly included in the calculation of the fair value of the instruments.

Except for the 2012-1 founders’ warrants, the fair value of the warrants and options was measured using the Black-Scholes model.

The fair value of 2012-1 founders’ warrants was determined using the Monte Carlo valuation model to take into account the exercise conditions, which depend on the realized gain compared to the expected stock market listing price.

The probability of meeting the performance conditions for the 2016 BSPCE, BSA and OSA performance plans was reassessed as of December 31, 2021. As a consequence , no new instrument became issuable.


BSPCE	Share price (in euros)	Exercise price (in euros)	Volatility		Maturity (in years)	Risk-free rate		Yield		Value of initial plan (in thousands of euros)	Expense for the year ended 2021 (in thousands of euros)	Expense for the year ended 2020 (in thousands of euros)	Expense for the year ended 2019 (in thousands of euros)
BSPCE 2012-1	5.26	5.26	41	%	3.49	0.20	%	0.00	%	307	—	—	—
BSPCE 2012-2	6.65	6.63	44.3% - 47.6%		5 - 7.30	0.84% - 1.22%		0.00	%	288	—	—	—
BSPCE 04-2013	6.30	6.30	56	%	5	0.90	%	0.00	%	167	—	—	—
BSPCE 08-2013	6.30	5.92	256	%	7	0.90	%	0.00	%	152	—	—	—
BSPCE 09-2014	18.68	18.68	58	%	5.5/6/6.5	0.64	%	0.00	%	932	—	—	—
BSPCE 2015-1	18.57	18.57	58% - 62% - 61%		5.5/6/6.5	0.39	%	0.00	%	50	—	—	—
BSPCE 2015-2	18.57	18.57	58% - 62% - 61%		5.5/6/6.5	0.39	%	0.00	%	650	—	—	—
BSPCE 2015-3	20.28	20.28	61% - 62% - 61%		5.5/6/6.5	0.56	%	0.00	%	483	—	—	—
BSPCE 2016 Ordinary	14.46	14.46	59% - 62% - 60%		5.5/6/6.5	0.32	%	0.00	%	1,080	—	—	10
BSPCE 2016 Performance	14.46	14.46	59	%	5	0.19	%	0.00	%	1,212	32	99	79
BSPCE 2017 Ordinary	15.93	15.93	58% - 61% - 59%		5.5/6/6.5	0.23	%	0.00	%	1,000	0	8	86
BSPCE 2017 Performance	15.93	15.93	59	%	5	0.11	%	0.00	%	622	—	—	—
BSPCE 2017	15.93	15.93	59	%	5	0.11	%	0.00	%	627	—	—	—
BSPCE 2017 Project	15.93	15.93	59	%	5	0.11	%	0.00	%	94	—	—	—
Total BSPCE	n.a.	n.a.	n.a.		n.a.	n.a.		n.a.		n.a.	32	107	175


BSA	Share price (in euros)	Exercise price (in euros)	Volatility		Maturity (in years)	Risk-free rate		Yield		Value of initial plan (in thousands of euros)	Expense for the year ended 2021 (in thousands of euros)	Expense for the year ended 2020 (in thousands of euros)	Expense for the year ended 2019 (in thousands of euros)
BSA 2012	6.00	6.00	49	%	10	0.96	%	0.00	%	183	—	—	—
BSA 2013	6.30	6.37	156	%	6	0.90	%	0.00	%	1	—	—	—
BSA 2014	18.68	17.67	57	%	5	0.41	%	0.00	%	—	—	—	—
BSA 2015-1	17.67	17.67	58	%	5	0.26% - 0.27%		0.00	%	63	—	—	—
BSA 2015-2	17.67	19.54	58%-58%-57%-58%		5/5.1/5.3/5.4	0.39	%	0.00	%	16	—	—	—
BSA 2015-3	19.54	19.54	58% - 60%		4.6 – 9.6	0.25% - 0.91%		0.00	%	284	—	—	—
BSA 2016o-1	13.74	13.74	57	%	2.4	0.00	%	0.00	%	37	—	—	—
BSA 2016p-1	13.74	13.74	57	%	2.4	0.00	%	0.00	%	143	—	—	(41)
BSA 2016-2	15.01	15.01	57	%	2.4	0.00	%	0.00	%	—	—	—	—
BSA 2017o-1	15.76	15.76	33	%	2.4	0.00	%	0.00	%	—	—	—	—
BSA 2018-1	13.55	13.55	38	%	4.8	0.7% - 0.1%		0.00	%	2	—	—	—
BSA 2018-2	16.102	16.102	38	%	4.8	0.7% - 0.1%		0.00	%	1	—	—	—
BSA 2019-1	11.66	11.66	37	%	9.8/9.9	0.16% - 0.50%		0.00	%	24	—	—	24
BSA 2020	—	6.59	38	%	10	-0.13%/ -0.07%		0.00	%	19	—	19	—
BSA 2021 (a)	13.47	13.47	39.10	%	10	0.27	%	0.00	%	44	44	—	—
BSA 2021 (b)	n.a.	13.64	n.a.		10	0.27	%	0.00	%	—	—	—	—
Total BSA	n.a.	n.a.	n.a.		n.a.	n.a.		n.a.		n.a.	44	19	(16)


OSA	Share price (in euros)	Exercise price (in euros)	Volatility		Maturity (in years)	Risk-free rate		Yield		Value of initial plan (in thousands of euros)	Expense for the year ended 2021 (in thousands of euros)	Expense for the year ended 2020 (in thousands of euros)	Expense for the year ended 2019 (in thousands of euros)
OSA 2016 Ordinary	13.05	13.05	59% - 62% - 60%		5.5 / 6 /6.5	0.32	%	0.00	%	117	—	—	—
OSA 2016 Performance	13.05	13.05	59	%	5	0.19	%	0.00	%	69	—	—	—
OSA 2016-2	14.26	14.26	58% - 62% - 59%		5.5 / 6 /6.5	0.04	%	0.00	%	27	—	—	3
OSA 2017 Ordinary	15.93	14.97	58% - 61% - 59%		5.5 / 6 /6.5	0.23	%	0.00	%	31	—	—	1
OSA 2017 Performance	15.93	14.97	59	%	5	0.11	%	0.00	%	35	—	—	—
OSA 2018	12.87	12.87	35	%	5.5 / 6 /6.5	0.00	%	0.00	%	252	—	7	66
OSA 2019-1	11.08	11.08	38.1% / 37.4%		6 /6.5	0.103% / 0.149%		0.00	%	140	17	49	38
OSA 2019-2	6.41	6.41	37	%	10	0.40	%	0.00	%	252	—	—	436
OSA 2020	6.25	6.25	38	%	10	0.31	%	0.00	%	939	329	453	—
OSA 2021-04 O	13.60	13.74	38.9% - 37.8% - 38.3%		5.5 / 6 /6.5	-0.38%/ -0.33%/ -0.28%		0.00	%	684	188	—	—
OSA 2021-04 P	13.60	13.74	39.10	%	10	0.03	%	0.00	%	1,816	131	—
OSA 2021-06 O	12.20	12.99	39.2% / 37.9% / 38.1%		5.5 / 6 /6.5	-0.35 %/ -0.3 %/ -0.26 %		0.00	%	246	79	—	—
OSA 2021-06 P	12.20	12.99	39.10	%	10	0.13	%	0.00	%	212	16	—
Total OSA	n.a.	n.a.	n.a.		n.a.	n.a.		n.a.		n.a.	760	509	543


AGA	Share price (in euros)	Exercise price (in euros)	Volatility	Maturity (in years)	Risk-free rate		Yield		Value of initial plan (in thousands of euros)	Expense for the year ended 2021 (in thousands of euros)	Expense for the year ended 2020 (in thousands of euros)	Expense for the year ended 2019 (in thousands of euros)
AGA 2018-1	12.87	0.00	n.a.	n.a.	0.00	%	0.00	%	4,951	16	268	2,052
AGA 2018-2	12.87	0.00	n.a.	n.a.	0.00	%	0.00	%	75	—	21	37
AGA 2019-1	10.90	0.00	n.a.	n.a.	0.19% / 0.141%		0.00	%	4,776	422	1,884	1,529
AGA 2020	5.90	0.00	n.a.	n.a.	-0.74%/-0.69%		0.00	%	287	144	116	—
AGA 2021	13.60	0.00	n.a.	n.a.	-0.63%/ -0.59%		0.00	%	4,869	1,784	—	—
Total AGA	n.a.	n.a.	n.a.	n.a.	n.a.		n.a.		n.a.	2,366	2,289	3,618


(in thousands of euros)	BSPCE	BSA	OSA	AGA	Total
Expense for the year ended December 31, 2021	32	44	760	2,366	3,202


(in thousands of euros)	BSPCE	BSA	OSA	AGA	Total
Expense for the year ended December 31, 2020	107	19	509	2,289	2,924


(in thousands of euros)	BSPCE	BSA	OSA	AGA	Total
Expense for the year ended December 31, 2019	175	(16)	543	3,618	4,320

Net financial income (loss)

12 Months Ended

Dec. 31, 2021

Income, expense, gains or losses of financial instruments [abstract]

Net financial income (loss)


	For the years ended December 31,
(in thousands of euros)	2021	2020	2019
Income from cash and cash equivalents	—	—	105
Foreign exchange gains	6,347	104	599
Other financial income	13	97	133
Total financial income	6,360	201	837
Interest cost	(383)	4,676	(4,434)
IFRS 16 related interests	(288)	(333)	(359)
Foreign exchange losses	(109)	(1,697)	(176)
Total financial expenses	(780)	2,646	(4,970)
Net financial income (loss)	5,580	2,847	(4,133)

For the year ended December 31, 2021, the interest cost was a negative net amount of €383 thousands, mainly due to the EIB loan interest and discounting impact (see Note 12.1 Conditional advance, bank loan and loans from government and public authorities) which was a net income of €4.2 million in 2021 as a result of the EIB royalties sales reforecast catch up effect and the accretion of the debt cost, offset by €1.8 million impact of EIB fixed interest cost.

For the year ended December 31, 2020, the interest cost was a positive net amount of €4.7 million, substantially due to the EIB loan interests and discounting impact (see Note 12.1 Conditional advance, bank loan and loans from government and public authorities) which was a net income of €4.8 million in 2020 as a result of the EIB royalties sales reforecast catch up effect and the accretion of the debt cost, offset by €1.7 million impact of EIB fixed interest cost.

In 2021, the Company had foreign exchange gains for the total amount of €6.3 million. This impact was primarily arising from the foreign exchange gains realized by the Company related to the HSBC bank account denominated in U.S. dollars.

In 2020, the Company had foreign exchange losses for the total amount of €1.7 million. This impact was first arising from retaining $113.3 million from the gross proceeds of the global offering in a US dollar bank account.

Income tax

12 Months Ended

Dec. 31, 2021

Income taxes paid (refund) [abstract]

Income tax

Accounting policy

The Company and its subsidiaries are subject to income tax in their respective jurisdictions.

Deferred taxes are recognized on a full provision basis using the liability method for all temporary differences between the tax basis and accounting basis of assets and liabilities in the financial statements.

The main temporary differences relate to tax loss carryforwards. The prevailing income tax rates on the reporting date are used to determine deferred taxes. Deferred tax assets, which mainly arise as a result of tax loss carryforwards, are only recognized to the extent that it is probable that sufficient taxable income will be available in the future against which to offset the tax loss carryforwards or the temporary differences. Management uses its best judgment to determine such probability. Given the Company’s current stage of development and its short-term earnings outlook, the Company is unable to make sufficiently reliable forecasts of future earnings and accordingly, deferred tax assets have not been recognized and offset only to the extent of deferred tax liabilities in the same taxable entities.

Detail of income tax

As of December 31, 2021, in accordance with the applicable legislation, the Company has €284 million of evergreen tax losses in France, in comparison with €235 million and €184.3 million of evergreen tax losses in France as of December 31, 2020 and 2019, respectively. For fiscal years ended on or after December 31, 2018, the use of tax loss carryforwards in France is capped at €1.0 million, plus 50% of the portion of profits in excess of that limit.

The cumulative tax loss carryforwards for the U.S. entities of the Company totaled $3.4 million as of December 31, 2021, $4.4 million as of December 31, 2020 and $4.8 million in the United States as of December 31, 2019. The tax loss carryforwards that were generated before January 1, 2018 will expire 20 years after they were generated; those generated after that date have an indefinite carryforward. The tax loss carryforwards in the U.S. comply with the federal and each state’s Net Operating Loss (“NOL”) rules updated by the Tax Cuts and Jobs Act (“TCJA”) of 2017.

The following table reconciles the Company’s theoretical tax expense to its effective tax expense:


	For the year ended December 31,
(in thousands of euros)	2021		2020		2019
Net loss	(47,003)		(33,590)		(50,915)
Effective tax expense	5		9		3
Recurring loss before tax	(47,058)		(33,581)		(50,912)
Theoretical tax rate (statutory rate in France)	26.50	%	28.00	%	31.00	%
Theoretical tax (benefit) expense	(12,470)		(9,403)		(15,782)
Share-based payment	848		819		1,339
Other temporary differences	117		(6)		(1)
Other non-taxable items	(644)		(540)		(736)
Unrecognized tax losses	12,154		9,138		15,177
Effective tax expense	5		9		3
Effective tax rate	0.00	%	0.00	%	0.00	%

The cumulative net unrecognized deferred tax assets amounted to €75.4 million in 2021, including €14.0 million of 2021 net operating loss carryforwards in comparison with €60.2 million in 2020, including €59.6 million of 2020 net operating loss carryforwards and €51.0 million in 2019, including €49.6 million of 2019 net operating loss carryforwards.

The deferred tax rate of the Company is 25.8% in 2021, 26.5% in 2020, and 25.49% in 2019, based on enacted tax rate reductions in future years.

Segment reporting	12 Months Ended
Segment reporting	Dec. 31, 2021
Disclosure of operating segments [abstract]
Segment reporting	Segment reporting In accordance with IFRS 8 – Operating Segments, reporting by operating segment is derived from the internal organization of the Company’s activities; it reflects management’s viewpoint and is established based on internal reporting used by the chief operating decision maker (the Company’s Chief Executive Officer and Chairmen of the Executive Board and of the Supervisory Board) to allocate resources and to assess performance. The Company operates in a single operating segment: research and development in product candidates that harness principles of physics to transform cancer treatment. The assets, liabilities and operating loss realized are primarily located in France. Revenue in 2021, 2020 and 2019 was derived mainly from the charging-back of shared external clinical research organization costs, in connection with the development support provided by the Company to PharmaEngine as part of the Company's License and Collaboration Agreement in Asia by Nanobiotix S.A. (see Note 15). For territorial analysis purposes, management allocates revenue based on the place of delivery of licenses or on the place in which services are provided.

Loss per share

12 Months Ended

Dec. 31, 2021

Earnings per share [abstract]

Loss per share

Accounting policy

Loss per share is calculated by dividing the net loss due to shareholders of the Company by the weighted average number of ordinary shares outstanding during the period.

The diluted loss per share is calculated by dividing the results by the weighted average number of common shares in circulation, increased by all dilutive potential common shares. The dilutive potential common shares include, in particular, the share subscription warrants, stock options and founder subscription warrants as detailed in Note 17.

Dilution is defined as a reduction of earnings per share or an increase of loss per share. When the exercise of outstanding share options and warrants decreases loss per share, they are considered to be anti-dilutive and excluded from the calculation of loss per share.


	For the year ended December 31,
	2021	2020	2019
Net loss for the period (in thousands of euros)	(47,063)	(33,590)	(50,915)
Weighted average number of shares	34,733,418	24,385,827	21,631,514
Basic loss per share (in euros)	(1.35)	(1.38)	(2.35)
Diluted loss per share (in euros)	(1.35)	(1.38)	(2.35)

Instruments providing deferred access to the capital are considered to be anti-dilutive because they result in a decrease in the loss per share. Therefore, diluted loss per share is identical to basic loss per share as all equity instruments issued but not granted, representing as of December 31, 2021, 3,006,532 potential additional ordinary shares, have been considered antidilutive.

Commitments	12 Months Ended
Commitments	Dec. 31, 2021
Disclosure Of Commitments [Abstract]
Commitments	Commitments 22.1 Obligations under the loan agreement with the EIB In the event the EIB loan is repaid early, or in the event of a change of control after repayment of the loan, the amount of royalties due will be equal to the net present value of the royalties as determined by an independent expert, such amount not to be less than €35.0 million. The EIB finance contract contains covenants that impose restrictions on the operation of the Company's business but no financial covenants that the Company is required to comply with. In certain circumstances, including any material adverse change, a change of control of the Company or if Dr. Laurent Levy, Chairman of the Executive Board, ceases to hold office, the Company may be required to pay a cancellation fee. If Dr. Laurent Levy ceases to hold a certain number of shares or ceases to be an officer, the EIB may require early repayment of the loan. 22.2 Obligations under the terms of the rental agreements part of the IFRS 16 exemptions The obligations of the Company related to the leases falling under the practical expedients (leases related to low-value assets and short-term leases) are as follow: •One short term lease for an office by Nanobiotix Corp., of which the annual rent is €140 thousand; and •Leases related to low-value assets for Nanobiotix S.A.’s printers, of which the annual rent is around €10 thousand. 22.3 Obligations related to the MD Anderson agreement In January 2019, the Company and the University of Texas MD Anderson Cancer Center, world prominent center of research, education, prevention and care for cancer patients announced a large-scale research collaboration. The collaboration will support multiple new Phase I/II clinical trials involving around 340 patients with Nanobiotix’s first-in-class agent NBTXR3 for use in treating several cancer types – including head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers. As part of the funding for this collaboration, Nanobiotix is committed to pay approximately $11 million for those clinical trials during the collaboration, and made an initial $1.0 million payment at the commencement of the collaboration and a second $1.0 million payment on February 3, 2020. Additional payments will be made in the 6 months following a patient enrollment, and expense is recorded in the statement of consolidated operations during the course of the collaboration on the basis of patients enrolled during the relevant period, with the balance payable upon enrollment of the final patient for all studies. Nanobiotix may also be required to pay an additional one-time milestone payment upon (i) grant of the first regulatory approval by the Food and Drug Administration in the United States and (ii) the date on which a specified number of patients have been enrolled in the clinical trials. The milestone payment increases on an annual basis ranging from $2.2 million to $16.4 million. The amount will be determined on the basis of patients enrolled in the clinical trials at the date of FDA registration. This number increases every year and varies between $2.2 million (if it had been payable in 2020) and $16.4 million (if payable in 2030). As of December 31, 2021, €1.8 million have already been invoiced since the beginning of the collaboration and €1.0 million remain in prepaid expenses. An additional payment will also occur in the event of a successful first registration of NBTXR3 with the FDA. 22.4 Obligations related to the termination of the PharmaEngine agreement In March 2021, the Company and PharmaEngine mutually agreed to terminate the license and collaboration agreement entered into in August 2012. During the year ended December 31, 2021, the Company paid $6.5 million to PharmaEngine (€5.4 million converted at the exchange rate on the payment date) in accordance with the termination agreement signed between the parties. PharmaEngine is eligible to receive additional payments of $1 million upon receipt by the Company of clinical study reports and of $5 million upon the second regulatory approval of NBTXR3 in any jurisdiction in the world and for any indication. The Company has also agreed to pay royalties to PharmaEngine at low single-digit royalty rates with respect to sales of NBTXR3 in the Asia-Pacific region for a 10-year period beginning at the date of the first sales in the region.

Related parties

12 Months Ended

Dec. 31, 2021

Related parties

Key management personnel compensation

The compensation presented below, granted to the members of the Executive Board and Supervisory Board was recognized in expenses over the period shown:


	For the year ended December 31,
(in thousands of euros)	2021	2020	2019
Salaries, wages and benefits	1,245	1,073	1,306
Share-based payments	2,018	1,723	2,066
Supervisory Board’s fees	375	70	70
Total compensation to related parties	3,638	2,866	3,442

The methods used to measure share-based payments are presented in Note 17.

Subsequent events	12 Months Ended
Subsequent events	Dec. 31, 2021
Disclosure of non-adjusting events after reporting period [abstract]
Subsequent events	Subsequent events Accounting policy The statements of consolidated financial position and statements of consolidated operations are adjusted for post-closing events prior to the approval of the financial statements for issuance as long as they have a significant impact of the amounts presented at the closing date of the statement of financial position. If they do not, they are disclosed. Detail of subsequent events Considerations arising from the Russia-Ukraine war Russia launched in February 2022 the invasion of Ukraine, which, in addition to creating humanitarian concerns, may also impact the health care ecosystem in the form of delayed clinical trials. Clinical trial sites originally appointed in Russia and Ukraine for the clinical trial NANORAY-312 were not actively opened at the time of such conflict and, consequently, did not recruit patients. While backup options are being identified and the replacement of such sites by sites located in other countries is actively conducted by the Company, it is currently impossible to exclude any delay in this clinical trial activity, even if no significant delay has been identified as of the date of issuance of this Annual Report. Share capital increase On March 11, 2022, the share capital of the Company was increased by a nominal amount of €1,500, through the issuance of 50,000 new ordinary shares with a nominal value of €0.03 each, increasing the Company’s share capital from €1,044,776.16 to €1,046,276.16, as a result of the definitive acquisition of 50,000 AGA 2020. Such acquisition was acknowledged by the Executive Board on March 11, 2022.

Consolidation principles and methods (Policies)	12 Months Ended
Consolidation principles and methods (Policies)	Dec. 31, 2021
Significant Accounting Policies [Abstract]
General principles, Statement of Compliance and Basis of Presentation	General principles The statement of consolidated financial position as of December 31, 2021 and 2020 and the statements of consolidated operations, the statements of consolidated comprehensive loss, the consolidated changes in shareholders’ equity and statements of consolidated cash flows for the years ended December 31, 2021, 2020 and 2019 were prepared under management’s supervision and were approved by the Executive Board of the Company (the “Executive Board”) and reviewed by the Supervisory Board of the Company (the “Supervisory Board”) on March 30, 2022. All amounts presented in the consolidated financial statements are presented in thousands of euros, unless stated otherwise. Some figures have been rounded. Accordingly, the totals in some tables may not be the exact sums of component items. The preparation of the consolidated financial statements in accordance with International Financial Reporting Standards (‘‘IFRS’’) requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements (see Note 3.2 for additional information). The consolidated financial statements have been prepared using the historical cost measurement basis, with the exception of financial assets and liabilities, which are measured at fair value. The consolidated financial statements were prepared on a going concern basis. The Executive Board determined it is appropriate to apply a going concern assumption because the Company’s historical losses are due to the innovative nature of the products it is developing, which necessitates a research and development phase spanning several years. With cash and cash equivalents of €83,921 thousand as of December 31, 2021, as compared to €119,151 thousand as of December 31, 2020, the Company believes it has sufficient resources to continue operating for at least twelve months following the consolidated financial statements’ publication. Statement of Compliance and Basis of Presentation The consolidated financial statements have been prepared in accordance with IFRS, International Accounting Standards (“IAS”) as issued by the International Accounting Standards Board (“IASB”) as well as interpretations issued by the IFRS Interpretations Committee (“IFRS-IC”) and the Standard Interpretations Committee (the “SIC”), which application is mandatory as of December 31, 2021. The consolidated financial statements are also compliant with IFRS as adopted by the European Union. Those are available on the European Commission website: https://ec.europa.eu/info/law/international-accounting-standards-regulation-ec-no-1606-2002 The accounting principles used to prepare the consolidated financial statements for the fiscal year ended December 31, 2021 are identical to those used for the previous year except for the standards listed below that required adoption in 2021. Application of New or Amended Standards and Interpretations The Company adopted the following standards, amendments and interpretations, whose application was mandatory for periods beginning on or after January 1, 2021: •Amendments to IAS 39, IFRS 9, IFRS 7 and IFRS 16 related to the interest rate benchmark reform - Phase 2; and •Amendments to IFRS 16 - Covid-19 Related rent concession. The application of these standards had no impact on the consolidated financial statements of the Company. Application of New or Amended Standards and Interpretations early adopted by the Company The Company elected to early adopt no new standards, amendments and interpretations which application was not yet mandatory for the year ended December 31, 2021. Application of New or Amended Standards and Interpretations not yet applied by the Company The application of the following new standards, amendments and interpretations was not yet mandatory for the year ended December 31, 2021 : •IFRS 17 - Insurance contracts and related amendments. No impact expected on the financial statements. •Amendment to IAS 1 - Classification of Liabilities as Current or Non-Current, Disclosure of significant accounting policies, and Update of Practice Statement 2 "Making materiality”. No significant impact expected on the financial statements. •Amendment to IAS 37 - Onerous Contracts - Cost of Fulfilling a Contract. No significant impact expected on the financial statements. •Amendment to IFRS 3 - Conceptual framework. No significant impact expected on the financial statements. •Amendment to IAS 8 - Definition of an accounting estimate. No significant impact expected on the financial statements. •Amendments to IAS 16 - Property, Plant and Equipment: Proceeds before Intended Use. No significant impact expected on the financial statements.
Basis of consolidation	3.1 Basis of consolidation Accounting policy In accordance with IFRS 10 – Consolidated Financial Statements, an entity is consolidated when it is controlled by the Company. The Company has decision-making authority over the financial and operating policies of all its subsidiaries and holds greater than 50% of the voting rights of each subsidiary. Accordingly, each of the Company’s subsidiaries has been fully consolidated from the date on which the Company obtained control over it. A subsidiary would be deconsolidated as of the date on which the Company no longer exercises control. All intra-Company balances, transactions, unrealized gains and losses resulting from intra-Company transactions and all intra-Company dividends are eliminated in full. The accounting methods of the Company’s subsidiaries are aligned with those of the Company. The consolidated financial statements are presented in euros, which is the reporting currency and the functional currency of the parent company, Nanobiotix S.A. The financial statements of consolidated foreign subsidiaries whose functional currency is not the euro are translated into euros for statement of financial position items at the closing exchange rate at the date of the statement of financial position and for the statement of operations, statement of comprehensive loss and statement of cash flow items at the average rate for the period presented, except where this method cannot be applied due to significant exchange rate fluctuations during the applicable period. The dollar to euro exchange rate used in the consolidated financial statements to convert the financial statements of the U.S. subsidiary were $1.1326 as of December 31, 2021 and an average of $1.1835 for the year ended December 31, 2021 (source: Banque de France) compared with $1.2271 and $1.1413, for 2020 and $1.1234 and $1.1196 for 2019, respectively. The resulting currency translation adjustments are recorded in other comprehensive income (loss) as a cumulative currency translation adjustment. Consolidated entities As of December 31, 2021, the Company involves one parent entity, “Nanobiotix S.A.,” and five wholly owned subsidiaries: •Nanobiotix Corp., incorporated in the State of Delaware in the United States in September 2014; •Nanobiotix Germany GmbH, incorporated in Germany in October 2017; •Nanobiotix Spain S.L.U., incorporated in Spain in December 2017; •Curadigm S.A.S., incorporated on July 3, 2019 and located in France; and •Curadigm Corp., a wholly-owned subsidiary of Curadigm S.A.S., incorporated in the State of Delaware on January 7, 2020 and headquartered in Boston, Massachusetts. The consolidated financial statements as of and for the year ended December 31, 2021 include the operations of each of these subsidiaries from the date of their incorporation. Accordingly, the consolidated financial statements as of and for the year ended December 31, 2020 include the operations of each of these subsidiaries from the date of their incorporation. The consolidated financial statements as of and for the year ended December 31, 2019 include the operations of each of these subsidiaries from the date of their incorporation, excluding Curadigm Corp which was created in 2020.
Use of judgement, estimates and assumptions	3.2 Use of judgement, estimates and assumptions The preparation of consolidated financial statements in accordance with IFRS requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. The estimates and judgments used by management are based on historical information and on other factors, including expectations about future events considered to be reasonable given the circumstances. These estimates may be revised where the circumstances on which they are based change. Consequently, actual results may vary significantly from these estimates under different assumptions or conditions. The main items affected by the use of estimates are share-based payments, deferred tax assets, clinical trials accruals, revenue recognition and the fair value of financial instruments. Measurement of share-based payments The Company measures the fair value of stock options (OSA), founders’ warrants (BSPCE), warrants (BSA) and free shares (AGA) granted to employees, members of the Supervisory Board and consultants based on actuarial models. These actuarial models require that the Company use certain calculation assumptions with respect to characteristics of the grants (e.g., vesting terms) and market data (e.g., expected share volatility) (see Note 17). Deferred tax assets Deferred taxes are recognized for temporary differences arising from the difference between the tax basis and the accounting basis of the Company’s assets and liabilities that appear in its financial statements. The primary temporary differences are related to the tax losses that can be carried forward or backward, depending on the jurisdiction. Enacted tax rates are used to measure deferred taxes (see Note 19). The deferred tax assets are recorded in the accounts only to the extent that it is probable that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow income projections judged to be sufficiently reliable to be made, the Company has not recognized deferred tax assets in relation to tax losses carryforwards in the Statements of Consolidated Financial Position. Clinical trial accruals Clinical trial expenses, although not yet billed in full, are estimated for each study and a provision accrual is recognized accordingly. See Note 13.1 for information regarding the clinical trial accruals as of December 31, 2021 and 2020. Revenue recognition In order to determine the amount and timing of revenue under the contract with LianBio, the Company is required to use significant judgments, mainly with respect to identifying performance obligations of the Company and determining the timing of satisfaction of support services provided to LianBio. See Note 15 for additional detail regarding the Company’s accounting policies for its additional sources of revenue. Fair value of financial assets and liabilities The fair value measurement of the loan granted by European Investment Bank (“EIB”) requires the Company to assess the amount of additional interest (“royalties”, as defined by the royalty agreement with EIB) that will be due according to the loan agreement during a royalty calculation period commencing on January 1, 2021. The royalties due during this period will be determined and calculated based on the number of tranches that have been withdrawn and will be indexed to the Company’s annual sales turnover. For the purpose of measuring the fair value of the EIB loan, the Company forecasts the sales that it expects to generate during the royalty period, taking into consideration the operational assumptions such as market release dates of the products, growth and penetration rate in each market. (see notes 4.2 and 12 for details about this loan and the accounting treatment applied).
Intangible assets	Accounting policies In accordance with IAS 38 – Intangible Assets, intangible assets are carried at their acquisition cost. Research and Development costs Research costs are recorded in expenses in the period during which they are incurred. Under IAS 38 – Intangible Assets, development costs may only be capitalized as intangible assets if the following criteria are met: •it is technically feasible to complete the development of the intangible asset so that it will be available for use or sale; •the Company intends to complete the development of the intangible asset and use or sell it; •the Company has the ability to use or sell the intangible asset; •it is probable that the intangible asset will generate future economic benefits; •adequate technical, financial and other resources are available to complete the development of the intangible asset; and •the Company is able to reliably measure the expenditures attributable to the development of the intangible asset. The Company believes that because of the risks and uncertainties related to the grant of regulatory approval for the commercialization of its product candidates, the technical feasibility of completing its development projects will only be demonstrated when requisite approvals are obtained for the commercialization of products. Accordingly, pursuant to IAS 38, the Company has recognized all of its research and development costs incurred as an expense in 2021 and prior periods. Patents Costs incurred by the Company in connection with the filing of patent applications are recognized as an expense until such time as the relevant patents are obtained, in line with the treatment of research and development costs. Once the patents are obtained from relevant authorities, their related patent costs are amortized on a straight-line basis over the patent protection period. The useful life of the patents is reassessed each year, according to IAS 36. Software The costs of acquiring software licenses are recognized as assets on the basis of the costs incurred to acquire and implement the software to which the license relates. These costs are amortized on a straight-line basis over the life of the license. Recoverable amount of intangible assets Intangible assets with a definite useful life are tested for impairment when there are events or changes in circumstances that indicate that the asset might be impaired. Impairment tests involve comparing the carrying amount of an intangible asset with its recoverable amount. The recoverable amount of an asset is the higher of (i) its fair value less costs to sell and (ii) its value in use. If the recoverable amount of any asset is below its carrying amount, an impairment loss is recognized to reduce the carrying amount to the recoverable amount.
Property, plant and equipment	Accounting policies Property, plant and equipment are recorded at their acquisition cost. Major renovations and improvements necessary to bring an asset to the working condition for its use as intended by the Company’s management are capitalized. The cost of repairs, maintenance and other renovation work is expensed as incurred. Property, plant and equipment are depreciated on a straight-line basis according to the estimated useful life of the relevant assets. The depreciation periods used are as follows: •General fixtures and fittings, building work: 5 to 10 years; •Technical installations, equipment and industrial tooling: 3 to 10 years; and •Office and IT equipment and furniture: 1 to 10 years. Recoverable amount of property, plant and equipment Property, plant and equipment with a definite useful life are tested for impairment when there are events or changes in circumstances that indicate that the asset might be impaired. An impairment loss is recognized for the excess of the carrying amount of the asset over its recoverable amount. The recoverable amount of an asset is equal to the higher of (i) its fair value less costs to sell and (ii) its value in use.
Non-current financial assets	Accounting policies Non-current financial assets are recognized and measured in accordance with IFRS 9 – Financial Instruments. No non-current financial assets are estimated at fair value through other comprehensive income (OCI). Pursuant to IFRS 9 – Financial Instruments, financial assets are classified in three categories according to their nature and the intention of management: •Financial assets at fair value through profit and loss; •Financial assets at fair value through other comprehensive income; and •Financial assets at amortized cost. All regular way purchases and sales of financial assets are recognized at the settlement date. Financial assets at fair value through profit or loss This category includes marketable securities, cash and cash equivalents. They represent financial assets held for trading purposes, i.e., assets acquired by the Company to be sold in the short-term. They are measured at fair value and changes in fair value are recognized in the consolidated statements of operations as financial income or expense, as applicable. Financial assets at amortized cost This category includes other financial assets (non-current), trade receivables (current) and other receivables and related accounts (current). Other financial assets (non-current) include advances and security deposits and guarantees granted to third parties as well as term deposits and restricted cash, which are not considered as cash equivalents. They are non-derivative financial assets with fixed or determinable payments that are not listed on an active market. They are initially recognized at fair value plus transaction costs that are directly attributable to the acquisition or issue of the financial asset, except trade receivables that are initially recognized at the transaction price as defined in IFRS 15. After initial recognition, these financial assets are measured at amortized cost using the effective interest rate method when both of the following conditions are met: •The financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows; and •The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. Gains and losses are recorded in the consolidated statements of operations when they are derecognized, subject to modification of contractual cash flows and/or impaired. IFRS 9 – Financial Instruments requires an entity to recognize a loss allowance for expected credit losses on a financial asset at amortized cost at each Statement of Financial Position date. The amount of the loss allowance for expected credit losses equals: (i) the 12 - month expected credit losses or (ii) the full lifetime expected credit losses. The latter applies if credit risk has increased significantly since initial recognition of the financial instrument. An impairment is recognized, where applicable, on a case–by–case basis to take into account collection difficulties which are likely to occur based on information available at the time of preparation of the financial statements. Disputed receivables are written-off when certain and precise evidence shows that recovery is impossible, and existing credit loss allowance are released. Financial assets and liabilities are monitored for any indication of impairment. Under IFRS 9, the impairment model is based on the accounting on expected credit losses during the life of the financial assets. A financial asset is impaired if its credit risk, determined with both historic and prospective data, increased significantly since its initial booking. The loss will impact the net income (loss) recorded to the statement of operations.
Trade receivables	Trade receivablesIn 2020, trade receivables related mainly to invoices issued to PharmaEngine, in connection with the charging-back of shared external clinical research organization costs under the License and Collaboration Agreement as amended (see Note 4 for more detail on the License and Collaboration Agreement). This agreement terminated in March 31, 2021 and the related receivables have been settled.
Cash and cash equivalents	Accounting policy Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other reasons. They are easily converted into known amounts of cash and are subject to an insignificant risk of changes in value. Cash and cash equivalents consist of liquid assets that are available immediately and term deposits. Cash equivalents are measured at amortized cost.
Capital issued	Accounting policies Ordinary shares are classified in shareholders’ equity. The cost of equity transactions that are directly attributable to the issue of new shares or options is recognized in shareholders’ equity as a deduction from the proceeds of the issue.
Provisions	Accounting policies Provisions for contingencies and charges Provisions for contingencies and charges reflect obligations resulting from various disputes and risks which due dates and amounts are uncertain, that the Company may face as part of its normal business activities. A provision is recognized when the Company has a present obligation (legal or constructive) as a result of a past event, where it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. The amount recorded in provisions is a best estimate of the outflow of resources that will be required to settle the obligation, discounted, if required, at year-end. Provisions for retirement obligations Company employees receive the retirement benefits provided for by law in France: •Lump-sum retirement benefit paid by the Company to employees upon retirement (defined benefit plan); and •Pension benefits paid by social security agencies, which are financed through employer and employee contributions (State defined contribution plan). The cost of retirement benefits payable under defined benefit plans is estimated using the projected credit unit cost method. Based on this method, the cost of retirement is recorded in income such that the amount is distributed uniformly over the term of the employee’s career. Past service cost related to non-vested benefits is recognized as an expense (increase in the benefits granted) or as income (reduction in the benefits granted) when the plan amendment or curtailment occurs. Actuarial gains and losses are recognized directly and in full in other comprehensive income (loss) under equity. Retirement benefit obligations are measured at the present value of future estimated payments by reference to market yields on high quality corporate bonds with a maturity equivalent to that estimated for the plan. The Company uses experts to carry out an annual valuation of the plans. The Company's payments to defined contribution plans are recognized as expenses in each period to which they relate. As of December 31, 2021 and 2020, the Company updated the parameters for calculating the lump-sum retirement benefit plan to take recent changes into account. The salary increase rate, staff turnover and discount rate were all updated (see Note 11.2 for further details on assumptions used).
Financial liabilities	Accounting policies The Company receives assistance in the form of grants, conditional advances and interest-free loans. Under IFRS, a repayable advance that does not require the payment of annual interest is considered to be an interest-free loan. The difference between the amount of the advance at historical cost and the advance discounted at the Company's average borrowing rate is considered to be a government grant. These grants are deferred over the estimated duration of the projects they finance. The long-term (more than one year) portion of conditional advances is recognized in non-current financial liabilities and the short-term portion in current financial liabilities. Non-repayable conditional loans are treated as government grants when there is reasonable assurance that the Company will comply with the conditions for non-repayment. Otherwise, they are classified in liabilities. Government grants made available to offset expenses or losses already incurred, or as immediate financial assistance to the Company with no future related costs, are recognized in income in the period in which the grant is allocated. Financial liabilities are recognized and measured in accordance with IFRS 9 – Financial Instruments. Financial liabilities, including trade and other payables are valued at amortized cost. Financial liabilities at amortized cost Loans and other financial liabilities are recognized and measured in accordance with IFRS 9 – Financial Instruments. They are recognized at amortized cost, which is defined under IFRS 9 as the initial value of a financial asset or liability, after deduction of reimbursement of principal, increased or decreased by the accumulated amortization, calculated using the effective interest rate method. Transaction costs directly attributable to the acquisition or issuance of financial liabilities are deducted from the financial liabilities. The costs are then amortized on an actuarial basis over the life of the liability using the effective interest rate, namely the rate that exactly discounts estimated future cash flows to the net carrying amount of the financial liability in order to determine its amortized cost.
Trade and other payables	Accounting policies Accounting policies for Trade and other payables are described in Note 12, ‘‘Financial Liabilities.’’ Accrued expenses Taking into account the time lag between the time at which treatment costs are incurred in studies or clinical trials and the time at which such costs are invoiced, the Company estimates an amount of accrued expenses to record in the financial statements at each reporting date. The treatment costs for patients were estimated for each study based on contracts signed with clinical research centers conducting the trials, taking into account the length of the treatment and the date of injection of each patient. The total amount estimated for each study has been reduced by the amount of invoices received at the closing date.
Revenue and other income	Accounting policies Revenue Revenue is recognized in accordance with IFRS 15. Under IFRS 15, revenue is recognized when the Company satisfies a performance obligation by transferring a distinct good or service (or a distinct bundle of goods and/or services) to a customer, i.e. when the customer obtains control of these goods or services. An asset is transferred when the customer obtains control of the asset (or service). Given the wide spectrum of therapeutic research and development opportunities, aside from the fields that the Company intends to research and develop with its own scientific and financial resources, the Company has entered and expects to enter into license and collaboration agreements with third parties in certain specific fields that have generated or will generate revenue. Therefore, each agreement has been and will be analyzed, on a case-by-case basis to determine whether the arrangement contains performance obligations to the other party and, if so, to identify the nature of these performance obligations in order to determine the appropriate accounting under IFRS 15 principles of the amounts that the Company has received or is entitled to receive from the other party e.g.: •Development services performed by the Company to create or enhance an intellectual property controlled by the client, for which revenue is recognized over time, when services are rendered; •A transfer of control of an existing intellectual property of the Company for which revenue is recognized at the time such control is transferred; •A license: ◦If the license is assessed to be a right to access the Company’s intellectual property as it exists throughout the license period, revenue is recognized over the license period; or ◦If the license is a right to use the Company’s intellectual property as it exists (in term of forms and functionality), revenue is recognized when the other party is able to use and benefit from the license; or •Product supply for which the revenue is recognized once the control over the delivered products is transferred. Contingent revenue arising from successful milestones or sales-based royalties are not recognized before the related milestone has been reached or sale has occurred. Application to the license and collaboration agreement with PharmaEngine Under the License and Collaboration Agreement, the Company’s and PharmaEngine’s rights are clearly identified and, financial terms are defined in the contract. The contract has commercial substance (the Company’s cash flows have been affected by the terms of the contract) and the Company has collected and is entitled to collect in the future consideration in exchange for the goods and services transferred to PharmaEngine. The Company identified three performance obligations in the License and Collaboration Agreement described under Note 4 above: •the license of the right to use the Company’s patent and know-how; •the support provided by the Company to PharmaEngine until the first regulatory approval is granted in PharmaEngine’s territory that the Company views as a series of distinct periods of access to information and experience that is satisfied over time; and •the supply of NBTXR3 to PharmaEngine. An upfront payment of $1.0 million was fully recognized as revenue when the license was transferred to PharmaEngine in 2012. Development milestones constitute variable payments that are recognized over-time. As milestone payment timing was defined to reflect the efforts of both parties over time and were amended to reflect all changes in the contractual development plan, the Company concluded that the terms of variable payments reflect its efforts to satisfy the performance obligation related to each development phase and that no portion if any of such consideration that would relate to the license would impact the timing of recognition because of the highly probable collectability requirement. On this basis, the first milestone payment of $1 million (upon signature of the first amendment that allowed PharmaEngine to benefit from the results of the Company’s clinical studies for soft-tissue sarcoma indication) and the second milestone payment of $1 million (first patient’s injection with NBTXR3 in soft tissue sarcoma study in Asia) were received and recognized in 2014 and 2016, respectively. The next milestone will be received following the first filing for regulatory approval for marketing NBTXR3 in PharmaEngine ’s territory, which had not occurred as of December 31, 2021. Royalties are considered at market conditions and will be fully recognized once the subsequent sales occur. In March 2021, the Company and PharmaEngine mutually agreed to terminate the license and collaboration agreement. See note 4 Significant Transactions. Application of IFRS 15 to the license and collaboration agreement with LianBio Under the clause 8.5 of the license and collaboration agreement between the Company and LianBio, LianBio has the final decision on development and marketing activities in its territory. Consequently, the agreement does not qualify as a partnership under IFRS 11, which requires joint control and unanimous approval of strategic decisions by both parties. The agreement falls within the scope of IFRS 15. We identified the separate performance obligations of the contract under IFRS 15. The agreement includes the following obligations to LianBio: •an exclusive license, under the Company's intellectual property, to develop and market the licensed products; •the right to actively participate in global Phase III registration trials to obtain marketing approval in China; •if a pivotal trial is initiated by the Company in another country, the right to obtain a license and the right to reference efficacy data from the study and regulatory filings and approvals; •if a Phase I and Phase II trial is initiated by the Company, the right to obtain access to and a license to all clinical data and regulatory filings relating to such clinical trial; and •the requirement to purchase products under license to the Company. The Company's know-how as disclosed and made available to LianBio could not technically be used by LianBio, or by a third party, to manufacture the licensed products. The provision of additional know-how data and information by the Company is necessary to enable a third party to manufacture the licensed products. This information will only be provided if the Company, at any time following a change of control of the Company, fails to provide at least 80% of LianBio's forecasted need for licensed products in a given calendar year. The license cannot be separated because LianBio cannot benefit from the license alone (i.e. without the ongoing manufacturing service provided by the Company). On this basis, we concluded that the license and the manufacturing service are not distinct. As the license is not separate, any services performed in connection with the clinical trials cannot be analyzed as a separate service provided by the Company to LianBio, because LianBio cannot benefit from the clinical trials alone. LianBio has the exclusive right to purchase and sell the licensed products in its territory but has no enforceable obligation to make the purchases. Accordingly, the agreement contains only one performance obligation: the manufacturing and the supply by Nanobiotix to LianBio of the licensed products. In consideration for this exclusive right to purchase and sell the licensed products granted to LianBio, the Company received on June 15, 2021, a non-refundable upfront payment of $20 million and may receive up to $220 million in potential additional payments upon the achievement of certain development and commercialization milestones. The development milestones events refer to the effort provided by LianBio to register the licensed product as a drug and to enroll patients in the global phase III registrational study in head and neck within 18 months and the receipt of marketing authorization for the Licensed Product in the territory for any indication in the field. The Company is entitled to receive sales milestones payments, once the aggregate net sales of the Licensed product in the territory achieve graduated amounts. No revenue is to be recognized when such a right is granted. The upfront payment and milestone payments are considered as advance payments for future deliverables. Therefore, no revenue will be recognized until the first sales of the licensed products occur. In accordance with paragraph 106 of IFRS 15, upon receipt of an upfront payment from LianBio, the Company shall recognize a contractual liability to the extent of the upfront payment. The Company shall derecognize this contractual liability (and recognize revenue) when it transfers the licensed products. The upfront payment and milestone payments must be allocated to the sales of licensed products. Significant judgment will be required to determine how to allocate the upfront payments to the sales of licensed products. Nanobiotix will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. The method of recognizing these revenues is also yet to be determined. Grants Due to its innovative approach to nanomedicine, the Company has received various grants and other assistance from the government of France and French public authorities since its creation. The funds are intended to finance its operations or specific recruitments. Grants are recognized in income as the corresponding expenses are incurred and independently of cash flows received. Research tax credit The French tax authorities grant a research tax credit (Crédit d’Impôt Recherche, or “CIR”), to companies in order to encourage them to conduct technical and scientific research. Companies demonstrating that they have incurred research expenditures that meet the required criteria (research expenses in France or, since January 1, 2005, other countries in the European Community or the European Economic Area that have signed a tax treaty with France containing an administrative assistance clause) receive a tax credit that can theoretically be compensated with the income tax due on the profits of the financial year during which the expenses have been incurred and the following three years. Any unused portion of the credit is then refunded by the French Treasury. If the Company can be qualified as small and medium-sized enterprises, in France the “PME”, it can request immediate refund of the remaining tax credit, without application of the three-year period). The Company has received research tax credits since its creation. These amounts are recognized as "Other income" in the fiscal year in which the corresponding charges or expenses were incurred. The portion related to capitalized expenses is deducted from the amount of capitalized expenses on the statements of financial position and from the amortization charges for these expenses on the statements of operations.
Operating expenses	Accounting policies Leases included in the practical expedients under the IFRS 16 standard and used by the Company (low value asset and short-term leases) are recognized in operating expenses. Payments made for these leases are expensed, net of any incentives, on a straight-line basis over the contract term (see Note 22).
Share-based payments	Accounting policy The Company has adopted a number of compensation plans since its inception. As of December 31, 2021, the Company had nine (9) outstanding founders’ warrant plans, twelve (12) outstanding warrant plans, nine (9) stock option plans and two (2) outstanding free shares plans. These share-based compensation plans are settled in equity instruments. The Company has applied IFRS 2 – Share-based Payment to all equity instruments granted to employees since 2006. As required by IFRS 2 – Share-based Payment, the cost of remuneration paid in the form of equity instruments is recognized as an expense, with a corresponding increase in shareholders’ equity for the vesting period during which the rights with respect to the equity instruments are earned. The fair value of the equity instruments granted to employees is measured using the Black-Scholes or Monte Carlo model, as described below.
Income tax	Accounting policy The Company and its subsidiaries are subject to income tax in their respective jurisdictions. Deferred taxes are recognized on a full provision basis using the liability method for all temporary differences between the tax basis and accounting basis of assets and liabilities in the financial statements. The main temporary differences relate to tax loss carryforwards. The prevailing income tax rates on the reporting date are used to determine deferred taxes. Deferred tax assets, which mainly arise as a result of tax loss carryforwards, are only recognized to the extent that it is probable that sufficient taxable income will be available in the future against which to offset the tax loss carryforwards or the temporary differences. Management uses its best judgment to determine such probability. Given the Company’s current stage of development and its short-term earnings outlook, the Company is unable to make sufficiently reliable forecasts of future earnings and accordingly, deferred tax assets have not been recognized and offset only to the extent of deferred tax liabilities in the same taxable entities.
Segment reporting	In accordance with IFRS 8 – Operating Segments, reporting by operating segment is derived from the internal organization of the Company’s activities; it reflects management’s viewpoint and is established based on internal reporting used by the chief operating decision maker (the Company’s Chief Executive Officer and Chairmen of the Executive Board and of the Supervisory Board) to allocate resources and to assess performance. The Company operates in a single operating segment: research and development in product candidates that harness principles of physics to transform cancer treatment. The assets, liabilities and operating loss realized are primarily located in France. Revenue in 2021, 2020 and 2019 was derived mainly from the charging-back of shared external clinical research organization costs, in connection with the development support provided by the Company to PharmaEngine as part of the Company's License and Collaboration Agreement in Asia by Nanobiotix S.A. (see Note 15). For territorial analysis purposes, management allocates revenue based on the place of delivery of licenses or on the place in which services are provided.
Loss per share	Accounting policy Loss per share is calculated by dividing the net loss due to shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. The diluted loss per share is calculated by dividing the results by the weighted average number of common shares in circulation, increased by all dilutive potential common shares. The dilutive potential common shares include, in particular, the share subscription warrants, stock options and founder subscription warrants as detailed in Note 17. Dilution is defined as a reduction of earnings per share or an increase of loss per share. When the exercise of outstanding share options and warrants decreases loss per share, they are considered to be anti-dilutive and excluded from the calculation of loss per share.
Subsequent events	Accounting policyThe statements of consolidated financial position and statements of consolidated operations are adjusted for post-closing events prior to the approval of the financial statements for issuance as long as they have a significant impact of the amounts presented at the closing date of the statement of financial position. If they do not, they are disclosed.

Intangible assets (Tables)

12 Months Ended

Dec. 31, 2021

Intangible assets other than goodwill [abstract]

Schedule of intangible assets

The change in intangible assets breaks down as follows:


(in thousands of euros)	As of As of January 1, 2021	Increases	Decreases	Transfer	Currency translation	As of December 31, 2021
Patents	65	—	—	—	—	65
Software	651	5	—	—	—	657
Intangible assets in progress	—	—	—	—	—	—
Gross book value of intangible assets	717	5	—	—	—	722
Patents	(65)	—	—	—	—	(65)
Software	(630)	(22)	—	—	—	(652)
Accumulated depreciation of intangible assets (1)	(695)	(22)	—	—	—	(717)
Net book value of intangible assets	21	(17)	—	—	—	4

(1)Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses


(in thousands of euros)	As of January 1, 2020	Increases	Decreases	Transfer	Currency translation	As of December 31, 2020
Patents	65	—	—	—	—	65
Software	584	11	(5)	61	—	651
Intangible assets in progress	61	—	—	(61)	—	—
Gross book value of intangible assets	710	11	(5)	—	—	717
Patents	(65)	—	—	—	—	(65)
Software	(483)	(152)	5	(0)	(0)	(630)
Accumulated depreciation of intangible assets (1)	(548)	(152)	5	—	—	(695)
Net book value of intangible assets	163	(141)	—	(0)	(0)	21

(1)Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses

Property, plant and equipment (Tables)

12 Months Ended

Dec. 31, 2021

Property, plant and equipment [abstract]

Schedule of property, plant and equipment

The change in property, plant and equipment is as follows:


(in thousands of euros)	As of January 1, 2021	Increases	Decreases	Transfer	Currency translation	As of December 31, 2021
Fixtures, fittings and installations	3,313	5	—	—	—	3,318
Right of use – Buildings	7,171	1,362	(139)	—	—	8,393
Technical equipment	2,061	73	—	1	—	2,135
Office and IT equipment	988	53	(35)	—	4	1,010
Transport equipment	31	—	—	—	3	33
Right of use – Transport equipment	65	—	(38)	—	1	28
Tangible assets in progress	1	97	—	(0)	—	98
Prepayments on tangible assets	—	—	—	(0)	—	—
Gross book value of tangible assets	13,630	1,590	(212)	—	8	15,017
Fixtures, fittings and installations	(1,320)	(320)	—	—	—	(1,641)
Right of use – Buildings	(1,739)	(901)	30	—	—	(2,610)
Technical equipment	(1,466)	(178)	—	—	—	(1,644)
Office and IT equipment	(783)	(124)	34	—	(3)	(875)
Transport equipment	(31)	—	—	—	(3)	(33)
Right of use – Transport equipment	(36)	(12)	20	—	(1)	(28)
Accumulated depreciation of tangible assets(1)	(5,374)	(1,534)	84	—	(6)	(6,831)
Net book value of tangible assets	8,256	56	(129)	—	3	8,186


(in thousands of euros)	As of January 1, 2020	Increases	Decreases	Other movements & transfer.	Currency translation	As of December 31, 2020
Fixtures, fittings and installations	3,297	16	—	—	—	3,313
Right of use – Buildings	6,766	418	(14)	—	—	7,171
Technical equipment	2,019	42	—	—	—	2,061
Office and IT equipment	957	37	(1)	—	(4)	988
Transport equipment	34	—	—	—	(3)	31
Right of use – Transport equipment	115	—	(41)	(5)	(4)	65
Tangible assets in progress	11	1	—	(11)	—	1
Prepayments on tangible assets	—	—	—	—	—	—
Gross book value of tangible assets	13,197	515	(57)	(15)	(11)	13,630
Fixtures, fittings and installations	(1,001)	(320)	—	—	—	(1,320)
Right of use – Buildings	(829)	(911)	—	2	—	(1,739)
Technical equipment	(1,272)	(194)	—	—	—	(1,466)
Office and IT equipment	(629)	(157)	1	—	2	(783)
Transport equipment	(34)	—	—	1	3	(31)
Right of use – Transport equipment	(45)	(35)	42	—	1	(36)
Accumulated depreciation of tangible assets(1)	(3,811)	(1,616)	43	4	6	(5,374)
Net book value of tangible assets	9,386	(1,101)	(14)	(12)	(4)	8,256

(1)Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses

Non-current financial assets (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure of financial assets [abstract]

Disclosure of changes in non-current financial assets

The change in non-current financial assets breaks down as follows:


(in thousands of euros)	Liquidity contract - Cash account(1)	Other long-term investments pledged as collateral	Security deposits paid	Total
Net book value as of December 31, 2019	131	—	399	529
Additions	—	—	9	9
Decreases	(27)	—	(5)	(31)
Currency translation adjustments	—	—	(2)	(2)
Net book value as of December 31, 2020	105	—	401	505
Additions	—	—	9	9
Decreases	(6)	—	—	(6)
Transfer	—	—	8	8
Currency translation adjustments	—	—	3	3
Net book value as of December 31, 2021	98	—	421	519

(1)See note 10.2 Treasury shares

Trade receivables and other current assets (Tables)

12 Months Ended

Dec. 31, 2021

Subclassifications of assets, liabilities and equities [abstract]

Disclosure of break down of trade receivables


	As of December 31,
(in thousands of euros)	2021	2020
Trade receivables	—	62
Trade receivables	—	62

Trade receivables break down as follows:


	As of December 31,
(in thousands of euros)	2021	2020
Due in 3 months or less	—	62
Due between 3 and 6 months	—	—
Due between 6 and 12 months	—	—
Due after more than 12 months	—	—
Trade receivables	—	62

Disclosure of break down of other current assets

Other current assets break down as follows:


	As of December 31,
(in thousands of euros)	2021	2020
Research tax credit receivable	2,490	1,927
VAT receivable	1,058	971
Prepaid expenses	2,213	2,217
Other receivables	3,378	920
Other current assets	9,139	6,035

Disclosure of changes in research tax credit receivables

The change in research tax credit receivables breaks down as follows:


(in thousands of euros)
Receivable as of December 31, 2019			5,688
Refund of 2018 research tax credit – Nanobiotix SA			(3,251)
Refund of 2019 research tax credit – Nanobiotix SA			(2,374)
Refund of 2019 research tax credit – Curadigm SAS			(64)
2020 research tax credit – Nanobiotix SA			1,858
2020 research tax credit – Curadigm SAS			69
Receivable as of December 31, 2020			1,927
Refund of 2020 research tax credit – Nanobiotix SA			(1,858)
Refund of 2020 research tax credit – Curadigm SAS			(69)
2021 research tax credit – Nanobiotix SA			2,272
2021 research tax credit – Curadigm SAS			218
Receivable as of December 31, 2021			2,490

Cash and cash equivalents (Tables)

12 Months Ended

Dec. 31, 2021

Subclassifications of assets, liabilities and equities [abstract]

Summary of cash and cash equivalents

Detail of cash and cash equivalents

Cash and cash equivalent break down as follows:


(in thousands of euros)	As of December 31, 2021	As of December 31, 2020
Cash and bank accounts	83,921	119,151
Net cash and cash equivalents	83,921	119,151

Share Capital (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]

Disclosure of detail of share capital transactions

Detail of share capital transactions


(in thousands or number of shares)	Nature of transaction	Share Capital	Premiums related to share capital	Number of shares
December 31, 2019		672	153,139	22,415,039
March 6, 2020	Capital increase	9	0	316,083
June 24, 2020	Subscription of 2020 warrants	—	1	—
June 26, 2020	Subscription of 2020 warrants	—	1	—
June 29, 2020	Subscription of 2020 warrants	—	2	—
June 30, 2020	Subscription of 2020 warrants	—	1	—
July 27, 2020	Capital increase	—	—	6,000
July 28, 2020	Private placement Capital increase	99	20,030	3,300,000
July 28, 2020	Private placement Capital increase transaction costs	—	(1,387)	—
December 16, 2020	U.S. Initial public offering initial deal € - Nasdaq (€11.14)	56	20,609	1,855,000
December 16, 2020	U.S. Initial public offering initial deal $ - Nasdaq ($13.50)	163	60,494	5,445,000
December 18, 2020	U.S. Initial public offering green shoe $ - Nasdaq ($13.50)	33	12,165	1,095,000
December 18, 2020	U.S. Initial public offering costs	—	(9,322)	—
December 31, 2020		1,033	255,735	34,432,122
March 31, 2021	Capital increase AGA 2018-1	1	—	24,500
March 31, 2021	Capital increase AGA 2019-1	11	—	369,250
April 20, 2021	Warrants attribution	—	(11)	—
May 31, 2021	Warrants subscription (BSA 2021)	—	43	—
December 31, 2021		1,045	255,767	34,825,872

Disclosure of detail of change in founders' warrants, warrants and free shares

The following tables summarize activity in these plans during the years ended December 31, 2021 and 2020.

Founders’ warrants (BSPCE)


Type	Grant date	Exercise price (in euros)	Outstanding at January 1, 2021	Issued	Exercised	Forfeited	Outstanding at December 31, 2021	Number of shares issuable
BSPCE 2012-2	December 18, 2012	6.63	100,000	—	—	—	100,000	100,000
BSPCE 08-2013	August 28, 2013	5.92	50,000	—	—	—	50,000	50,000
BSPCE 09-2014	September 16, 2014	18.68	86,150	—	—	—	86,150	86,150
BSPCE 2015-1	February 10, 2015	18.57	68,450	—	—	—	68,450	68,450
BSPCE 2015-3	June 10, 2015	20.28	30,700	—	—	(350)	30,350	30,350
BSPCE 2016	February 2, 2016	14.46	202,617	—	—	(1,776)	200,841	200,841
BSPCE 2017	January 7, 2017	15.93	180,850	—	—	(1,350)	179,500	179,500
Total			718,767	—	—	(3,476)	715,291	715,291


Type	Grant date	Exercise price (in euros)	Outstanding at January 1, 2020	Issued	Exercised	Forfeited	Outstanding at December 31, 2020	Number of shares issuable
BSPCE 2012-2	December 18, 2012	6.63	100,000	—	—	—	100,000	100,000
BSPCE 08-2013	August 28, 2013	5.92	50,000	—	—	—	50,000	50,000
BSPCE 09-2014	September 16, 2014	18.68	92,100	—	—	(5,950)	86,150	86,150
BSPCE 2015-1	February 10, 2015	18.57	70,950	—	—	(2,500)	68,450	68,450
BSPCE 2015-3	June 10, 2015	20.28	38,400	—	—	(7,700)	30,700	30,700
BSPCE 2016	February 2, 2016	14.46	212,969	—	—	(10,352)	202,617	202,617
BSPCE 2017	January 7, 2017	15.93	187,166	—	—	(6,316)	180,850	180,850
Total			751,585	—	—	(32,818)	718,767	718,767

BSA)


Type	Grant date	Exercise price (in euros)	Outstanding at January 1, 2021	Issued	Exercised	Forfeited	Outstanding at December 31, 2021	Number of shares issuable
BSA 04-12	May 4, 2012	6.00	30,000	—	—	—	30,000	30,000
BSA 2013	April 10, 2013	6.37	6,000	—	—	—	6,000	6,000
BSA 2014	September 16, 2014	17.67	10,000	—	—	—	10,000	10,000
BSA 2015-1	February 10, 2015	17.67	21,000	—	—	—	21,000	21,000
BSA 2015-2(a)	June 25, 2015	19.54	64,000	—	—	—	64,000	64,000
BSA 2015-2(b)	June 25, 2015	19.54	—	—	—	—	—	—
BSA 2016	February 2, 2016	13.74	36,208	—	—	(36,208)	—	—
BSA 2016-2	November 3, 2016	15.01	8,000	—	—	(8,000)	—	—
BSA 2017	January 7, 2017	15.76	18,000	—	—	—	18,000	18,000
BSA 2018-1	March 6, 2018	13.55	28,000	—	—	—	28,000	28,000
BSA 2018-2	July 27, 2018	16.102	5,820	—	—	—	5,820	5,820
BSA 2019-1	March 29, 2019	11.66	18,000	—	—	—	18,000	18,000
BSA 2020	March 17, 2020	6.59	18,000	—	—	—	18,000	18,000
BSA 2021 (a)	April 21, 2021	13.47	—	48,103	—	(33,672)	14,431	14,431
BSA 2021 (b)	April 21, 2021	13.64	—	30,000	—	—	30,000	30,000
Total			263,028	78,103	—	(77,880)	263,251	263,251


Type	Grant date	Exercise price (in euros)	Outstanding at January 1, 2020	Issued	Exercised	Forfeited	Outstanding at December 31, 2020	Number of shares issuable
BSA 04-12	May 4, 2012	6.00	30,000	—	—	—	30,000	30,000
BSA 2013	April 10, 2013	6.37	6,000	—	—	—	6,000	6,000
BSA 2014	September 16, 2014	17.67	10,000	—	—	—	10,000	10,000
BSA 2015-1	February 10, 2015	17.67	21,000	—	—	—	21,000	21,000
BSA 2015-2(a)	June 25, 2015	19.54	64,000	—	—	—	64,000	64,000
BSA 2015-2(b)	June 25, 2015	19.54	6,000	—	—	(6,000)	—	—
BSA 2016	February 2, 2016	13.74	36,208	—	—	—	36,208	36,208
BSA 2016-2	November 3, 2016	15.01	8,000	—	—	—	8,000	8,000
BSA 2017	January 7, 2017	15.76	18,000	—	—	—	18,000	18,000
BSA 2018-1	March 6, 2018	13.55	28,000	—	—	—	28,000	28,000
BSA 2018-2	July 27, 2018	16.102	5,820	—	—	—	5,820	5,820
BSA 2019-1	March 29, 2019	11.660	18,000	—	—	—	18,000	18,000
BSA 2020	March 17, 2020	6.59	—	18,000	—	—	18,000	18,000
Total			251,028	18,000	—	(6,000)	263,028	263,028

AGA)


Type	Grant date	Exercise price (in euros)	Outstanding at January 1, 2021	Issued	Definitively acquired	Forfeited	Outstanding at December 31, 2021	Number of shares exercisable
AGA 2018-1	March 6, 2018	n.a.	24,500	—	(24,500)	—	—	—
AGA 2018-2	July 27, 2018	n.a.	—	—	—	—	—	—
AGA 2019-1	March 29, 2019	n.a.	372,000	—	(369,250)	(2,750)	—	—
AGA 2020	March 11, 2020	n.a.	50,000	—	—	—	50,000	50,000
AGA 2021	April 20, 2021	n.a.	—	362,515	—	(2,003)	360,512	360,512
Total			446,500	362,515	(393,750)	(4,753)	410,512	410,512


Type	Grant date	Exercise price (in euros)	Outstanding at January 1, 2020	Issued	Definitively acquired	Forfeited	Outstanding at December 31, 2020	Number of shares exercisable
AGA 2018-1	March 6, 2018	n.a.	355,250	—	(316,083)	(14,667)	24,500	24,500
AGA 2018-2	July 27, 2018	n.a.	6,000	—	(6,000)	—	—	—
AGA 2019-1	March 29, 2019	n.a.	385,000	—	—	(13,000)	372,000	372,000
AGA 2020	March 11, 2020	n.a.	—	50,000	—	—	50,000	50,000
Total			746,250	50,000	(322,083)	(27,667)	446,500	446,500

Disclosure of detail of change in stock options

OSA)


Type	Grant date	Exercise price (in euros)	Outstanding at January 1, 2021	Issued	Exercised	Forfeited	Outstanding at December 31, 2021	Number of shares issuable
OSA 2016-1	February 2, 2016	13.05	400	—	—	—	400	400
OSA 2016-2	November 3, 2016	14.26	4,000	—	—	—	4,000	4,000
OSA 2017	January 7, 2017	14.97	500	—	—	—	500	500
OSA 2018	March 6, 2018	12.87	52,000	—	—	—	52,000	52,000
OSA 2019-1	March 29, 2019	11.08	28,750	—	—	(500)	28,250	28,250
OSA LLY 2019	October 24, 2019	6.41	500,000	—	—	—	500,000	500,000
OSA 2020	March 11, 2020	6.25	400,709	—	—	(13,253)	387,456	387,456
OSA 2021-04	April 20, 2021	13.74	—	571,200	—	(80,000)	491,200	491,200
OSA 2021-06	June 21, 2021	12.99	—	120,000	—	—	120,000	120,000
Total			986,359	691,200	—	(93,753)	1,583,806	1,583,806


Type	Grant date	Exercise price (in euros)	Outstanding at January 1, 2020	Issued	Exercised	Forfeited	Outstanding at December 31, 2020	Number of shares issuable
OSA 2016-1	February 2, 2016	13.05	400	—	—	—	400	400
OSA 2016-2	November 3, 2016	14.26	4,000	—	—	—	4,000	4,000
OSA 2017	January 7, 2017	14.97	500	—	—	—	500	500
OSA 2018	March 6, 2018	12.87	54,000	—	—	(2,000)	52,000	52,000
OSA 2019-1	March 29, 2019	11.08	30,250	—	—	(1,500)	28,750	28,750
OSA LLY 2019	October 24, 2019	6.41	500,000	—	—	—	500,000	500,000
OSA 2020	March 11, 2020	6.25	—	407,972	—	(7,263)	400,709	400,709
Total			589,150	407,972	—	(10,763)	986,359	986,359

Provisions (Tables)

12 Months Ended

Dec. 31, 2021

Provisions [abstract]

Disclosure of changes in provisions


(in thousands of euros)	As of January 1, 2021	Increases	Decreases	As of December 31, 2021
Lump-sum retirement benefits	414	—	(97)	318
Non-current provisions	414	—	(97)	318
Provisions for disputes	40	54	—	94
Provision for charges	—	16	—	16
Current provisions	40	70	—	110
Total provisions	454	70	(97)	428


(in thousands of euros)	As of January 1, 2020	Increases	Decreases(1)	As of December 31, 2020
Lump-sum retirement benefits	331	83	—	414
Non-current provisions	331	83	—	414
Provisions for disputes	—	40	—	40
Provision for charges	164	—	(164)	—
Current provisions	164	40	(164)	40
Total provisions	495	123	(164)	454

(1)See Statement of consolidated cash flows and Note 16.4 for the nature of these decreases

Disclosure of commitments for retirement benefits

Commitments for retirement benefits


	As of December 31,
(in thousands of euros)	2021	2020
Provision as of beginning of period	414	331
Cost of services	84	76
Interests / discounting costs	1	3
Expense for the period	85	79
Gains or losses related to experience	(133)	(61)
Gains or losses related to change in demographic assumptions	(5)	3
Gains or losses related to change in financial assumptions	(43)	62
Actuarial gains or losses recognized in other comprehensive income	(182)	4
Provision as of end of period	318	414

Disclosure of assumptions used to measure retirement benefits

The assumptions used to measure lump-sum retirement benefits are as follows:


Measurement date	December 31, 2021	December 31, 2020
Retirement assumptions	Management: Age 66 Non-management: Age 64	Management: Age 66 Non-management: Age 64
Social security contribution rate	42.01 %	44 %
Discount rate	0.98 %	0.33 %
Mortality tables	Regulatory table INSEE 2015 -2017	Regulatory table INSEE 2014 -2016
Salary increase rate (including inflation)	Executive: 3% Non-Executive: 2.5%	Executive: 3% Non-Executive: 2.5%
Staff turnover	Constant average rate of 5.86%	Constant average rate of 5.86%
Duration	20 years	17 years

Disclosure of sensitivity analysis for actuarial assumptions

The sensitivity to the discount rate and to the salary growth is as follows:


Discount rate	0.73%	0.98%	1.23%
Defined Benefit Obligation as of December 31, 2021 (in thousands of euros)	333	318	303

Financial liabilities (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure of financial liabilities [abstract]

Summary of changes in financial liabilities

Details of financial liabilities


	As of December 31,
(in thousands of euros)	2021	2020
Lease liabilities – Short term	1,126	1,197
Repayable BPI loan advances - Short term	800	500
PGE*	1,086	141
EIB Loan – Short term	5,192	3,033
Total current financial liabilities	8,204	4,872
Lease liabilities – Long term	5,393	4,991
Repayable BPI loan advances – Long term	2,259	2,975
PGE*	8,982	9,922
EIB loan – Long term	21,182	26,218
Total non-current financial liabilities	37,816	44,107
Total financial liabilities	46,020	48,979

(*)”PGE”or in French “Prêts garantis par l’Etat” are state-guaranteed loans

Detail of financial instruments included in the statements of financial position and impact on income


	As of December 31, 2021
(in thousands of euros)	Book value on the statement of financial position	Financial assets carried at fair value through profit or loss	Assets and liabilities carried at amortized cost	Fair value(1)
Non-current financial assets
Non-current financial assets	519	97	421	519
Trade receivables	—	—	—	—
Cash and cash equivalents	83,921	—	83,921	83,921
Total assets	84,440	97	84,343	84,440
Financial liabilities
Non-current financial liabilities	38,733	—	38,733	38,733
Current financial liabilities	7,288	—	7,288	7,288
Trade payables and other payables	6,482	—	6,482	6,482
Total liabilities	52,503	—	52,503	52,503


	As of December 31, 2020
(in thousands of euros)	Book value on the statement of financial position	Financial assets carried at fair value through profit or loss	Assets and liabilities carried at amortized cost	Fair value (1)
Non-current financial assets
Non-current financial assets	505	104	401	505
Trade receivables	62	—	62	62
Cash and cash equivalents	119,151	—	119,151	119,151
Total assets	119,717	104	119,613	119,717
Financial liabilities
Non-current financial liabilities	44,107	—	44,107	44,107
Current financial liabilities	4,872	—	4,872	4,872
Trade payables and other payables	7,106	—	7,106	7,106
Total liabilities	56,085	—	56,085	56,085

Disclosure of detailed information about conditional advance, bank loan and loans from government and public authorities

Conditional advances and loans from government and public authorities


(in thousands of euros)	Bpifrance advance	Interest-free Bpifrance loan	EIB Loan	Curadigm Bpifrance advance	Total
As of January 1, 2020	2,165	1,210	34,746	—	38,121
Principal received	—	—	—	350	350
Impact of discounting and accretion	19	14	(1,736)	(65)	(1,769)
Accumulated fixed interest expense accrual	32	—	1,731	—	1,763
Accumulated variable interest expense accrual	—	—	(4,789)	—	(4,789)
Repayment	—	(250)	(700)	—	(950)
As of December 31, 2020	2,216	974	29,251	285	32,727
Principal received	—	—	—	—	—
Impact of discounting and accretion	17	19	(5,817)	16	(5,765)
Accumulated fixed interest expense accrual	32	—	1,758	—	1,790
Accumulated variable interest expense accrual	—	—	4,214	—	4,214
Repayment	—	(500)	(3,033)	—	(3,533)
As of December 31, 2021	2,266	493	26,374	300	29,433

Bank loan


(in thousands of euros)	HSBC “PGE” (1)	Bpifrance “PGE” (1)	Total
As of January 1, 2020	—	—	—
Principal received	5,000	5,000	10,000
Impact of discounting and accretion	14	34	47
Accumulated fixed interest expense accrual (2)	7	10	17
As of December 31, 2020	5,020	5,044	10,064
Principal received	17	(14)	3
Impact of discounting and accretion	26	120	146
Accumulated fixed interest expense accrual (3)	(33)	(112)	(145)
As of December 31, 2021	5,030	5,038	10,068

(1)”PGE”or in French “Prêts garantis par l’Etat” are state-guaranteed loans

Disclosure of reconciliation of changes in lease liabilities

The table below shows the detail of changes in lease liabilities recognized on the statements of financial position over the periods disclosed:


(in thousands of euros)			Lease liabilities
As of January 1st, 2020			6,405
New lease contracts			521
Impact of discounting of the new lease contracts			(94)
Fixed interest expense			333
Repayment of lease			(928)
Early termination of lease contracts			(49)
As of December 31, 2020			6,188
Engagement			1,476
Impact of discounting and accretion			(110)
Accumulated fixed interest expense accrual			288
Repayment of lease			(1,195)
Early termination of lease contracts			(128)
As of December 31, 2021			6,519

Disclosure of maturity analysis for advances loans and lease liabilities

The due dates for repayment of the advances loans and lease liabilities at their nominal value and including fixed-rate interest are as follows:


	As of December 31, 2021
(in thousands of euros)	Less than 1 year	Between 1 and 3 years	Between 3 and 5 years	More than 5 years
Bpifrance	300	1,300	808	—
Interest-free Bpifrance loan	500	—	—	—
Curadigm interest-free Bpifrance advance	—	200	150	—
HSBC “PGE” (1)	661	2,572	1,904	—
Bpifrance “PGE” (1)	425	2,662	2,237	—
EIB fixed rate loan	5,192	28,762	—	—
Lease liabilities	1,126	2,252	2,247	1,714
Total	8,204	37,747	7,346	1,714

Trade payables and other current liabilities (Tables)

12 Months Ended

Dec. 31, 2021

Subclassifications of assets, liabilities and equities [abstract]

Disclosure of trade and other payables

Details of trade and other payables


	As of December 31,
(in thousands of euros)	2021	2020
Accrued expenses - clinical trials	1,486	1,532
Trade payables & other accruals	4,996	5,574
Total trade and other payables	6,482	7,106

Disclosure of other current liabilities

Other current liabilities


	As of December 31,
(in thousands of euros)	2021	2020
Tax liabilities	258	283
Payroll tax and other payroll liabilities	4,820	6,248
Other payables	453	491
Other current liabilities	5,531	7,022

Disclosure of deferred income and contract liabilities

Deferred revenues and contract liabilities


	As of December 31,
(in thousands of euros)	2021	2020
Deferred revenues and contract liabilities	16,518	—
Deferred revenues and contract liabilities	16,518	—

Financial instruments included in the statement of financial position and impact on income (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure of detailed information about financial instruments [abstract]

Disclosure of details of non-current financial assets

Detail of financial instruments included in the statements of financial position and impact on income


	As of December 31, 2021
(in thousands of euros)	Book value on the statement of financial position	Financial assets carried at fair value through profit or loss	Assets and liabilities carried at amortized cost	Fair value(1)
Non-current financial assets
Non-current financial assets	519	97	421	519
Trade receivables	—	—	—	—
Cash and cash equivalents	83,921	—	83,921	83,921
Total assets	84,440	97	84,343	84,440
Financial liabilities
Non-current financial liabilities	38,733	—	38,733	38,733
Current financial liabilities	7,288	—	7,288	7,288
Trade payables and other payables	6,482	—	6,482	6,482
Total liabilities	52,503	—	52,503	52,503


	As of December 31, 2020
(in thousands of euros)	Book value on the statement of financial position	Financial assets carried at fair value through profit or loss	Assets and liabilities carried at amortized cost	Fair value (1)
Non-current financial assets
Non-current financial assets	505	104	401	505
Trade receivables	62	—	62	62
Cash and cash equivalents	119,151	—	119,151	119,151
Total assets	119,717	104	119,613	119,717
Financial liabilities
Non-current financial liabilities	44,107	—	44,107	44,107
Current financial liabilities	4,872	—	4,872	4,872
Trade payables and other payables	7,106	—	7,106	7,106
Total liabilities	56,085	—	56,085	56,085

Disclosure of details of financial liabilities

Details of financial liabilities


	As of December 31,
(in thousands of euros)	2021	2020
Lease liabilities – Short term	1,126	1,197
Repayable BPI loan advances - Short term	800	500
PGE*	1,086	141
EIB Loan – Short term	5,192	3,033
Total current financial liabilities	8,204	4,872
Lease liabilities – Long term	5,393	4,991
Repayable BPI loan advances – Long term	2,259	2,975
PGE*	8,982	9,922
EIB loan – Long term	21,182	26,218
Total non-current financial liabilities	37,816	44,107
Total financial liabilities	46,020	48,979

(*)”PGE”or in French “Prêts garantis par l’Etat” are state-guaranteed loans

Detail of financial instruments included in the statements of financial position and impact on income


	As of December 31, 2021
(in thousands of euros)	Book value on the statement of financial position	Financial assets carried at fair value through profit or loss	Assets and liabilities carried at amortized cost	Fair value(1)
Non-current financial assets
Non-current financial assets	519	97	421	519
Trade receivables	—	—	—	—
Cash and cash equivalents	83,921	—	83,921	83,921
Total assets	84,440	97	84,343	84,440
Financial liabilities
Non-current financial liabilities	38,733	—	38,733	38,733
Current financial liabilities	7,288	—	7,288	7,288
Trade payables and other payables	6,482	—	6,482	6,482
Total liabilities	52,503	—	52,503	52,503


	As of December 31, 2020
(in thousands of euros)	Book value on the statement of financial position	Financial assets carried at fair value through profit or loss	Assets and liabilities carried at amortized cost	Fair value (1)
Non-current financial assets
Non-current financial assets	505	104	401	505
Trade receivables	62	—	62	62
Cash and cash equivalents	119,151	—	119,151	119,151
Total assets	119,717	104	119,613	119,717
Financial liabilities
Non-current financial liabilities	44,107	—	44,107	44,107
Current financial liabilities	4,872	—	4,872	4,872
Trade payables and other payables	7,106	—	7,106	7,106
Total liabilities	56,085	—	56,085	56,085

Disclosure of effect of changes in exchange rates


	For the year ended December 31, 2021
Impact	Net income		Equity
(in thousands of euros)	Increase	Decrease	Increase	Decrease
USD / Euro exchange rate	45	(45)	87	(87)
Total	45	(45)	87	(87)


	For the year ended December 31, 2020
Impact	Net income		Equity
(in thousands of euros)	Increase	Decrease	Increase	Decrease
USD / Euro exchange rate	5	(5)	124	(124)
Total	5	(5)	124	(124)

Revenues and other income (Tables)

12 Months Ended

Dec. 31, 2021

Revenue [abstract]

Schedule of revenues and other income

The following table summarizes the Company’s revenues and other income per category for the years ended December 31, 2021, 2020, and 2019.


	For the year ended December 31,
(in thousands of euros)	2021	2020	2019
Services	5	50	40
Other sales	5	—	28
Total revenues	10	50	68
Research tax credit	2,490	1,927	2,437
Subsidies	126	526	20
Other	21	10	17
Total other income	2,637	2,462	2,473
Total revenues and other income	2,647	2,512	2,541

Operating expenses (Tables)

12 Months Ended

Dec. 31, 2021

Analysis of income and expense [abstract]

Summary of research and development expense

Research and development expenses


	For the year ended December 31,
(in thousands of euros)	2021	2020	2019
Purchases, sub-contracting and other expenses	(19,562)	(12,734)	(16,804)
Payroll costs (including share-based payments)	(9,605)	(10,306)	(11,980)
Depreciation, amortization and provision expenses(1)	(1,211)	(1,290)	(1,627)
Total research and development expenses	(30,378)	(24,330)	(30,411)

(1)see note 16.4 Depreciation, amortization and provision expenses

Summary of selling, general and administrative expenses

Selling, General and Administrative (SG&A) expenses


	For the year ended December 31,
(in thousands of euros)	2021	2020	2019
Purchases, fees and other expenses	(9,638)	(6,482)	(9,435)
Payroll costs (including share-based payments)	(9,379)	(7,789)	(9,205)
Depreciation, amortization and provision expenses (1)	(417)	(340)	(270)
Total SG&A expenses	(19,434)	(14,611)	(18,909)

(1)see note 16.4 Depreciation, amortization and provision expenses

Summary of payroll costs

Payroll costs


	For the year ended December 31,
(in thousands of euros)	2021	2020	2019
Wages and salaries	(11,391)	(11,141)	(11,876)
Payroll taxes	(4,308)	(3,953)	(4,913)
Share-based payments	(3,201)	(2,924)	(4,320)
Retirement benefit obligations	(84)	(76)	(76)
Total payroll costs	(18,984)	(18,094)	(21,185)
Average headcount	96	97	112
End-of-period headcount	100	90	110

Summary of depreciation, amortization and provision expenses

Depreciation, amortization and provision expenses by function are detailed as follows:


	For the year ended December 31, 2021
(in thousands of euros)	R&D	SG&A	Total
Amortization expense of intangible assets	(34)	(10)	(45)
Amortization expense of tangible assets	(1,109)	(406)	(1,515)
Provision for charges	(68)	—	(68)
Total depreciation, amortization and provision expenses	(1,211)	(416)	(1,628)


	For the year ended December 31, 2020
(in thousands of euros)	R&D	SG&A	Total
Amortization expense of intangible assets	(152)	(23)	(176)
Amortization expense of tangible assets	(1,250)	(329)	(1,579)
Utilization of provision for disputes	145	—	145
Provision for charges	—	(40)	(40)
Reversal of provision for disputes	—	19	19
Total depreciation, amortization and provision expenses	(1,257)	(373)	(1,630)


	For the year ended December 31, 2019
(in thousands of euros)	R&D	SG&A	Total
Amortization expense of intangible assets	(289)	(3)	(292)
Depreciation expense of property, plant and equipment	(1,208)	(270)	(1,478)
Utilization of provision for charges	—	55	55
Provision for charges	(112)	(52)	(164)
Total depreciation, amortization and provision expenses	(1,609)	(270)	(1,879)

Summary of other operating income (expense)

OTHER OPERATING INCOME AND EXPENSES


	For the year ended December 31, 2021
(in thousands of euros)	2021	2020
Contract termination indemnity (PharmaEngine)	(5,414)	—
Total Other operating income and expenses	(5,414)	—

Share-based payments (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure of terms and conditions of share-based payment arrangement [abstract]

Disclosure of number and weighted average remaining contractual life of founders' warrants, warrants, and free shares oustanding

The number of options and warrants outstanding on December 31, 2021 and their main characteristics, are detailed below:

Founders’ warrants


	Pre-2021 founders’ warrant plans
	BSPCE 2012-2	BSPCE 08-2013	BSPCE 09-2014	BSPCE 2015-1	BSPCE 2015-03
Type of underlying asset	New shares	New shares	New shares	New shares	New shares
Number of founder’s warrants granted	100,000	50,000	97,200	71,650	53,050
Date of shareholders' resolution approving the plan	05/04/2012	06/28/2013	06/18/2014	06/18/2014	06/18/2014
Grant date	12/18/2012	08/28/2013	09/16/2014	02/10/2015	06/10/2015
Contractual expiration date	12/18/2022	08/28/2023	09/16/2024	02/10/2025	06/10/2025
Grant price	—	—	—	—	—
Exercise price	€6.63	€5.92	€18.68	€18.57	€20.28
Number of founders’ warrants as of Number of founders’ warrants as of December 31, 2021	100,000	50,000	86,150	68,450	30,350
Number of founders’ warrants exercised	—	—	—	—	—
Including founders’ warrants exercised during the period	—	—	—	—	—
Number of founders’ warrants lapsed or cancelled	—	—	11,050	3,200	22,700
Including founders’ warrants lapsed or cancelled during the period	—	—	—	—	350


	Pre-2021 founders’ warrant plans
	BSPCE 2016 Ordinary	BSPCE 2016 Performance	BSPCE 2017 Ordinary	BSPCE 2017
Type of underlying asset	New shares	New shares	New shares	New shares
Number of founder’s warrants granted	126,400	129,250	117,650	80,000
Date of shareholders' resolution approving the plan	06/25/2015	06/25/2015	06/23/2016	06/23/2016
Grant date	02/02/2016	02/02/2016	01/07/2017	01/07/2017
Contractual expiration date	02/02/2026	02/02/2026	01/08/2027	01/07/2027
Grant price	—	—	—	—
Exercise price	€14.46	€14.46	€15.93	€15.93
Number of founders’ warrants as of December 31, 2021	100,567	100,274	99,500	80,000
Number of founders’ warrants exercised	333	—	—	—
Including founders’ warrants exercised during the period	—	—	—	—
Number of founders’ warrants lapsed or cancelled	25,500	28,976	18,150	—
Including founders’ warrants lapsed or cancelled during the period	350	1,426	1,350	—

Warrants


	Pre-2021 warrant plans
	BSA 04-2012	BSA 2013	BSA 2014	BSA 2015-1	BSA 2015-2 (a)	BSA 2015-2 (b)	BSA 2016 ordinary
Type of warrants	New shares	New shares	New shares	New shares	New shares	New shares	New shares
Number of warrants granted	52,500	10,000	14,000	26,000	64,000	6,000	18,103
Date of shareholders' resolution approving the plan	05/04/2012	05/04/2012	06/18/2014	06/18/2014	06/18/2014	06/25/2015	06/25/2015
Grant date	05/04/2012	04/10/2013	09/16/2014	02/10/2015	06/25/2015	06/25/2015	02/02/2016
Contractual expiration date	05/04/2022	04/10/2023	09/16/2024	02/10/2025	06/25/2025	06/25/2020	02/02/2021
Grant price	€0.60	€2.50	€4.87	€4.87	€5.00	€2.80	€1.67
Exercise price	€6.00	€6.37	€17.67	€17.67	€19.54	€19.54	€13.74
Number of warrants as of December 31, 2021	30,000	6,000	10,000	21,000	64,000	—	—
Number of warrants exercised	22,500	—	—	—	—	—	—
Including warrants exercised during the period	—	—	—	—	—	—	—
Number of warrants lapsed or cancelled	—	4,000	4,000	5,000	—	6,000	18,103
Including warrants lapsed or cancelled during the period	—	—	—	—	—	—	18,103


	Pre-2021 warrant plans
	BSA 2016 performance	BSA 2016-2	BSA 2017	BSA 2018-1	BSA 2018-2	BSA 2019-1	BSA 2020
Type of warrants	New shares	New shares	New shares	New shares	New shares	New shares	New shares
Number of warrants granted	18,105	8,000	18,000	28,000	5,820	18,000	18,000
Date of shareholders' resolution approving the plan	06/25/2015	06/23/2016	06/23/2016	06/14/2017	05/23/2018	05/23/2018	04/11/2019
Grant date	02/02/2016	11/03/2016	01/07/2017	03/06/2018	07/27/2018	03/29/2019	03/17/2020
Contractual expiration date	02/02/2021	11/03/2021	01/07/2022	03/06/2023	07/27/2028	03/29/2029	03/17/2030
Grant price	€1.67	€2.03	€2.26	€1.62	€2.36	€1.15	€0.29
Exercise price	€13.74	€15.01	€15.76	€13.55	€16.102	€11.66	€6.59
Number of warrants as of December 31, 2021	—	—	18,000	28,000	5,820	18,000	18,000
Number of warrants exercised	—	—	—	—	—	—	—
Including warrants exercised during the period	—	—	—	—	—	—	—
Number of warrants lapsed or cancelled	18,105	8,000	—	—	—	—	—
Including warrants lapsed or cancelled during the period	18,105	8,000	—	—	—	—	—


	2021 warrants
	BSA 2021 (a)	BSA 2021 (b)
Type of warrants	New shares	New shares
Number of warrants granted	48,103	30,000
Date of shareholders' resolution approving the plan	11/30/2020	11/30/2020
Grant date	04/20/2021	04/20/2021
Contractual expiration date	04/20/2031	04/20/2031
Grant price	€2.95	€0.68
Number of warrants as of Exercise price	€13.47	€13.64
Number of warrants as of December 31, 2021	14,431	30,000
Number of warrants exercised	—	—
Including warrants exercised during the period	—	—
Number of warrants lapsed or cancelled	33,672	—
Including warrants lapsed or cancelled during the period	33,672	—

Free shares


	Pre-2021 free shares plan not yet vested				2021 free shares plan
	AGA 2018-1	AGA 2018-2	AGA 2019-1	AGA 2020	AGA 2021
Type of underlying assets	New shares	New shares	New shares	New shares	New shares
Number of free shares granted	396,250	6,000	438,250	50,000	362,515
Date of shareholders' resolution approving the plan	06/14/2017	05/23/2018	05/23/2018	04/11/2019	11/30/2020
Grant date	03/06/2018	07/27/2018	03/29/2019	03/11/2020	04/20/2021
Grant price	—	—	—	—	—
Exercise price	—	—	—	—	—
Number of free shares as of December 31, 2021	—	—	—	50,000	360,512
Number of free shares exercised	340,583	6,000	369,250	—	—
Including free shares exercised during the period	24,500	—	369,250	—	—
Number of free shares lapsed or cancelled	55,667	—	69,000	—	2,003
Including free shares lapsed or cancelled during the period	—	—	2,750	—	2,003


	BSPCE	BSA	OSA	AGA	Total
Total number of shares underlying grants outstanding as of December 31, 2021	715,291	263,251	1,583,806	410,512	2,972,860


	BSPCE	BSA	OSA	AGA	Total
Total number of shares underlying grants outstanding as of December 31, 2020	718,767	263,028	986,359	446,500	2,414,654


	BSPCE	BSA	OSA	AGA	Total
Total number of shares underlying grants outstanding as of December 31, 2019	751,585	251,028	589,150	746,250	2,338,013

Disclosure of number and weighted average remaining contractual life of share options outstanding

Stock options


	Pre-2021 stock option plans
	OSA 2016-1 Performance	OSA 2016-2	OSA 2017 Ordinary	OSA 2018	OSA 2019-1	OSA LLY 2019	OSA 2020
Type of underlying asset	New shares	New shares	New shares	New shares	New shares	New shares	New shares
Number of options granted	6,400	4,000	3,500	62,000	37,500	500,000	407,972
Date of shareholders' resolution approving the plan	06/25/2015	06/23/2016	06/23/2016	06/14/2017	05/23/2018	04/11/2019	04/11/2019
Grant date	02/02/2016	11/03/2016	01/07/2017	03/06/2018	03/29/2019	10/24/2019	03/11/2020
Contractual expiration date	02/02/2026	11/03/2026	01/07/2027	03/06/2028	03/29/2029	10/24/2029	03/11/2030
Grant price	—	—	—	—	—	—	—
Exercise price	€13.05	€14.26	€14.97	€12.87	€11.08	€6.41	€6.25
Number of options as of December 31, 2021	400	4,000	500	52,000	28,250	500,000	387,456
Number of options exercised	—	—	—	—	—	—	—
Number of options as of Including options exercised during the period	—	—	—	—	—	—	—
Number of options lapsed or cancelled	6,000	—	3,000	10,000	9,250	—	13,253
Including options lapsed or cancelled during the period	—	—	—	—	500	—	13,253


	2021 stock option plans
	OSA 2021-04	OSA 2021-06
Type of underlying asset	New shares	New shares
Number of options granted	571,200	120,000
Date of shareholders' resolution approving the plan	11/30/2020	04/28/2021
Grant date	04/20/2021	06/21/2021
Contractual expiration date	04/20/2031	06/21/2031
Grant price	—	—
Exercise price	€13.74	€12.99
Number of options as of December 31, 2021	491,200	120,000
Number of options exercised	—	—
Number of options as of Including options exercised during the period	—	—
Number of options lapsed or cancelled	80,000	—
Including options lapsed or cancelled during the period	80,000	—


	BSPCE	BSA	OSA	AGA	Total
Total number of shares underlying grants outstanding as of December 31, 2021	715,291	263,251	1,583,806	410,512	2,972,860


	BSPCE	BSA	OSA	AGA	Total
Total number of shares underlying grants outstanding as of December 31, 2020	718,767	263,028	986,359	446,500	2,414,654


	BSPCE	BSA	OSA	AGA	Total
Total number of shares underlying grants outstanding as of December 31, 2019	751,585	251,028	589,150	746,250	2,338,013

Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period

The probability of meeting the performance conditions for the 2016 BSPCE, BSA and OSA performance plans was reassessed as of December 31, 2021. As a consequence , no new instrument became issuable.


BSPCE	Share price (in euros)	Exercise price (in euros)	Volatility		Maturity (in years)	Risk-free rate		Yield		Value of initial plan (in thousands of euros)	Expense for the year ended 2021 (in thousands of euros)	Expense for the year ended 2020 (in thousands of euros)	Expense for the year ended 2019 (in thousands of euros)
BSPCE 2012-1	5.26	5.26	41	%	3.49	0.20	%	0.00	%	307	—	—	—
BSPCE 2012-2	6.65	6.63	44.3% - 47.6%		5 - 7.30	0.84% - 1.22%		0.00	%	288	—	—	—
BSPCE 04-2013	6.30	6.30	56	%	5	0.90	%	0.00	%	167	—	—	—
BSPCE 08-2013	6.30	5.92	256	%	7	0.90	%	0.00	%	152	—	—	—
BSPCE 09-2014	18.68	18.68	58	%	5.5/6/6.5	0.64	%	0.00	%	932	—	—	—
BSPCE 2015-1	18.57	18.57	58% - 62% - 61%		5.5/6/6.5	0.39	%	0.00	%	50	—	—	—
BSPCE 2015-2	18.57	18.57	58% - 62% - 61%		5.5/6/6.5	0.39	%	0.00	%	650	—	—	—
BSPCE 2015-3	20.28	20.28	61% - 62% - 61%		5.5/6/6.5	0.56	%	0.00	%	483	—	—	—
BSPCE 2016 Ordinary	14.46	14.46	59% - 62% - 60%		5.5/6/6.5	0.32	%	0.00	%	1,080	—	—	10
BSPCE 2016 Performance	14.46	14.46	59	%	5	0.19	%	0.00	%	1,212	32	99	79
BSPCE 2017 Ordinary	15.93	15.93	58% - 61% - 59%		5.5/6/6.5	0.23	%	0.00	%	1,000	0	8	86
BSPCE 2017 Performance	15.93	15.93	59	%	5	0.11	%	0.00	%	622	—	—	—
BSPCE 2017	15.93	15.93	59	%	5	0.11	%	0.00	%	627	—	—	—
BSPCE 2017 Project	15.93	15.93	59	%	5	0.11	%	0.00	%	94	—	—	—
Total BSPCE	n.a.	n.a.	n.a.		n.a.	n.a.		n.a.		n.a.	32	107	175


BSA	Share price (in euros)	Exercise price (in euros)	Volatility		Maturity (in years)	Risk-free rate		Yield		Value of initial plan (in thousands of euros)	Expense for the year ended 2021 (in thousands of euros)	Expense for the year ended 2020 (in thousands of euros)	Expense for the year ended 2019 (in thousands of euros)
BSA 2012	6.00	6.00	49	%	10	0.96	%	0.00	%	183	—	—	—
BSA 2013	6.30	6.37	156	%	6	0.90	%	0.00	%	1	—	—	—
BSA 2014	18.68	17.67	57	%	5	0.41	%	0.00	%	—	—	—	—
BSA 2015-1	17.67	17.67	58	%	5	0.26% - 0.27%		0.00	%	63	—	—	—
BSA 2015-2	17.67	19.54	58%-58%-57%-58%		5/5.1/5.3/5.4	0.39	%	0.00	%	16	—	—	—
BSA 2015-3	19.54	19.54	58% - 60%		4.6 – 9.6	0.25% - 0.91%		0.00	%	284	—	—	—
BSA 2016o-1	13.74	13.74	57	%	2.4	0.00	%	0.00	%	37	—	—	—
BSA 2016p-1	13.74	13.74	57	%	2.4	0.00	%	0.00	%	143	—	—	(41)
BSA 2016-2	15.01	15.01	57	%	2.4	0.00	%	0.00	%	—	—	—	—
BSA 2017o-1	15.76	15.76	33	%	2.4	0.00	%	0.00	%	—	—	—	—
BSA 2018-1	13.55	13.55	38	%	4.8	0.7% - 0.1%		0.00	%	2	—	—	—
BSA 2018-2	16.102	16.102	38	%	4.8	0.7% - 0.1%		0.00	%	1	—	—	—
BSA 2019-1	11.66	11.66	37	%	9.8/9.9	0.16% - 0.50%		0.00	%	24	—	—	24
BSA 2020	—	6.59	38	%	10	-0.13%/ -0.07%		0.00	%	19	—	19	—
BSA 2021 (a)	13.47	13.47	39.10	%	10	0.27	%	0.00	%	44	44	—	—
BSA 2021 (b)	n.a.	13.64	n.a.		10	0.27	%	0.00	%	—	—	—	—
Total BSA	n.a.	n.a.	n.a.		n.a.	n.a.		n.a.		n.a.	44	19	(16)


AGA	Share price (in euros)	Exercise price (in euros)	Volatility	Maturity (in years)	Risk-free rate		Yield		Value of initial plan (in thousands of euros)	Expense for the year ended 2021 (in thousands of euros)	Expense for the year ended 2020 (in thousands of euros)	Expense for the year ended 2019 (in thousands of euros)
AGA 2018-1	12.87	0.00	n.a.	n.a.	0.00	%	0.00	%	4,951	16	268	2,052
AGA 2018-2	12.87	0.00	n.a.	n.a.	0.00	%	0.00	%	75	—	21	37
AGA 2019-1	10.90	0.00	n.a.	n.a.	0.19% / 0.141%		0.00	%	4,776	422	1,884	1,529
AGA 2020	5.90	0.00	n.a.	n.a.	-0.74%/-0.69%		0.00	%	287	144	116	—
AGA 2021	13.60	0.00	n.a.	n.a.	-0.63%/ -0.59%		0.00	%	4,869	1,784	—	—
Total AGA	n.a.	n.a.	n.a.	n.a.	n.a.		n.a.		n.a.	2,366	2,289	3,618


(in thousands of euros)	BSPCE	BSA	OSA	AGA	Total
Expense for the year ended December 31, 2021	32	44	760	2,366	3,202


(in thousands of euros)	BSPCE	BSA	OSA	AGA	Total
Expense for the year ended December 31, 2020	107	19	509	2,289	2,924


(in thousands of euros)	BSPCE	BSA	OSA	AGA	Total
Expense for the year ended December 31, 2019	175	(16)	543	3,618	4,320

Disclosure of indirect measurement of fair value of goods or services received, share options granted during period


OSA	Share price (in euros)	Exercise price (in euros)	Volatility		Maturity (in years)	Risk-free rate		Yield		Value of initial plan (in thousands of euros)	Expense for the year ended 2021 (in thousands of euros)	Expense for the year ended 2020 (in thousands of euros)	Expense for the year ended 2019 (in thousands of euros)
OSA 2016 Ordinary	13.05	13.05	59% - 62% - 60%		5.5 / 6 /6.5	0.32	%	0.00	%	117	—	—	—
OSA 2016 Performance	13.05	13.05	59	%	5	0.19	%	0.00	%	69	—	—	—
OSA 2016-2	14.26	14.26	58% - 62% - 59%		5.5 / 6 /6.5	0.04	%	0.00	%	27	—	—	3
OSA 2017 Ordinary	15.93	14.97	58% - 61% - 59%		5.5 / 6 /6.5	0.23	%	0.00	%	31	—	—	1
OSA 2017 Performance	15.93	14.97	59	%	5	0.11	%	0.00	%	35	—	—	—
OSA 2018	12.87	12.87	35	%	5.5 / 6 /6.5	0.00	%	0.00	%	252	—	7	66
OSA 2019-1	11.08	11.08	38.1% / 37.4%		6 /6.5	0.103% / 0.149%		0.00	%	140	17	49	38
OSA 2019-2	6.41	6.41	37	%	10	0.40	%	0.00	%	252	—	—	436
OSA 2020	6.25	6.25	38	%	10	0.31	%	0.00	%	939	329	453	—
OSA 2021-04 O	13.60	13.74	38.9% - 37.8% - 38.3%		5.5 / 6 /6.5	-0.38%/ -0.33%/ -0.28%		0.00	%	684	188	—	—
OSA 2021-04 P	13.60	13.74	39.10	%	10	0.03	%	0.00	%	1,816	131	—
OSA 2021-06 O	12.20	12.99	39.2% / 37.9% / 38.1%		5.5 / 6 /6.5	-0.35 %/ -0.3 %/ -0.26 %		0.00	%	246	79	—	—
OSA 2021-06 P	12.20	12.99	39.10	%	10	0.13	%	0.00	%	212	16	—
Total OSA	n.a.	n.a.	n.a.		n.a.	n.a.		n.a.		n.a.	760	509	543


(in thousands of euros)	BSPCE	BSA	OSA	AGA	Total
Expense for the year ended December 31, 2021	32	44	760	2,366	3,202


(in thousands of euros)	BSPCE	BSA	OSA	AGA	Total
Expense for the year ended December 31, 2020	107	19	509	2,289	2,924


(in thousands of euros)	BSPCE	BSA	OSA	AGA	Total
Expense for the year ended December 31, 2019	175	(16)	543	3,618	4,320

Net financial income (loss) (Tables)

12 Months Ended

Dec. 31, 2021

Income, expense, gains or losses of financial instruments [abstract]

Summary of net financial income (loss)


	For the years ended December 31,
(in thousands of euros)	2021	2020	2019
Income from cash and cash equivalents	—	—	105
Foreign exchange gains	6,347	104	599
Other financial income	13	97	133
Total financial income	6,360	201	837
Interest cost	(383)	4,676	(4,434)
IFRS 16 related interests	(288)	(333)	(359)
Foreign exchange losses	(109)	(1,697)	(176)
Total financial expenses	(780)	2,646	(4,970)
Net financial income (loss)	5,580	2,847	(4,133)

Income tax (Tables)

12 Months Ended

Dec. 31, 2021

Income taxes paid (refund) [abstract]

Schedule of reconciliation between statutory and effective income tax

The following table reconciles the Company’s theoretical tax expense to its effective tax expense:


	For the year ended December 31,
(in thousands of euros)	2021		2020		2019
Net loss	(47,003)		(33,590)		(50,915)
Effective tax expense	5		9		3
Recurring loss before tax	(47,058)		(33,581)		(50,912)
Theoretical tax rate (statutory rate in France)	26.50	%	28.00	%	31.00	%
Theoretical tax (benefit) expense	(12,470)		(9,403)		(15,782)
Share-based payment	848		819		1,339
Other temporary differences	117		(6)		(1)
Other non-taxable items	(644)		(540)		(736)
Unrecognized tax losses	12,154		9,138		15,177
Effective tax expense	5		9		3
Effective tax rate	0.00	%	0.00	%	0.00	%

Loss per share (Tables)

12 Months Ended

Dec. 31, 2021

Earnings per share [abstract]

Schedule of basic and diluted loss per share


	For the year ended December 31,
	2021	2020	2019
Net loss for the period (in thousands of euros)	(47,063)	(33,590)	(50,915)
Weighted average number of shares	34,733,418	24,385,827	21,631,514
Basic loss per share (in euros)	(1.35)	(1.38)	(2.35)
Diluted loss per share (in euros)	(1.35)	(1.38)	(2.35)

Related parties (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure of significant transactions

The compensation presented below, granted to the members of the Executive Board and Supervisory Board was recognized in expenses over the period shown:


	For the year ended December 31,
(in thousands of euros)	2021	2020	2019
Salaries, wages and benefits	1,245	1,073	1,306
Share-based payments	2,018	1,723	2,066
Supervisory Board’s fees	375	70	70
Total compensation to related parties	3,638	2,866	3,442

Company information (Details) $ in Thousands, € in Millions		1 Months Ended				3 Months Ended	6 Months Ended	8 Months Ended	10 Months Ended	12 Months Ended
Company information (Details) $ in Thousands, € in Millions	Jun. 15, 2021 USD ($)	Jun. 30, 2021 EUR (€)	Jun. 30, 2021 USD ($)	May 31, 2021 USD ($) study	Mar. 31, 2021 USD ($)	Mar. 31, 2021 USD ($)	Jun. 30, 2021 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 USD ($)
Termination of PharmaEngine License and Collaboration Agreement, NBTXR3
Disclosure Of Information Related To The Company [Line Items]
Upfront payment				$ 4,000	$ 2,500		€ 5.4		$ 6,500	€ 5.4	$ 6,500
Milestone payment upon receipt of clinical study reports					1,000	$ 1,000
Milestone payment upon second regulatory approval					$ 5,000	$ 5,000
Royalties agreement, period					10 years	10 years
Termination of PharmaEngine License and Collaboration Agreement, NBTXR3 \| Maximum
Disclosure Of Information Related To The Company [Line Items]
Onerous contracts provision					$ 12,500	$ 12,500
LianBio, NBTXR3
Disclosure Of Information Related To The Company [Line Items]
Number of global registrational studies supported \| study				5
Upfront payment received	$ 20,000	€ 16.5	$ 20,000					$ 20,000
LianBio, NBTXR3 \| Maximum
Disclosure Of Information Related To The Company [Line Items]
Potential development and commercial milestones payments				$ 220,000				$ 220,000	$ 220,000		$ 220,000

General Information, Statement of Compliance and Basis of Presentation (Details) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
General Information, Statement of Compliance and Basis of Presentation [Abstract]
Cash and cash equivalents	€ 83,921	€ 119,151	€ 35,094	€ 36,203

Consolidation principles and methods (Details)	12 Months Ended
Consolidation principles and methods (Details)	Dec. 31, 2021 parent_entity subsidiary	Dec. 31, 2020	Dec. 31, 2019
Significant Accounting Policies [Abstract]
Closing foreign exchange rate	1.1326	1.2271	1.1234
Average foreign exchange rate	1.1835	1.1413	1.1196
Number of parent entities \| parent_entity	1
Number of subsidiaries \| subsidiary	5

Significant transactions (Details) € in Thousands, $ in Thousands			1 Months Ended									3 Months Ended	6 Months Ended	8 Months Ended	10 Months Ended	12 Months Ended							101 Months Ended
	Jun. 15, 2021 USD ($)	Feb. 03, 2020 USD ($)	Jun. 30, 2021 EUR (€)	Jun. 30, 2021 USD ($)	May 31, 2021 USD ($) study	Mar. 31, 2021 USD ($)	Jul. 31, 2020	Mar. 31, 2019 EUR (€)	Jan. 31, 2019 USD ($) patient	Oct. 31, 2018 EUR (€)	Jul. 31, 2018 EUR (€)	Mar. 31, 2021 USD ($)	Jun. 30, 2021 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 EUR (€)	Dec. 31, 2016 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2021 USD ($)	Aug. 31, 2012 USD ($)
Disclosure of transactions between related parties [line items]
Increase in loans and conditional advances \| €																€ 0		€ 10,350	€ 14,000
Prepaid expenses \| €																2,213		2,217
LianBio, NBTXR3
Disclosure of transactions between related parties [line items]
Number of global registrational studies supported \| study					5
Upfront payment received	$ 20,000		€ 16,500	$ 20,000										$ 20,000
LianBio, NBTXR3 \| Maximum
Disclosure of transactions between related parties [line items]
Potential development and commercial milestones payments					$ 220,000																			$ 220,000
PharmaEngine, NBTWR3
Disclosure of transactions between related parties [line items]
Upfront payment received																						$ 1,000
Development milestones payments received																				$ 1,000	$ 1,000
Total payments received under agreement																							$ 3,000
Termination of PharmaEngine License and Collaboration Agreement, NBTXR3
Disclosure of transactions between related parties [line items]
Upfront payment					$ 4,000	$ 2,500							€ 5,400		$ 6,500	5,400	$ 6,500
Milestone payment upon receipt of clinical study reports						1,000						$ 1,000
Milestone payment upon second regulatory approval						$ 5,000						$ 5,000
Royalties agreement, period						10 years						10 years
MD Anderson Cancer Center, NBTXR3
Disclosure of transactions between related parties [line items]
Upfront payment		$ 1,000							$ 1,000
Number of patients \| patient									340
Contractual capital commitments									$ 11,000
Milestone payment, deferment period									6 months
Prepaid expenses \| €																€ 1,000		€ 1,600
EIB fixed rate loan
Disclosure of transactions between related parties [line items]
Royalties agreement, period											6 years
Increase in loans and conditional advances \| €								€ 14,000		€ 16,000
Borrowings, interest rate								5.00%		6.00%								4.00%
Borrowing, maturity																		5 years
Undrawn borrowing facilities \| €																		€ 10,000
Borrowing, deferment period																		1 year
Borrowing, deferment period to request funds							12 months
EIB fixed rate loan \| Maximum
Disclosure of transactions between related parties [line items]
Notional amount \| €											€ 40,000
Top of range \| PharmaEngine, NBTWR3
Disclosure of transactions between related parties [line items]
Potential development and commercial milestones payments																									$ 56,000
Top of range \| MD Anderson Cancer Center, NBTXR3
Disclosure of transactions between related parties [line items]
Milestone payment increase																	16,400
Top of range \| EIB fixed rate loan
Disclosure of transactions between related parties [line items]
Notional amount \| €											€ 40,000
Bottom of range \| MD Anderson Cancer Center, NBTXR3
Disclosure of transactions between related parties [line items]
Milestone payment increase																	$ 2,200

Intangible assets (Details) - EUR (€) € in Thousands	12 Months Ended
Intangible assets (Details) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	€ 21	€ 163
Increases	(17)	(141)
Decreases	0	0
Transfer	0	0
Currency translation	0	0
Intangible assets at end of period	4	21
Gross book value of intangible assets
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	717	710
Increases	5	11
Decreases	0	(5)
Transfer	0	0
Currency translation	0	0
Intangible assets at end of period	722	717
Gross book value of intangible assets \| Patents
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	65	65
Increases	0	0
Decreases	0	0
Transfer	0	0
Currency translation	0	0
Intangible assets at end of period	65	65
Gross book value of intangible assets \| Software
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	651	584
Increases	5	11
Decreases	0	(5)
Transfer	0	61
Currency translation	0	0
Intangible assets at end of period	657	651
Gross book value of intangible assets \| Intangible assets in progress
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	0	61
Increases	0	0
Decreases	0	0
Transfer	0	(61)
Currency translation	0	0
Intangible assets at end of period	0	0
Accumulated depreciation of intangible assets
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	(695)	(548)
Increases	(22)	(152)
Decreases	0	5
Transfer	0	0
Currency translation	0	0
Intangible assets at end of period	(717)	(695)
Accumulated depreciation of intangible assets \| Patents
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	(65)	(65)
Increases	0	0
Decreases	0	0
Transfer	0	0
Currency translation	0	0
Intangible assets at end of period	(65)	(65)
Accumulated depreciation of intangible assets \| Software
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	(630)	(483)
Increases	(22)	(152)
Decreases	0	5
Transfer	0	0
Currency translation	0	0
Intangible assets at end of period	€ (652)	€ (630)

Property, plant and equipment - Additional Information (Details) € in Thousands	12 Months Ended
	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€) lease_contract
Disclosure of detailed information about property, plant and equipment [line items]
Increase in right-of-use assets	€ 56	€ (1,101)
Disposals, property, plant and equipment	€ 129	€ 14
Number of new lease contracts \| lease_contract		2
Lease contract, Villejuif
Disclosure of detailed information about property, plant and equipment [line items]
Lease contract, extended period	4 years
Addition to annual rent expense		€ 15
Lease contract, Wattignies
Disclosure of detailed information about property, plant and equipment [line items]
Addition to annual rent expense		35
Gross book value of tangible assets
Disclosure of detailed information about property, plant and equipment [line items]
Increase in right-of-use assets	€ 1,590	515
Disposals, property, plant and equipment	212	57
Fixtures, fittings and installations \| Gross book value of tangible assets
Disclosure of detailed information about property, plant and equipment [line items]
Increase in right-of-use assets	5	16
Disposals, property, plant and equipment	€ 0	0
Fixtures, fittings and installations \| Bottom of range
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation periods of property, plant and equipment	5 years
Fixtures, fittings and installations \| Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation periods of property, plant and equipment	10 years
Right of use – Buildings \| Gross book value of tangible assets
Disclosure of detailed information about property, plant and equipment [line items]
Increase in right-of-use assets	€ 1,362	418
Disposals, property, plant and equipment	139	14
Right of use – Buildings \| Gross book value of tangible assets \| Lease contract, Villejuif
Disclosure of detailed information about property, plant and equipment [line items]
Additions to right-of-use assets	1,390
Addition to annual rent expense	€ (25)
Right of use – Buildings \| Gross book value of tangible assets \| Lease contract, Oberkampf street
Disclosure of detailed information about property, plant and equipment [line items]
Additions to right-of-use assets		155
Right of use – Buildings \| Gross book value of tangible assets \| Lease contract, Faubourg Saint-Antoine
Disclosure of detailed information about property, plant and equipment [line items]
Additions to right-of-use assets		140
Right of use – Buildings \| Gross book value of tangible assets \| Lease contract, Alfortville
Disclosure of detailed information about property, plant and equipment [line items]
Disposals, property, plant and equipment		43
Right of use – Buildings \| Gross book value of tangible assets \| Lease contract, parking Villejuif
Disclosure of detailed information about property, plant and equipment [line items]
Additions to right-of-use assets		30
Right of use – Buildings \| Bottom of range
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation periods of property, plant and equipment	5 years
Right of use – Buildings \| Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation periods of property, plant and equipment	10 years
Technical equipment \| Gross book value of tangible assets
Disclosure of detailed information about property, plant and equipment [line items]
Increase in right-of-use assets	€ 73	42
Disposals, property, plant and equipment	€ 0	0
Technical equipment \| Bottom of range
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation periods of property, plant and equipment	3 years
Technical equipment \| Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation periods of property, plant and equipment	10 years
Office and IT equipment \| Gross book value of tangible assets
Disclosure of detailed information about property, plant and equipment [line items]
Increase in right-of-use assets	€ 53	37
Disposals, property, plant and equipment	€ 35	1
Office and IT equipment \| Bottom of range
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation periods of property, plant and equipment	1 year
Office and IT equipment \| Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation periods of property, plant and equipment	10 years
Transport equipment \| Gross book value of tangible assets
Disclosure of detailed information about property, plant and equipment [line items]
Increase in right-of-use assets	€ 0	0
Disposals, property, plant and equipment	€ 0	0
Transport equipment \| Bottom of range
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation periods of property, plant and equipment	1 year
Transport equipment \| Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation periods of property, plant and equipment	10 years
Right of use – Transport equipment \| Gross book value of tangible assets
Disclosure of detailed information about property, plant and equipment [line items]
Increase in right-of-use assets	€ 0	0
Disposals, property, plant and equipment	€ 38	€ 41
Right of use – Transport equipment \| Bottom of range
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation periods of property, plant and equipment	1 year
Right of use – Transport equipment \| Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation periods of property, plant and equipment	10 years

Property, plant and equipment - Schedule of Property, Plant and Equipment (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	€ 8,256	€ 9,386
Increases	56	(1,101)
Decreases	(129)	(14)
Transfer	0	(12)
Currency translation	3	(4)
Property, plant and equipment at end of period	8,186	8,256
Gross book value of tangible assets
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	13,630	13,197
Increases	1,590	515
Decreases	(212)	(57)
Transfer	0	(15)
Currency translation	8	(11)
Property, plant and equipment at end of period	15,017	13,630
Gross book value of tangible assets \| Fixtures, fittings and installations
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	3,313	3,297
Increases	5	16
Decreases	0	0
Transfer	0	0
Currency translation	0	0
Property, plant and equipment at end of period	3,318	3,313
Gross book value of tangible assets \| Right of use – Buildings
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	7,171	6,766
Increases	1,362	418
Decreases	(139)	(14)
Transfer	0	0
Currency translation	0	0
Property, plant and equipment at end of period	8,393	7,171
Gross book value of tangible assets \| Technical equipment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	2,061	2,019
Increases	73	42
Decreases	0	0
Transfer	1	0
Currency translation	0	0
Property, plant and equipment at end of period	2,135	2,061
Gross book value of tangible assets \| Office and IT equipment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	988	957
Increases	53	37
Decreases	(35)	(1)
Transfer	0	0
Currency translation	4	(4)
Property, plant and equipment at end of period	1,010	988
Gross book value of tangible assets \| Transport equipment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	31	34
Increases	0	0
Decreases	0	0
Transfer	0	0
Currency translation	3	(3)
Property, plant and equipment at end of period	33	31
Gross book value of tangible assets \| Right of use – Transport equipment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	65	115
Increases	0	0
Decreases	(38)	(41)
Transfer	0	(5)
Currency translation	1	(4)
Property, plant and equipment at end of period	28	65
Gross book value of tangible assets \| Tangible assets in progress
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	1	11
Increases	97	1
Decreases	0	0
Transfer	0	(11)
Currency translation	0	0
Property, plant and equipment at end of period	98	1
Gross book value of tangible assets \| Prepayments on tangible assets
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	0	0
Increases	0	0
Decreases	0	0
Transfer	0	0
Currency translation	0	0
Property, plant and equipment at end of period	0	0
Accumulated depreciation of tangible assets
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(5,374)	(3,811)
Increases	(1,534)	(1,616)
Decreases	84	43
Transfer	0	4
Currency translation	(6)	6
Property, plant and equipment at end of period	(6,831)	(5,374)
Accumulated depreciation of tangible assets \| Fixtures, fittings and installations
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(1,320)	(1,001)
Increases	(320)	(320)
Decreases	0	0
Transfer	0	0
Currency translation	0	0
Property, plant and equipment at end of period	(1,641)	(1,320)
Accumulated depreciation of tangible assets \| Right of use – Buildings
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(1,739)	(829)
Increases	(901)	(911)
Decreases	30	0
Transfer	0	2
Currency translation	0	0
Property, plant and equipment at end of period	(2,610)	(1,739)
Accumulated depreciation of tangible assets \| Technical equipment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(1,466)	(1,272)
Increases	(178)	(194)
Decreases	0	0
Transfer	0	0
Currency translation	0	0
Property, plant and equipment at end of period	(1,644)	(1,466)
Accumulated depreciation of tangible assets \| Office and IT equipment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(783)	(629)
Increases	(124)	(157)
Decreases	34	1
Transfer	0	0
Currency translation	(3)	2
Property, plant and equipment at end of period	(875)	(783)
Accumulated depreciation of tangible assets \| Transport equipment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(31)	(34)
Increases	0	0
Decreases	0	0
Transfer	0	1
Currency translation	(3)	3
Property, plant and equipment at end of period	(33)	(31)
Accumulated depreciation of tangible assets \| Right of use – Transport equipment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(36)	(45)
Increases	(12)	(35)
Decreases	20	42
Transfer	0	0
Currency translation	(1)	1
Property, plant and equipment at end of period	€ (28)	€ (36)

Non-current financial assets - Disclosure of Changes in Non-current Financial Assets (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure of financial assets [line items]
Non-current financial assets at beginning of period	€ 505	€ 529
Additions	9	9
Decreases	(6)	(31)
Transfer	8
Currency translation adjustments	3	(2)
Non-current financial assets at end of period	519	505
Liquidity contract - Cash account \| Financial assets at fair value, class
Disclosure of financial assets [line items]
Non-current financial assets at beginning of period	105	131
Additions	0	0
Decreases	(6)	(27)
Transfer	0
Currency translation adjustments	0	0
Non-current financial assets at end of period	98	105
Other long-term investments pledged as collateral \| Financial assets at amortised cost, class
Disclosure of financial assets [line items]
Non-current financial assets at beginning of period	0	0
Additions	0	0
Decreases	0	0
Transfer	0
Currency translation adjustments	0	0
Non-current financial assets at end of period	0	0
Security deposits paid \| Financial assets at amortised cost, class
Disclosure of financial assets [line items]
Non-current financial assets at beginning of period	401	399
Additions	9	9
Decreases	0	(5)
Transfer	8
Currency translation adjustments	3	(2)
Non-current financial assets at end of period	€ 421	€ 401

Non-current financial assets - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Detailed Information About Non-current Financial Assets [Line Items]
Increase (decrease) in financial assets	€ 14	€ (24)
Additions	9	€ 9
Security deposits paid
Disclosure Of Detailed Information About Non-current Financial Assets [Line Items]
Increase (decrease) in financial assets	20
Additions	€ 9

Trade receivables and other current assets - Disclosure of Break Down of Trade Receivables (Details) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Trade receivables	€ 0	€ 62
Due in 3 months or less
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Trade receivables	0	62
Due between 3 and 6 months
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Trade receivables	0	0
Due between 6 and 12 months
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Trade receivables	0	0
Due after more than 12 months
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Trade receivables	€ 0	€ 0

Trade receivables and other current assets - Disclosure of Break Down of Other Current Assets (Details) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Subclassifications of assets, liabilities and equities [abstract]
Research tax credit receivable	€ 2,490	€ 1,927	€ 5,688
VAT receivable	1,058	971
Prepaid expenses	2,213	2,217
Other receivables	3,378	920
Other current assets	€ 9,139	€ 6,035

Trade receivables and other current assets - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Prepaid expenses	€ 2,213	€ 2,217
Prepaid expenses related to insurance for Directors and Officers	600
Current advances to suppliers	3,043	805
2021 Tax Year
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Research tax credit	2,500
2020 Tax Year
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Research tax credit		1,900
Nanobiotix S.A. \| 2021 Tax Year
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Research tax credit	2,272
Nanobiotix S.A. \| 2020 Tax Year
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Research tax credit		1,858
Curadigm SAS \| 2021 Tax Year
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Research tax credit	218
Curadigm SAS \| 2020 Tax Year
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Research tax credit		69
MD Anderson Cancer Center, NBTXR3
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Prepaid expenses	€ 1,000	€ 1,600

Trade receivables and other current assets - Disclosure of Changes in Research Tax Credit Receivables (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Research tax credit receivable at beginning of period	€ 1,927	€ 5,688
Research tax credit receivable at end of period	2,490	1,927
2018 Tax Year \| Nanobiotix S.A.
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Refund of research tax credit		(3,251)
2019 Tax Year \| Nanobiotix S.A.
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Refund of research tax credit		(2,374)
2019 Tax Year \| Curadigm SAS
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Refund of research tax credit		(64)
2020 Tax Year
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Research tax credit		1,900
2020 Tax Year \| Nanobiotix S.A.
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Refund of research tax credit	(1,858)
Research tax credit		1,858
2020 Tax Year \| Curadigm SAS
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Refund of research tax credit	(69)
Research tax credit		€ 69
2021 Tax Year
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Research tax credit	2,500
2021 Tax Year \| Nanobiotix S.A.
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Research tax credit	2,272
2021 Tax Year \| Curadigm SAS
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Research tax credit	€ 218

Cash and cash equivalents - Summary of Cash and Cash Equivalents (Details) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Subclassifications of assets, liabilities and equities [abstract]
Cash and bank accounts	€ 83,921	€ 119,151
Net cash and cash equivalents	€ 83,921	€ 119,151	€ 35,094	€ 36,203

Cash and cash equivalents - Additional Information (Details) € in Thousands, $ in Millions		1 Months Ended				6 Months Ended	8 Months Ended	10 Months Ended	12 Months Ended
	Jun. 15, 2021 USD ($)	Jun. 30, 2021 EUR (€)	Jun. 30, 2021 USD ($)	May 31, 2021 USD ($)	Mar. 31, 2021 USD ($)	Jun. 30, 2021 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 EUR (€)
Disclosure of Cash and Cash Equivalents [Line Items]
Decrease in cash and cash equivalents									€ 35,230		€ (84,056)	€ 1,109
Loans repayments									2,833		€ 250	€ 500
EIB Loan
Disclosure of Cash and Cash Equivalents [Line Items]
Loans repayments									3,000
BPI loan
Disclosure of Cash and Cash Equivalents [Line Items]
Loans repayments									500
LianBio, NBTXR3
Disclosure of Cash and Cash Equivalents [Line Items]
Upfront payment received	$ 20.0	€ 16,500	$ 20.0				$ 20.0
Termination of PharmaEngine License and Collaboration Agreement, NBTXR3
Disclosure of Cash and Cash Equivalents [Line Items]
Upfront payment				$ 4.0	$ 2.5	€ 5,400		$ 6.5	€ 5,400	$ 6.5

Share Capital - Disclosure of Detail of Share Capital Transactions (Details)																			12 Months Ended
	May 31, 2021 EUR (€)	Apr. 20, 2021 EUR (€)	Apr. 01, 2021 EUR (€)	Mar. 31, 2021 EUR (€) shares	Mar. 17, 2021 EUR (€)	Dec. 18, 2020 EUR (€) shares	Dec. 18, 2020 $ / shares	Dec. 16, 2020 EUR (€) € / shares shares	Dec. 16, 2020 $ / shares	Jul. 28, 2020 EUR (€) shares	Jul. 27, 2020 EUR (€) shares	Jun. 30, 2020 EUR (€)	Jun. 29, 2020 EUR (€)	Jun. 26, 2020 EUR (€)	Jun. 24, 2020 EUR (€)	Mar. 06, 2020 EUR (€) shares	Apr. 09, 2019 € / shares	Apr. 09, 2019 $ / shares	Dec. 31, 2021 EUR (€) shares	Dec. 31, 2020 EUR (€) shares	Dec. 31, 2019 EUR (€) shares
Disclosure of classes of share capital [line items]
Equity at beginning of period																			€ 70,468,000	€ (1,908,000)	€ 14,243,000
Capital increase			€ 11,077.5		€ 735						€ 180								0	102,942,000	28,079,000
Subscription of warrants																			43,000	5,000	21,000
U.S. Initial public offering costs offset																				(10,700,000)	1,030,000
Equity at end of period																			26,790,000	70,468,000	(1,908,000)
IPO initial deal, Euro
Disclosure of classes of share capital [line items]
Issue of equity, price per share (in euro or dollar per share) \| € / shares								€ 11.14
IPO initial deal, US Dollar
Disclosure of classes of share capital [line items]
Issue of equity, price per share (in euro or dollar per share) \| $ / shares									$ 13.50
IPO green shoe, US Dollar
Disclosure of classes of share capital [line items]
Issue of equity, price per share (in euro or dollar per share) \| $ / shares							$ 13.50
Share Capital
Disclosure of classes of share capital [line items]
Equity at beginning of period																			1,032,963.66	672,451.17	589,000
Capital increase										€ 99,000						€ 9,000			12,000	361,000	77,000
Equity at end of period																			€ 1,044,776.16	€ 1,032,963.66	€ 672,451.17
Number of shares outstanding at beginning of period (in shares) \| shares																			34,432,122	22,415,039	19,633,373
Capital increase, net (in shares) \| shares										3,300,000	6,000					316,083			393,750	12,017,083	2,566,666
Number of shares outstanding at end of period (in shares) \| shares																			34,825,872	34,432,122	22,415,039
Share Capital \| AGA 2018-1
Disclosure of classes of share capital [line items]
Capital increase				€ 1,000
Capital increase, net (in shares) \| shares				24,500
Share Capital \| AGA 2018-2
Disclosure of classes of share capital [line items]
Capital increase				€ 11,000
Capital increase, net (in shares) \| shares				369,250
Share Capital \| IPO initial deal, Euro
Disclosure of classes of share capital [line items]
Capital increase								€ 56,000
Capital increase, net (in shares) \| shares								1,855,000
Issue of equity, price per share (in euro or dollar per share) \| € / shares																	€ 11.14
Share Capital \| IPO initial deal, US Dollar
Disclosure of classes of share capital [line items]
Capital increase								€ 163,000
Capital increase, net (in shares) \| shares								5,445,000
Issue of equity, price per share (in euro or dollar per share) \| $ / shares																		$ 13.50
Share Capital \| IPO green shoe, US Dollar
Disclosure of classes of share capital [line items]
Capital increase						€ 33,000
Capital increase, net (in shares) \| shares						1,095,000
Issue of equity, price per share (in euro or dollar per share) \| $ / shares																		$ 13.50
Premiums related to share capital
Disclosure of classes of share capital [line items]
Equity at beginning of period																			€ 255,735,000	€ 153,139,000	€ 122,799,000
Capital increase										€ 20,030,000						€ 0				102,591,000	28,002,000
Subscription of warrants	€ 43,000	€ (11,000)										€ 1,000	€ 2,000	€ 1,000	€ 1,000				32,000	5,000	8,000
U.S. Initial public offering costs offset						€ (9,322,000)				€ (1,387,000)											1,030,000
Equity at end of period																			€ 255,767,000	€ 255,735,000	€ 153,139,000
Premiums related to share capital \| IPO initial deal, Euro
Disclosure of classes of share capital [line items]
Capital increase								€ 20,609,000
Premiums related to share capital \| IPO initial deal, US Dollar
Disclosure of classes of share capital [line items]
Capital increase								€ 60,494,000
Premiums related to share capital \| IPO green shoe, US Dollar
Disclosure of classes of share capital [line items]
Capital increase						€ 12,165,000

Share Capital - Capital Issued (Details)										1 Months Ended	12 Months Ended
Share Capital - Capital Issued (Details)	Dec. 18, 2020 EUR (€) shares	Dec. 18, 2020 $ / shares	Dec. 16, 2020 € / shares shares	Dec. 16, 2020 $ / shares shares	Jul. 28, 2020 EUR (€) shares	Jul. 27, 2020 shares	Mar. 06, 2020 shares	Apr. 09, 2019 € / shares	Apr. 09, 2019 $ / shares	Dec. 31, 2020 EUR (€) € / shares shares	Dec. 31, 2021 EUR (€) € / shares shares	Dec. 31, 2020 EUR (€) € / shares shares	Dec. 31, 2019 EUR (€) € / shares shares	Dec. 31, 2018 EUR (€) shares
Disclosure of classes of share capital [line items]
Equity										€ 70,468,000	€ 26,790,000	€ 70,468,000	€ (1,908,000)	€ 14,243,000
Par value per share (euro per share) \| € / shares										€ 0.03	€ 0.03	€ 0.03	€ 0.03
Share issue related cost												€ 10,700,000	€ (1,030,000)
Initial offering costs											€ 349,000	10,359,000	1,438,000
IPO initial deal, US Dollar
Disclosure of classes of share capital [line items]
Issue of equity, price per share (in euro or dollar per share) \| $ / shares				$ 13.50
IPO initial deal, Euro
Disclosure of classes of share capital [line items]
Issue of equity, price per share (in euro or dollar per share) \| € / shares			€ 11.14
IPO green shoe, US Dollar
Disclosure of classes of share capital [line items]
Issue of equity, price per share (in euro or dollar per share) \| $ / shares		$ 13.50
Share Capital
Disclosure of classes of share capital [line items]
Equity										€ 1,032,963.66	€ 1,044,776.16	€ 1,032,963.66	€ 672,451.17	€ 589,000
Number of shares outstanding \| shares										34,432,122	34,825,872	34,432,122	22,415,039	19,633,373
Capital increase, net (in shares) \| shares					3,300,000	6,000	316,083				393,750	12,017,083	2,566,666
Share Capital \| Initial Public Offering
Disclosure of classes of share capital [line items]
Capital increase, net (in shares) \| shares										8,395,000
Share Capital \| IPO initial deal, US Dollar
Disclosure of classes of share capital [line items]
Capital increase, net (in shares) \| shares			5,445,000	5,445,000
Issue of equity, price per share (in euro or dollar per share) \| $ / shares									$ 13.50
Share Capital \| IPO initial deal, Euro
Disclosure of classes of share capital [line items]
Capital increase, net (in shares) \| shares			1,855,000	1,855,000
Issue of equity, price per share (in euro or dollar per share) \| € / shares								€ 11.14
Share Capital \| IPO green shoe, US Dollar
Disclosure of classes of share capital [line items]
Capital increase, net (in shares) \| shares	1,095,000
Issue of equity, price per share (in euro or dollar per share) \| $ / shares									$ 13.50
Premiums related to share capital
Disclosure of classes of share capital [line items]
Equity										€ 255,735,000	€ 255,767,000	€ 255,735,000	€ 153,139,000	€ 122,799,000
Share issue related cost	€ 9,322,000				€ 1,387,000								€ (1,030,000)
Initial offering costs											€ 349,000

Share Capital - Treasury Shares (Details) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure of classes of share capital [line items]
Treasury shares	€ 202	€ 196
Treasury shares
Disclosure of classes of share capital [line items]
Number of shares outstanding	15,456	12,970

Share Capital - Disclosure of Detail of Change in Founders' Warrants, Warrants, Stock Options and Free Shares (Details)																							12 Months Ended
	Jun. 21, 2021 shares € / shares	Apr. 20, 2021 shares € / shares	Apr. 01, 2021 shares	Mar. 17, 2021 shares	Jul. 27, 2020 shares	Mar. 17, 2020 shares € / shares	Mar. 11, 2020 shares € / shares	Oct. 24, 2019 shares € / shares	Mar. 29, 2019 shares € / shares	Jul. 27, 2018 shares € / shares	Mar. 06, 2018 shares € / shares	Jan. 07, 2017 shares € / shares	Nov. 03, 2016 shares € / shares	Feb. 02, 2016 € / shares	Jun. 25, 2015 shares € / shares	Jun. 10, 2015 shares € / shares	Feb. 10, 2015 shares € / shares	Sep. 16, 2014 shares € / shares	Aug. 28, 2013 shares € / shares	Apr. 10, 2013 shares € / shares	Dec. 18, 2012 shares € / shares	May 04, 2012 shares € / shares	Dec. 31, 2021 shares € / shares	Dec. 31, 2020 shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, beginning of period (in shares)																							2,414,654	2,338,013
Outstanding, end of period (in shares)																							2,972,860	2,414,654
BSPCE
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, beginning of period (in shares)																							718,767	751,585
Issued (in shares)																							0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							(3,476)	(32,818)
Outstanding, end of period (in shares)																							715,291	718,767
Number of shares issuable (in shares)																							715,291	718,767
BSPCE 2012-2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares																					€ 6.63
Outstanding, beginning of period (in shares)																							100,000	100,000
Issued (in shares)																					100,000		0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							0	0
Outstanding, end of period (in shares)																							100,000	100,000
Number of shares issuable (in shares)																							100,000	100,000
BSPCE 08-2013
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares																			€ 5.92
Outstanding, beginning of period (in shares)																							50,000	50,000
Issued (in shares)																			50,000				0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							0	0
Outstanding, end of period (in shares)																							50,000	50,000
Number of shares issuable (in shares)																							50,000	50,000
BSPCE 09-2014
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares																		€ 18.68
Outstanding, beginning of period (in shares)																							86,150	92,100
Issued (in shares)																		97,200					0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							0	(5,950)
Outstanding, end of period (in shares)																							86,150	86,150
Number of shares issuable (in shares)																							86,150	86,150
BSPCE 2015-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares																	€ 18.57
Outstanding, beginning of period (in shares)																							68,450	70,950
Issued (in shares)																	71,650						0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							0	(2,500)
Outstanding, end of period (in shares)																							68,450	68,450
Number of shares issuable (in shares)																							68,450	68,450
BSPCE 2015-3
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares																€ 20.28
Outstanding, beginning of period (in shares)																							30,700	38,400
Issued (in shares)																53,050							0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							(350)	(7,700)
Outstanding, end of period (in shares)																							30,350	30,700
Number of shares issuable (in shares)																							30,350	30,700
BSPCE 2016
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares														€ 14.46
Outstanding, beginning of period (in shares)																							202,617	212,969
Issued (in shares)																							0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							(1,776)	(10,352)
Outstanding, end of period (in shares)																							200,841	202,617
Number of shares issuable (in shares)																							200,841	202,617
BSPCE 2017
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares												€ 15.93
Outstanding, beginning of period (in shares)																							180,850	187,166
Issued (in shares)																							0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							(1,350)	(6,316)
Outstanding, end of period (in shares)																							179,500	180,850
Number of shares issuable (in shares)																							179,500	180,850
BSA
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, beginning of period (in shares)																							263,028	251,028
Issued (in shares)																							78,103	18,000
Exercised (in shares)																							0	0
Forfeited (in shares)																							(77,880)	(6,000)
Outstanding, end of period (in shares)																							263,251	263,028
Number of shares issuable (in shares)																							263,251	263,028
BSA 04-12
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares																						€ 6.00
Outstanding, beginning of period (in shares)																							30,000	30,000
Issued (in shares)																						52,500	0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							0	0
Outstanding, end of period (in shares)																							30,000	30,000
Number of shares issuable (in shares)																							30,000	30,000
BSA 2013
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares																				€ 6.37
Outstanding, beginning of period (in shares)																							6,000	6,000
Issued (in shares)																				10,000			0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							0	0
Outstanding, end of period (in shares)																							6,000	6,000
Number of shares issuable (in shares)																							6,000	6,000
BSA 2014
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares																		€ 17.67					€ 40
Outstanding, beginning of period (in shares)																							10,000	10,000
Issued (in shares)																		14,000					0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							0	0
Outstanding, end of period (in shares)																							10,000	10,000
Number of shares issuable (in shares)																							10,000	10,000
BSA 2015-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares																	€ 17.67
Outstanding, beginning of period (in shares)																							21,000	21,000
Issued (in shares)																	26,000						0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							0	0
Outstanding, end of period (in shares)																							21,000	21,000
Number of shares issuable (in shares)																							21,000	21,000
BSA 2015-2(a)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares															€ 19.54
Outstanding, beginning of period (in shares)																							64,000	64,000
Issued (in shares)															64,000								0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							0	0
Outstanding, end of period (in shares)																							64,000	64,000
Number of shares issuable (in shares)																							64,000	64,000
BSA 2015-2(b)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares															€ 19.54
Outstanding, beginning of period (in shares)																							0	6,000
Issued (in shares)															6,000								0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							0	(6,000)
Outstanding, end of period (in shares)																							0	0
Number of shares issuable (in shares)																							0	0
BSA 2016
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares														13.74
Outstanding, beginning of period (in shares)																							36,208	36,208
Issued (in shares)																							0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							(36,208)	0
Outstanding, end of period (in shares)																							0	36,208
Number of shares issuable (in shares)																							0	36,208
BSA 2016-2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares													€ 15.01
Outstanding, beginning of period (in shares)																							8,000	8,000
Issued (in shares)													8,000										0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							(8,000)	0
Outstanding, end of period (in shares)																							0	8,000
Number of shares issuable (in shares)																							0	8,000
BSA 2017
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares												€ 15.76
Outstanding, beginning of period (in shares)																							18,000	18,000
Issued (in shares)												18,000											0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							0	0
Outstanding, end of period (in shares)																							18,000	18,000
Number of shares issuable (in shares)																							18,000	18,000
BSA 2018-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares											€ 13.55
Outstanding, beginning of period (in shares)																							28,000	28,000
Issued (in shares)											28,000												0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							0	0
Outstanding, end of period (in shares)																							28,000	28,000
Number of shares issuable (in shares)																							28,000	28,000
BSA 2018-2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares										€ 16.102
Outstanding, beginning of period (in shares)																							5,820	5,820
Issued (in shares)										5,820													0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							0	0
Outstanding, end of period (in shares)																							5,820	5,820
Number of shares issuable (in shares)																							5,820	5,820
BSA 2019-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares									€ 11.66
Outstanding, beginning of period (in shares)																							18,000	18,000
Issued (in shares)									18,000														0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							0	0
Outstanding, end of period (in shares)																							18,000	18,000
Number of shares issuable (in shares)																							18,000	18,000
BSA 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares						€ 6.59
Outstanding, beginning of period (in shares)																							18,000	0
Issued (in shares)						18,000																	0	18,000
Exercised (in shares)																							0	0
Forfeited (in shares)																							0	0
Outstanding, end of period (in shares)																							18,000	18,000
Number of shares issuable (in shares)																							18,000	18,000
BSA 2021 (a)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares		€ 13.47							€ 13.47
Outstanding, beginning of period (in shares)																							0
Issued (in shares)		48,103																					48,103
Exercised (in shares)																							0
Forfeited (in shares)																							(33,672)
Outstanding, end of period (in shares)																							14,431	0
Number of shares issuable (in shares)																							14,431
BSA 2021 (b)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares		€ 13.64				€ 13.64
Outstanding, beginning of period (in shares)																							0
Issued (in shares)		30,000																					30,000
Exercised (in shares)																							0
Forfeited (in shares)																							0
Outstanding, end of period (in shares)																							30,000	0
Number of shares issuable (in shares)																							30,000
OSA
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding at beginning of period (in shares)																							986,359	589,150
Issued (in shares)																							691,200	407,972
Exercised (in shares)																							0	0
Forfeited (in shares)																							(93,753)	(10,763)
Outstanding at end of period (in shares)																							1,583,806	986,359
Number of shares issuable (in shares)																							1,583,806	986,359
OSA 2016-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares														€ 13.05
Outstanding at beginning of period (in shares)																							400	400
Issued (in shares)																							0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							0	0
Outstanding at end of period (in shares)																							400	400
Number of shares issuable (in shares)																							400	400
OSA 2016-2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares													€ 14.26
Outstanding at beginning of period (in shares)																							4,000	4,000
Issued (in shares)													4,000										0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							0	0
Outstanding at end of period (in shares)																							4,000	4,000
Number of shares issuable (in shares)																							4,000	4,000
OSA 2017
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares												€ 14.97
Outstanding at beginning of period (in shares)																							500	500
Issued (in shares)																							0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							0	0
Outstanding at end of period (in shares)																							500	500
Number of shares issuable (in shares)																							500	500
OSA 2018
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares											€ 12.87
Outstanding at beginning of period (in shares)																							52,000	54,000
Issued (in shares)											62,000												0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							0	(2,000)
Outstanding at end of period (in shares)																							52,000	52,000
Number of shares issuable (in shares)																							52,000	52,000
OSA 2019-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares									€ 11.08
Outstanding at beginning of period (in shares)																							28,750	30,250
Issued (in shares)									37,500														0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							(500)	(1,500)
Outstanding at end of period (in shares)																							28,250	28,750
Number of shares issuable (in shares)																							28,250	28,750
OSA LLY 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares								€ 6.41
Outstanding at beginning of period (in shares)																							500,000	500,000
Issued (in shares)								500,000															0	0
Exercised (in shares)																							0	0
Forfeited (in shares)																							0	0
Outstanding at end of period (in shares)																							500,000	500,000
Number of shares issuable (in shares)																							500,000	500,000
OSA 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares							€ 6.25
Outstanding at beginning of period (in shares)																							400,709	0
Issued (in shares)							407,972																0	407,972
Exercised (in shares)																							0	0
Forfeited (in shares)																							(13,253)	(7,263)
Outstanding at end of period (in shares)																							387,456	400,709
Number of shares issuable (in shares)																							387,456	400,709
OSA 2021-04
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares		€ 13.74
Outstanding at beginning of period (in shares)																							0
Issued (in shares)		571,200																					571,200
Exercised (in shares)																							0
Forfeited (in shares)																							(80,000)
Outstanding at end of period (in shares)																							491,200	0
Number of shares issuable (in shares)																							491,200
OSA 2021-06
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares	€ 12.99
Outstanding at beginning of period (in shares)																							0
Issued (in shares)	120,000																						120,000
Exercised (in shares)																							0
Forfeited (in shares)																							0
Outstanding at end of period (in shares)																							120,000	0
Number of shares issuable (in shares)																							120,000
AGA
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, beginning of period (in shares)																							446,500	746,250
Issued (in shares)																							362,515	50,000
Exercised (in shares)																							(393,750)	(322,083)
Forfeited (in shares)																							(4,753)	(27,667)
Outstanding, end of period (in shares)																							410,512	446,500
Number of shares issuable (in shares)																							410,512	446,500
AGA 2018-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares											€ 0
Outstanding, beginning of period (in shares)																							24,500	355,250
Issued (in shares)				24,500							396,250												0	0
Exercised (in shares)																							(24,500)	(316,083)
Forfeited (in shares)																							0	(14,667)
Outstanding, end of period (in shares)																							0	24,500
Number of shares issuable (in shares)																							0	24,500
AGA 2018-2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares										€ 0
Outstanding, beginning of period (in shares)																							0	6,000
Issued (in shares)					6,000					6,000													0	0
Exercised (in shares)																							0	(6,000)
Forfeited (in shares)																							0	0
Outstanding, end of period (in shares)																							0	0
Number of shares issuable (in shares)																							0	0
AGA 2019-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares									€ 0
Outstanding, beginning of period (in shares)																							372,000	385,000
Issued (in shares)			369,250						438,250														0	0
Exercised (in shares)																							(369,250)	0
Forfeited (in shares)																							(2,750)	(13,000)
Outstanding, end of period (in shares)																							0	372,000
Number of shares issuable (in shares)																							0	372,000
AGA 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares							€ 0
Outstanding, beginning of period (in shares)																							50,000	0
Issued (in shares)							50,000																0	50,000
Exercised (in shares)																							0	0
Forfeited (in shares)																							0	0
Outstanding, end of period (in shares)																							50,000	50,000
Number of shares issuable (in shares)																							50,000	50,000
AGA 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share) \| € / shares		€ 0
Outstanding, beginning of period (in shares)																							0
Issued (in shares)		362,515																					362,515
Exercised (in shares)																							0
Forfeited (in shares)																							(2,003)
Outstanding, end of period (in shares)																							360,512	0
Number of shares issuable (in shares)																							360,512

Share Capital - Founders’ warrants (Details) - BSPCE	12 Months Ended
Share Capital - Founders’ warrants (Details) - BSPCE	Dec. 31, 2021 employee
Former employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of employees with service conditions lifted	3
Former Executive Board members
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of employees with service conditions lifted	2

Share Capital - Warrant Plans (Details)					12 Months Ended
Share Capital - Warrant Plans (Details)	Dec. 31, 2021 shares patient € / shares	Apr. 20, 2021 shares € / shares	Mar. 17, 2020 shares € / shares	Mar. 29, 2019 € / shares	Dec. 31, 2021 shares € / shares	Dec. 31, 2020 shares € / shares	Dec. 31, 2019 € / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Par value per share (euro per share) \| € / shares	€ 0.03				€ 0.03	€ 0.03	€ 0.03
BSA 2021 (a)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares)		48,103			48,103
Exercise price (in euros per share) \| € / shares		€ 13.47		€ 13.47
BSPCE exercise (in shares)					0
BSA 2021 (a) \| Supervisory Board
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares)		48,103
Number of ordinary share subscribed per each BSA (in shares)		1
Par value per share (euro per share) \| € / shares		€ 0.03
Exercise price (in euros per share) \| € / shares		€ 13.47
BSPCE exercise (in shares)	14,431
Maximum term of other equity instruments granted for share-based payment arrangement	10 years
Vesting requirements, minimum attendance	75.00%
Vesting requirements, attendance period	12 months
Vesting requirements, recommended dose determination, minimum number of patients \| patient	2
Vesting requirements, recommended dose determination, total number of patients enrolled \| patient	3
BSA 2021 (a) \| External Consultant
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares)		30,000
Number of ordinary share subscribed per each BSA (in shares)		1
Par value per share (euro per share) \| € / shares		€ 0.03
Exercise price (in euros per share) \| € / shares		€ 13.64
BSPCE exercise (in shares)	0
Maximum term of other equity instruments granted for share-based payment arrangement		10 years
BSA 2021 (a) In Replacement Of BSA 2016 \| Supervisory Board
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares)		18,103
BSA 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares)			18,000		0	18,000
Par value per share (euro per share) \| € / shares			€ 0.03
Exercise price (in euros per share) \| € / shares			€ 6.59
BSPCE exercise (in shares)					0	0

Share Capital - Stock Option Plans (Details)					12 Months Ended
Share Capital - Stock Option Plans (Details)	Jun. 21, 2021 shares patient € / shares	Apr. 20, 2021 shares € / shares	Nov. 30, 2020 € / shares	Mar. 11, 2020 shares € / shares	Dec. 31, 2021 shares employee € / shares	Dec. 31, 2020 shares € / shares	Dec. 31, 2019 € / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Par value per share (euro per share)					€ 0.03	€ 0.03	€ 0.03
OSA 2021-04
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares) \| shares		571,200			571,200
Exercise price (in euros per share)		€ 13.74
OSA 2021-04 O
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share)		13.74
OSA 2021-04 P
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share)		€ 13.74
OSA
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares) \| shares					691,200	407,972
Maximum term of options granted for share-based payment arrangement			10 years
OSA \| From first year of grant date
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements, maximum percentage exercised			10.00%
OSA \| From second year of grant date
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements, maximum percentage exercised			30.00%
OSA \| From third year of grant date
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements, maximum percentage exercised			60.00%
OSA \| Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements for share-based payment arrangement, vesting percentage			10.00%
Share price milestone, Euronext Paris			€ 24.00
OSA \| Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements for share-based payment arrangement, vesting percentage			10.00%
Share price milestone, Euronext Paris			€ 30.00
OSA \| Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements for share-based payment arrangement, vesting percentage			40.00%
Share price milestone, Euronext Paris			€ 40.00
OSA \| Tranche four
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements for share-based payment arrangement, vesting percentage			40.00%
Share price milestone, Euronext Paris			€ 60.00
OSA 2021-06 O
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share)	€ 12.99
OSA 2021-06 P
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros per share)	€ 12.99
OSA 2021-06
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares) \| shares	120,000				120,000
Exercise price (in euros per share)	€ 12.99
OSA 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares) \| shares				407,972	0	407,972
Number of ordinary share subscribed per each OSA \| shares				1
Exercise price (in euros per share)				€ 6.25
OSA 2020 \| Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements for share-based payment arrangement, vesting percentage				33.33%
OSA 2020 \| Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements for share-based payment arrangement, vesting percentage				33.33%
OSA 2020 \| Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements for share-based payment arrangement, vesting percentage				33.33%
Executive Board and Employees \| OSA 2021-04
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares) \| shares		571,200
Number of ordinary share subscribed per each OSA \| shares		1
Par value per share (euro per share)		€ 0.03
Exercise price (in euros per share)		€ 13.74
Maximum term of options granted for share-based payment arrangement		10 years
Executive Board and Employees \| OSA 2021-04 \| Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements for share-based payment arrangement, vesting percentage		33.33%
Executive Board and Employees \| OSA 2021-04 \| Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements for share-based payment arrangement, vesting percentage		33.33%
Executive Board and Employees \| OSA 2021-04 \| Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements for share-based payment arrangement, vesting percentage		33.33%
Executive Board and Employees \| OSA 2021-04 O
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares) \| shares		143,200
Executive Board and Employees \| OSA 2021-04 P
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares) \| shares		428,000
Bart Van Rhijn \| OSA 2021-06 O
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares) \| shares	60,000
Bart Van Rhijn \| OSA 2021-06 P
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares) \| shares	60,000
Bart Van Rhijn \| OSA 2021-06
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares) \| shares	120,000
Number of ordinary share subscribed per each OSA \| shares	1
Par value per share (euro per share)	€ 0.03
Exercise price (in euros per share)	€ 12.99
Anne-Juliette Hermant, Laurent Levy and Bart Van Rhijn \| OSA
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements, recommended dose determination, minimum number of patients \| patient	2
Vesting requirements, recommended dose determination, total number of patients enrolled \| patient	3
Executive Board and Alain Dostie \| OSA 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares) \| shares				300,000
Employees \| OSA 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares) \| shares				107,972
Par value per share (euro per share)				€ 0.03
Exercise price (in euros per share)				€ 6.25
Former Executive Board members \| OSA 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of employees with service conditions lifted \| employee					2
Number of employees with vesting conditions accelerated \| employee					1

Share Capital - Free Share Plans (Details)										12 Months Ended
Share Capital - Free Share Plans (Details)	Apr. 20, 2021 shares patient € / shares	Apr. 01, 2021 EUR (€) shares	Mar. 17, 2021 EUR (€) shares	Jul. 27, 2020 EUR (€) shares	Mar. 11, 2020 shares € / shares	Oct. 24, 2019	Mar. 29, 2019 shares	Jul. 27, 2018 shares	Mar. 06, 2018 shares	Dec. 31, 2021 EUR (€) shares employee € / shares	Dec. 31, 2020 EUR (€) shares € / shares	Dec. 31, 2019 EUR (€) € / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Par value per share (euro per share) \| € / shares										€ 0.03	€ 0.03	€ 0.03
Capital increase, net \| €		€ 11,077.5	€ 735	€ 180						€ 0	€ 102,942,000	€ 28,079,000
AGA 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares)	362,515									362,515
AGA 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares)					50,000					0	50,000
AGA
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares)										362,515	50,000
Maximum term of options granted for share-based payment arrangement in the event of death or disability of optionee						6 months
AGA 2018-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares)			24,500						396,250	0	0
Vesting requirements for share-based payment arrangement, acquisition period			3 years
AGA 2019-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares)		369,250					438,250			0	0
Vesting requirements for share-based payment arrangement, acquisition period		2 years
AGA 2018-2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares)				6,000				6,000		0	0
Vesting requirements for share-based payment arrangement, acquisition period				2 years
Executive Board and Employees \| AGA 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares)	362,515
Par value per share (euro per share) \| € / shares	€ 0.03
Vesting requirements for share-based payment arrangement, holding period	1 year
Vesting requirements for share-based payment arrangement, acquisition period	2 years
Vesting requirements, recommended dose determination, minimum number of patients \| patient	2
Vesting requirements, recommended dose determination, total number of patients enrolled \| patient	3
Executive Board and Employees \| AGA 2020 and AGA 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements for share-based payment arrangement, holding period					1 year
Vesting requirements for share-based payment arrangement, acquisition period					2 years
Vesting requirements for share-based payment arrangement, acquisition period for foreign tax residents					3 years
Anne-Juliette Hermant \| AGA 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares)					50,000
Par value per share (euro per share) \| € / shares					€ 0.03
Employees \| AGA
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of employees with service conditions lifted \| employee										7

Provisions - Disclosure of Changes in Provisions (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure of other provisions [table]
Other provisions at beginning of period	€ 454	€ 495
Increases	70	123
Decreases	(97)	(164)
Other provisions at end of period	428	454
Non-current provisions
Disclosure of other provisions [table]
Other provisions at beginning of period	414	331
Increases	0	83
Decreases	(97)	0
Other provisions at end of period	318	414
Lump-sum retirement benefits
Disclosure of other provisions [table]
Other provisions at beginning of period	414	331
Increases	0	83
Decreases	(97)	0
Other provisions at end of period	318	414
Current provisions
Disclosure of other provisions [table]
Other provisions at beginning of period	40	164
Increases	70	40
Decreases	0	(164)
Other provisions at end of period	110	40
Provisions for disputes
Disclosure of other provisions [table]
Other provisions at beginning of period	40	0
Increases	54	40
Decreases	0	0
Other provisions at end of period	94	40
Provision for charges
Disclosure of other provisions [table]
Other provisions at beginning of period	0	164
Increases	16	0
Decreases	0	(164)
Other provisions at end of period	€ 16	€ 0

Provisions - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of other provisions [table]
Provision used		€ 145	€ 55
Provision reversed	€ 97	164
Payable, period	5 years
Provisions for disputes
Disclosure of other provisions [table]
Provision used	€ 54	40
Provision reversed	0	0
Provision for charges
Disclosure of other provisions [table]
Provision reversed	€ 0	€ 164

Provisions - Disclosure of Commitments for Retirement Benefits (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Provisions [abstract]
Provisions of retirement benefits at beginning of period	€ 414	€ 331
Cost of services	84	76	€ 76
Interests / discounting costs	1	3
Expense for the period	85	79
Gains or losses related to experience	(133)	(61)
Gains or losses related to change in demographic assumptions	(5)	3
Gains or losses related to change in financial assumptions	(43)	62
Actuarial gains or losses recognized in other comprehensive income	(182)	4
Provisions of retirement benefits at end of period	€ 318	€ 414	€ 331

Provisions - Disclosure of Assumptions Used to Measure Retirement Benefits (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure of defined benefit plans [table]
Social security contribution rate	42.01%	44.00%
Discount rate	0.98%	0.33%
Staff turnover	0.0586%	0.0586%
Duration	20 years	17 years
Management
Disclosure of defined benefit plans [table]
Retirement assumptions	66 years	66 years
Non-management
Disclosure of defined benefit plans [table]
Retirement assumptions	64 years	64 years
Executive
Disclosure of defined benefit plans [table]
Salary increase rate (including inflation)	3.00%	3.00%
Non-executive
Disclosure of defined benefit plans [table]
Salary increase rate (including inflation)	0.025%	0.025%

Provisions - Disclosure of Sensitivity Analysis for Actuarial Assumptions (Details) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Actuarial assumption of discount rates if rates decrease by 25%	0.73%
Discount rate	0.98%	0.33%
Actuarial assumption of discount rates if rates increase by 25%	1.23%
Actuarial assumption of discount rates
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Net defined benefit liability if actuarial assumption of discount rates decrease by 25%	€ 333
Net defined benefit liability	318
Net defined benefit liability if actuarial assumption of discount rates increase by 25%	€ 303

Financial liabilities - Summary of Changes in Financial Liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Changes In Financial Liabilities [Line Items]
Current financial liabilities	€ 8,204	€ 4,872
Non-current financial liabilities	37,816	44,107
Total financial liabilities	46,020	48,979
Lease liabilities
Disclosure Of Changes In Financial Liabilities [Line Items]
Current financial liabilities	1,126	1,197
Non-current financial liabilities	5,393	4,991
Repayable BPI loan advances
Disclosure Of Changes In Financial Liabilities [Line Items]
Current financial liabilities	800	500
Non-current financial liabilities	2,259	2,975
PGE \| Long-term borrowings
Disclosure Of Changes In Financial Liabilities [Line Items]
Current financial liabilities	1,086	141
Non-current financial liabilities	8,982	9,922
EIB Loan \| Long-term borrowings
Disclosure Of Changes In Financial Liabilities [Line Items]
Current financial liabilities	5,192	3,033
Non-current financial liabilities	€ 21,182	€ 26,218

- Definition

The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity’s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity’s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity’s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity’s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity’s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity’s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]

+ References + Details

Financial liabilities - Additional Information (Details) € in Thousands		1 Months Ended					12 Months Ended
	Jul. 10, 2020 EUR (€) quarterly_instalment	Jul. 31, 2020	Jun. 30, 2020 EUR (€)	Mar. 31, 2019 EUR (€)	Oct. 31, 2018 EUR (€)	Jul. 31, 2018 EUR (€) tranche	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 EUR (€)	Dec. 31, 2018 EUR (€)
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Proceeds from borrowings							€ 0	€ 10,350	€ 14,000
Consolidated forecasted sales, period							6 years
Conditional Advances and Loans from Government and Public Authorities
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Impact of accretion and discounting							€ 5,765	1,769
Accumulated variable interest expense accrual							4,214	€ (4,789)
Banque Publique d’Investissement
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Advances, deferment period										18 months
Advances, interest rate										1.56%
Advances received										€ 2,100
Bpifrance
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Advances received			€ 350
Authorized amount to be advanced			500
Advances, outstanding amount							150
EIB Loan
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Number of tranches \| tranche						3
Proceeds from borrowings				€ 14,000	€ 16,000
Borrowing, deferment period to request funds		12 months
Royalties agreement, period						6 years
Borrowing, deferment period								1 year
Borrowings, interest rate				5.00%	6.00%			4.00%
Borrowing, maturity								5 years
Expected future royalty payments							3,400	€ 17,200
Accumulated variable interest expense accrual							4,200	4,800
Borrowings							33,900
EIB Loan \| Conditional Advances and Loans from Government and Public Authorities
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Impact of accretion and discounting							5,817	1,736
Accumulated variable interest expense accrual							4,214	€ (4,789)
EIB Loan \| Fixed interest rate
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Total interest payable							7,000
Interest payable							1,800
EIB Loan \| Floating interest rate
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Total interest payable							€ 3,400
EIB Loan \| Top of range
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Notional amount						€ 40,000
PGE Loan, HSBC France
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Notional amount			5,000
Proceeds from borrowings			€ 5,000
Borrowing, initial period bearing no interest			12 months
Borrowing, deferment period			1 year
Borrowings, interest rate			0.31%
Borrowing, guarantee fee							0.25%	0.25%
PGE Loan, HSBC France \| Top of range
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Borrowing, deferment period			5 years
PGE Loan, HSBC France \| Bottom of range
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Borrowing, deferment period			1 year
PGE Loan, BPI France
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Notional amount			€ 5,000					€ 350
Proceeds from borrowings	€ 5,000
Borrowing, initial period bearing no interest	12 months
Borrowings, interest rate	2.25%						1.36%	1.36%
Borrowing, maturity	6 years
Percentage of State-Guaranteed loan	0.90
Borrowing, subsequent period bearing interest	5 years
Borrowing, guarantee fee	1.61%						0.25%	0.25%
Number of quarterly instalments \| quarterly_instalment	20

Financial liabilities - Disclosure of Detailed Information about Conditional Advances and Loans From Government and Public Authorities (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Conditional Advances and Loans from Government and Public Authorities
Summary Of Conditional Advances, Banks Loans And Loans [Line Items]
Liabilities arising from financing activities at beginning of period	€ 32,727	€ 38,121
Changes in liabilities arising from financing activities [abstract]
Principal received	0	350
Impact of discounting and accretion	(5,765)	(1,769)
Accumulated fixed interest expense accrual	1,790	1,763
Accumulated variable interest expense accrual	4,214	(4,789)
Repayment	(3,533)	(950)
Liabilities arising from financing activities at end of period	29,433	32,727
Bpifrance advance \| Conditional Advances and Loans from Government and Public Authorities
Summary Of Conditional Advances, Banks Loans And Loans [Line Items]
Liabilities arising from financing activities at beginning of period	2,216	2,165
Changes in liabilities arising from financing activities [abstract]
Principal received	0	0
Impact of discounting and accretion	17	19
Accumulated fixed interest expense accrual	32	32
Accumulated variable interest expense accrual	0	0
Repayment	0	0
Liabilities arising from financing activities at end of period	2,266	2,216
Interest-free Bpifrance loan \| Conditional Advances and Loans from Government and Public Authorities
Summary Of Conditional Advances, Banks Loans And Loans [Line Items]
Liabilities arising from financing activities at beginning of period	974	1,210
Changes in liabilities arising from financing activities [abstract]
Principal received	0	0
Impact of discounting and accretion	19	14
Accumulated fixed interest expense accrual	0	0
Accumulated variable interest expense accrual	0	0
Repayment	(500)	(250)
Liabilities arising from financing activities at end of period	493	974
EIB Loan
Changes in liabilities arising from financing activities [abstract]
Accumulated variable interest expense accrual	4,200	4,800
EIB Loan \| Conditional Advances and Loans from Government and Public Authorities
Summary Of Conditional Advances, Banks Loans And Loans [Line Items]
Liabilities arising from financing activities at beginning of period	29,251	34,746
Changes in liabilities arising from financing activities [abstract]
Principal received	0	0
Impact of discounting and accretion	(5,817)	(1,736)
Accumulated fixed interest expense accrual	1,758	1,731
Accumulated variable interest expense accrual	4,214	(4,789)
Repayment	(3,033)	(700)
Liabilities arising from financing activities at end of period	26,374	29,251
Curadigm Bpifrance advance \| Conditional Advances and Loans from Government and Public Authorities
Summary Of Conditional Advances, Banks Loans And Loans [Line Items]
Liabilities arising from financing activities at beginning of period	285	0
Changes in liabilities arising from financing activities [abstract]
Principal received	0	350
Impact of discounting and accretion	16	(65)
Accumulated fixed interest expense accrual	0	0
Accumulated variable interest expense accrual	0	0
Repayment	0	0
Liabilities arising from financing activities at end of period	€ 300	€ 285

Financial liabilities - Disclosure of Detailed Information about Bank Loan (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Jul. 10, 2020	Jun. 30, 2020
Long-term borrowings
Summary Of Conditional Advances, Banks Loans And Loans [Line Items]
Liabilities arising from financing activities at beginning of period	€ 10,064	€ 0
Changes in liabilities arising from financing activities [abstract]
Principal received	3	10,000
Impact of discounting and accretion	146	47
Accumulated fixed interest expense accrual	(145)	17
Liabilities arising from financing activities at end of period	€ 10,068	€ 10,064
PGE Loan, HSBC France
Changes in liabilities arising from financing activities [abstract]
Borrowing, guarantee fee	0.25%	0.25%
Borrowings, interest rate				0.31%
PGE Loan, HSBC France \| Long-term borrowings
Summary Of Conditional Advances, Banks Loans And Loans [Line Items]
Liabilities arising from financing activities at beginning of period	€ 5,020	€ 0
Changes in liabilities arising from financing activities [abstract]
Principal received	17	5,000
Impact of discounting and accretion	26	14
Accumulated fixed interest expense accrual	(33)	7
Liabilities arising from financing activities at end of period	€ 5,030	€ 5,020
PGE Loan, BPI France
Changes in liabilities arising from financing activities [abstract]
Borrowing, guarantee fee	0.25%	0.25%	1.61%
Borrowings, interest rate	1.36%	1.36%	2.25%
PGE Loan, BPI France \| Long-term borrowings
Summary Of Conditional Advances, Banks Loans And Loans [Line Items]
Liabilities arising from financing activities at beginning of period	€ 5,044	€ 0
Changes in liabilities arising from financing activities [abstract]
Principal received	(14)	5,000
Impact of discounting and accretion	120	34
Accumulated fixed interest expense accrual	(112)	10
Liabilities arising from financing activities at end of period	€ 5,038	€ 5,044

Financial liabilities - Disclosure of Reconciliation of Changes in Lease Liabilities (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Summary Of Conditional Advances, Banks Loans And Loans [Line Items]
Fixed interest expense	€ 288	€ 333	€ 359
Lease liabilities
Summary Of Conditional Advances, Banks Loans And Loans [Line Items]
Liabilities arising from financing activities at beginning of period	6,188	6,405
New lease contracts	1,476	521
Impact of discounting of the new lease contracts	(110)	(94)
Fixed interest expense	288	333
Repayment of lease	(1,195)	(928)
Early termination of lease contracts	(128)	(49)
Liabilities arising from financing activities at end of period	€ 6,519	€ 6,188	€ 6,405

Financial liabilities - Disclosure of Maturity Analysis for Advances Loans and Lease Liabilities (Details) € in Thousands		1 Months Ended	12 Months Ended
	Jul. 10, 2020	Jun. 30, 2020	Dec. 31, 2021 EUR (€) borrowing	Dec. 31, 2020
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowing, number of PGE \| borrowing			2
Less than 1 year
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Lease liabilities			€ 1,126
Total			8,204
Between 1 and 3 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Lease liabilities			2,252
Total			37,747
Between 3 and 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Lease liabilities			2,247
Total			7,346
More than 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Lease liabilities			1,714
Total			1,714
Bpifrance \| Less than 1 year
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			300
Bpifrance \| Between 1 and 3 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			1,300
Bpifrance \| Between 3 and 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			808
Bpifrance \| More than 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			0
Interest-free Bpifrance loan \| Less than 1 year
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			500
Interest-free Bpifrance loan \| Between 1 and 3 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			0
Interest-free Bpifrance loan \| Between 3 and 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			0
Interest-free Bpifrance loan \| More than 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			0
Curadigm interest-free Bpifrance advance \| Less than 1 year
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			0
Curadigm interest-free Bpifrance advance \| Between 1 and 3 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			200
Curadigm interest-free Bpifrance advance \| Between 3 and 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			150
Curadigm interest-free Bpifrance advance \| More than 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			0
HSBC "PGE"
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowing, deferment period		1 year
HSBC "PGE" \| Less than 1 year
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			661
HSBC "PGE" \| Between 1 and 3 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			2,572
HSBC "PGE" \| Between 3 and 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			1,904
HSBC "PGE" \| More than 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			0
Bpifrance "PGE"
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowing, maturity	6 years
Bpifrance "PGE" \| Less than 1 year
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			425
Bpifrance "PGE" \| Between 1 and 3 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			2,662
Bpifrance "PGE" \| Between 3 and 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			2,237
Bpifrance "PGE" \| More than 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			0
EIB fixed rate loan
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowing, maturity				5 years
Borrowing, deferment period				1 year
EIB fixed rate loan \| Less than 1 year
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			5,192
EIB fixed rate loan \| Between 1 and 3 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			28,762
EIB fixed rate loan \| Between 3 and 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			0
EIB fixed rate loan \| More than 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			€ 0
HSBC "PGE" and Bpifrance "PGE"
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowing, maturity			5 years
Borrowing, deferment period			1 year

Trade payables and other current liabilities - Disclosure of Trade and Other Payables (Details) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Subclassifications of assets, liabilities and equities [abstract]
Accrued expenses - clinical trials	€ 1,486	€ 1,532
Trade payables & other accruals	4,996	5,574
Total trade and other payables	€ 6,482	€ 7,106

Trade payables and other current liabilities - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure of Trade Payables and Other Current Liabilities [Line Items]
Trade payables & other accruals	€ 4,996	€ 5,574
Decrease in payroll tax and other payroll liabilities	1,400
Payroll tax and other payroll liabilities	4,800	6,200
Deferred revenues and contract liabilities	16,518	€ 0
ICON Plc
Disclosure of Trade Payables and Other Current Liabilities [Line Items]
Trade payables & other accruals	447
LianBio, NBTXR3
Disclosure of Trade Payables and Other Current Liabilities [Line Items]
Deferred revenues and contract liabilities	€ 16,500

Trade payables and other current liabilities - Disclosure of Other Current Liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Subclassifications of assets, liabilities and equities [abstract]
Tax liabilities	€ 258	€ 283
Payroll tax and other payroll liabilities	4,820	6,248
Other payables	453	491
Other current liabilities	€ 5,531	€ 7,022

Trade payables and other current liabilities - Disclosure of Deferred Income and Contract Liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Subclassifications of assets, liabilities and equities [abstract]
Deferred revenues and contract liabilities	€ 16,518	€ 0

Financial instruments included in the statement of financial position and impact on income - Disclosure of Non-Current Financial Assets and Financial Liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about financial instruments [line items]
Total financial assets	€ 84,440	€ 119,717
Total financial assets, at fair value	84,440	119,717
Total financial liabilities	52,503	56,085
Total financial liabilities, at fair value	52,503	56,085
Financial liabilities at amortised cost
Disclosure of detailed information about financial instruments [line items]
Total financial liabilities	52,503	56,085
Non-current financial liabilities
Disclosure of detailed information about financial instruments [line items]
Total financial liabilities	38,733	44,107
Total financial liabilities, at fair value	38,733	44,107
Non-current financial liabilities \| Financial liabilities at amortised cost
Disclosure of detailed information about financial instruments [line items]
Total financial liabilities	38,733	44,107
Current financial liabilities
Disclosure of detailed information about financial instruments [line items]
Total financial liabilities	7,288	4,872
Total financial liabilities, at fair value	7,288	4,872
Current financial liabilities \| Financial liabilities at amortised cost
Disclosure of detailed information about financial instruments [line items]
Total financial liabilities	7,288	4,872
Trade payables and other payables
Disclosure of detailed information about financial instruments [line items]
Total financial liabilities	6,482	7,106
Total financial liabilities, at fair value	6,482	7,106
Trade payables and other payables \| Financial liabilities at amortised cost
Disclosure of detailed information about financial instruments [line items]
Total financial liabilities	6,482	7,106
Non-current financial assets
Disclosure of detailed information about financial instruments [line items]
Total financial assets	519	505
Total financial assets, at fair value	519	505
Trade receivables
Disclosure of detailed information about financial instruments [line items]
Total financial assets	0	62
Total financial assets, at fair value	0	62
Cash and cash equivalents
Disclosure of detailed information about financial instruments [line items]
Total financial assets	83,921	119,151
Total financial assets, at fair value	83,921	119,151
Financial assets carried at fair value through profit or loss
Disclosure of detailed information about financial instruments [line items]
Total financial assets	97	104
Financial assets carried at fair value through profit or loss \| Non-current financial assets
Disclosure of detailed information about financial instruments [line items]
Total financial assets	97	104
Financial assets at amortised cost
Disclosure of detailed information about financial instruments [line items]
Total financial assets	84,343	119,613
Financial assets at amortised cost \| Non-current financial assets
Disclosure of detailed information about financial instruments [line items]
Total financial assets	421	401
Financial assets at amortised cost \| Trade receivables
Disclosure of detailed information about financial instruments [line items]
Total financial assets	0	62
Financial assets at amortised cost \| Cash and cash equivalents
Disclosure of detailed information about financial instruments [line items]
Total financial assets	€ 83,921	€ 119,151

Financial instruments included in the statement of financial position and impact on income - Disclosure of Effect of Changes in Exchange Rates (Details) - Currency risk - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about financial instruments [line items]
Change in net income due to a 10% increase in exchange rate	€ 45	€ 5
Change in net income due to a 10% decrease in exchange rate	(45)	(5)
Change in equity due to a 10% increase in exchange rate	87	124
Change in equity due to a 10% decrease in exchange rate	(87)	(124)
USD / Euro exchange rate
Disclosure of detailed information about financial instruments [line items]
Change in net income due to a 10% increase in exchange rate	45	5
Change in net income due to a 10% decrease in exchange rate	(45)	(5)
Change in equity due to a 10% increase in exchange rate	87	124
Change in equity due to a 10% decrease in exchange rate	€ (87)	€ (124)

Financial instruments included in the statement of financial position and impact on income - Additional Information (Details) - EIB fixed rate loan € in Millions	1 Months Ended
	Jul. 31, 2018 EUR (€) tranche
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Number of tranches \| tranche	3
Top of range
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Notional amount \| €	€ 40

Revenues and other income - Additional Information (Details) € in Thousands, $ in Millions		1 Months Ended			8 Months Ended	12 Months Ended
	Jun. 15, 2021 USD ($)	Jun. 30, 2021 EUR (€)	Jun. 30, 2021 USD ($)	May 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 EUR (€)	Dec. 31, 2016 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2012 USD ($)	Jun. 30, 2020 EUR (€)
Disclosure of disaggregation of revenue from contracts with customers [line items]
Research tax credit utilization period						3 years
Revenues						€ 10	€ 50	€ 68
Subsidies						€ 126	€ 526	€ 20
Percentage of employees' net wages received via subsidies from French government							84.00%
PGE Loan, BPI France
Disclosure of disaggregation of revenue from contracts with customers [line items]
Subsidies							€ 187
Notional amount							350					€ 5,000
FRANCE
Disclosure of disaggregation of revenue from contracts with customers [line items]
Subsidies							€ 312
PharmaEngine, NBTWR3
Disclosure of disaggregation of revenue from contracts with customers [line items]
Upfront payment received \| $											$ 1.0
Development milestones payments received \| $									$ 1.0	$ 1.0
PharmaEngine, NBTWR3 \| Revenue by type
Disclosure of disaggregation of revenue from contracts with customers [line items]
Concentration risk percentage						100.00%	100.00%	100.00%
LianBio, NBTXR3
Disclosure of disaggregation of revenue from contracts with customers [line items]
Upfront payment received	$ 20.0	€ 16,500	$ 20.0		$ 20.0
Minimum threshold to provide additional know-how to third party under collaboration agreement				80.00%
Milestones achievement, period	18 months
LianBio, NBTXR3 \| Maximum
Disclosure of disaggregation of revenue from contracts with customers [line items]
Potential development and commercial milestones payments \| $				$ 220.0	$ 220.0

Revenues and other income - Schedule of Revenues and Other Income (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenues	€ 10	€ 50	€ 68
Research tax credit	2,490	1,927	2,437
Subsidies	126	526	20
Other	21	10	17
Other income	2,637	2,462	2,473
Total revenues and other income	2,647	2,512	2,541
Services
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenues	5	50	40
Other sales
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenues	€ 5	€ 0	€ 28

- Definition

The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 28
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_a&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 23
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_a&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 32
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard
-URIDate 2021-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 33
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard
-URIDate 2021-03-24

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 34
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard
-URIDate 2021-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 82
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_a&doctype=Standard
-URIDate 2021-03-24

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 103
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard
-URIDate 2021-03-24

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 102
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard
-URIDate 2021-03-24

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 5
-IssueDate 2021-01-01
-Paragraph 33
-Subparagraph b
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard
-URIDate 2021-03-24

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B12
-Subparagraph b
-Clause v
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B
-URIDate 2021-03-24

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2021-03-24

+ Details

Operating expenses - Summary of Research and Development Expenses (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Analysis of income and expense [abstract]
Purchases, sub-contracting and other expenses	€ (19,562)	€ (12,734)	€ (16,804)
Payroll costs (including share-based payments)	(9,605)	(10,306)	(11,980)
Depreciation, amortization, and provision expenses	(1,211)	(1,290)	(1,627)
Research and development expenses	€ (30,378)	€ (24,330)	€ (30,411)

Operating expenses - Research and Development, Additional Information (Details) € in Thousands	12 Months Ended
	Dec. 31, 2021 EUR (€) employee	Dec. 31, 2020 EUR (€) employee	Dec. 31, 2019 EUR (€) employee
Disclosure Of Operating Expenses [Line Items]
Decrease in employee benefit expense \| €	€ 774
Decrease in employee benefit expense, percentage	8.00%
End-of-period headcount \| employee	100	90	110
Increase (decrease) in number of employees \| employee	10
Share-based payments \| €	€ 3,201	€ 2,924	€ 4,320
R&D
Disclosure Of Operating Expenses [Line Items]
Increase in purchases, sub-contracting and other expenses \| €	€ 6,900
Increase in purchases, sub-contracting and other expenses, percentage	54.00%
End-of-period headcount \| employee	75	66	81
Increase (decrease) in number of employees \| employee	9	(15)	2
Share-based payments \| €	€ 677	€ 629	€ 902

Operating expenses - Summary of Selling, General and Administrative Expenses (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Analysis of income and expense [abstract]
Purchases, fees and other expenses	€ (9,638)	€ (6,482)	€ (9,435)
Payroll costs (including share-based payments)	(9,379)	(7,789)	(9,205)
Depreciation, amortization and provision expenses	(417)	(340)	(270)
Total SG&A expenses	€ (19,434)	€ (14,611)	€ (18,909)

Operating expenses - Selling, General and Administrative, Additional Information (Details) € in Thousands	12 Months Ended
	Dec. 31, 2021 EUR (€) employee factor	Dec. 31, 2020 EUR (€) employee	Dec. 31, 2019 EUR (€) employee
Disclosure Of Operating Expenses [Line Items]
Number of impacts \| factor	2
Short-term employee benefits expense	€ 15,700	€ 15,100	€ 16,800
Increase in employee benefit expense	€ (774)
Increase in employee benefit expense, percentage	(8.00%)
End-of-period headcount \| employee	100	90	110
Increase in number of employees \| employee	10
Share-based payments	€ 3,201	€ 2,924	€ 4,320
Selling, general and administrative expense
Disclosure Of Operating Expenses [Line Items]
Increase in rent, fees, and other expenses	€ 3,156
Increase in rent, fees, and other expenses, percentage	49.00%
Increase in employee benefit expense	€ 1,600
Increase in employee benefit expense, percentage	21.00%
End-of-period headcount \| employee	25	24	29
Increase in number of employees \| employee			6
Share-based payments	€ 2,500	€ 2,300	€ 3,400

Operating expenses - Summary of Payroll Costs (Details) € in Thousands	12 Months Ended
	Dec. 31, 2021 EUR (€) employee	Dec. 31, 2020 EUR (€) employee	Dec. 31, 2019 EUR (€) employee
Analysis of income and expense [abstract]
Wages and salaries	€ (11,391)	€ (11,141)	€ (11,876)
Payroll taxes	(4,308)	(3,953)	(4,913)
Share-based payments	(3,201)	(2,924)	(4,320)
Retirement benefit obligations	(84)	(76)	(76)
Total payroll costs	€ (18,984)	€ (18,094)	€ (21,185)
Average headcount \| employee	96	97	112
End-of-period headcount \| employee	100	90	110

Operating expenses - Payroll Costs, Additional Information (Details) € in Thousands	12 Months Ended
	Dec. 31, 2021 EUR (€) employee	Dec. 31, 2020 EUR (€) employee	Dec. 31, 2019 EUR (€) employee
Analysis of income and expense [abstract]
End-of-period headcount \| employee	100	90	110
Increase in number of employees \| employee	10
Short-term employee benefits expense \| €	€ 15,700	€ 15,100	€ 16,800
Share-based payments \| €	€ 3,201	€ 2,924	€ 4,320

Operating expenses - Summary of Depreciation, Amortization and Provision Expenses (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Operating Expenses [Line Items]
Amortization expense of intangible assets	€ (45)	€ (176)	€ (292)
Amortization expense of tangible assets	(1,515)	(1,579)	(1,478)
Utilization of provisions		145	55
Provision for charges	(68)	(40)	(164)
Reversal of provision for disputes		19
Total depreciation, amortization and provision expenses	(1,628)	(1,630)	(1,879)
R&D
Disclosure Of Operating Expenses [Line Items]
Amortization expense of intangible assets	(34)	(152)	(289)
Amortization expense of tangible assets	(1,109)	(1,250)	(1,208)
Utilization of provisions		145	0
Provision for charges	(68)	0	(112)
Reversal of provision for disputes		0
Total depreciation, amortization and provision expenses	(1,211)	(1,257)	(1,609)
SG&A
Disclosure Of Operating Expenses [Line Items]
Amortization expense of intangible assets	(10)	(23)	(3)
Amortization expense of tangible assets	(406)	(329)	(270)
Utilization of provisions		0	55
Provision for charges	0	(40)	(52)
Reversal of provision for disputes		19
Total depreciation, amortization and provision expenses	€ (416)	€ (373)	€ (270)

Operating expenses - Summary of Other Operating Income (Expense) (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Analysis of income and expense [abstract]
Contract termination indemnity (PharmaEngine)	€ (5,414)	€ 0
Total Other operating income and expenses	€ (5,414)	€ 0	€ 0

Operating expenses - Other Operating Income (Expense), Additional Information (Details) € in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 EUR (€)
Disclosure Of Operating Expenses [Line Items]
Contract termination indemnities	€ 5,414		€ 0
Termination of PharmaEngine License and Collaboration Agreement, NBTXR3
Disclosure Of Operating Expenses [Line Items]
Contract termination indemnities	€ 5,400	$ 6.5

Share-based payments - Additional Information (Details)		12 Months Ended
Share-based payments - Additional Information (Details)	Sep. 16, 2014 € / shares	Dec. 31, 2021 plan € / shares
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of preceding trading days taken into account in the determination of the share price on the grant date		20 days
BSPCE
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of share-based payment arrangement plans		9
BSA
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of share-based payment arrangement plans		12
OSA
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of share-based payment arrangement plans		9
AGA
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of share-based payment arrangement plans		2
BSA 2014
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Exercise price (in euros per share) \| € / shares	€ 17.67	€ 40

Share-based payments - Disclosure of Number and Weighted Average Remaining Contractual Life of Share Options Oustanding (Details)										12 Months Ended
	Jun. 21, 2021 shares € / shares	Apr. 20, 2021 shares € / shares	Mar. 11, 2020 shares € / shares	Oct. 24, 2019 shares € / shares	Mar. 29, 2019 shares € / shares	Mar. 06, 2018 shares € / shares	Jan. 07, 2017 shares € / shares	Nov. 03, 2016 shares € / shares	Feb. 02, 2016 shares € / shares	Dec. 31, 2021 shares	Dec. 31, 2020 shares	Dec. 31, 2019 shares
OSA
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Number of options granted (in shares)										691,200	407,972
Number of share options outstanding in share-based payment arrangement (in shares)										1,583,806	986,359	589,150
Number of options as of including options exercised during the period (in shares)										0	0
Options lapsed or cancelled during the period (in shares)										93,753	10,763
OSA 2016-1 Performance
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Number of options granted (in shares)									6,400
Exercise price (euro per share) \| € / shares									€ 0
Exercise price (in euros per share) \| € / shares									€ 13.05
Number of share options outstanding in share-based payment arrangement (in shares)										400
Number of options, exercised (in shares)										0
Number of options as of including options exercised during the period (in shares)										0
Number of options lapsed or cancelled (in shares)										6,000
Options lapsed or cancelled during the period (in shares)										0
OSA 2016-2
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Number of options granted (in shares)								4,000		0	0
Exercise price (euro per share) \| € / shares								€ 0
Exercise price (in euros per share) \| € / shares								€ 14.26
Number of share options outstanding in share-based payment arrangement (in shares)										4,000	4,000	4,000
Number of options, exercised (in shares)										0
Number of options as of including options exercised during the period (in shares)										0	0
Number of options lapsed or cancelled (in shares)										0
Options lapsed or cancelled during the period (in shares)										0	0
OSA 2017 Ordinary
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Number of options granted (in shares)							3,500
Exercise price (euro per share) \| € / shares							€ 0
Exercise price (in euros per share) \| € / shares							€ 14.97
Number of share options outstanding in share-based payment arrangement (in shares)										500
Number of options, exercised (in shares)										0
Number of options as of including options exercised during the period (in shares)										0
Number of options lapsed or cancelled (in shares)										3,000
Options lapsed or cancelled during the period (in shares)										0
OSA 2018
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Number of options granted (in shares)						62,000				0	0
Exercise price (euro per share) \| € / shares						€ 0
Exercise price (in euros per share) \| € / shares						€ 12.87
Number of share options outstanding in share-based payment arrangement (in shares)										52,000	52,000	54,000
Number of options, exercised (in shares)										0
Number of options as of including options exercised during the period (in shares)										0	0
Number of options lapsed or cancelled (in shares)										10,000
Options lapsed or cancelled during the period (in shares)										0	2,000
OSA 2019-1
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Number of options granted (in shares)					37,500					0	0
Exercise price (euro per share) \| € / shares					€ 0
Exercise price (in euros per share) \| € / shares					€ 11.08
Number of share options outstanding in share-based payment arrangement (in shares)										28,250	28,750	30,250
Number of options, exercised (in shares)										0
Number of options as of including options exercised during the period (in shares)										0	0
Number of options lapsed or cancelled (in shares)										9,250
Options lapsed or cancelled during the period (in shares)										500	1,500
OSA LLY 2019
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Number of options granted (in shares)				500,000						0	0
Exercise price (euro per share) \| € / shares				€ 0
Exercise price (in euros per share) \| € / shares				€ 6.41
Number of share options outstanding in share-based payment arrangement (in shares)										500,000	500,000	500,000
Number of options, exercised (in shares)										0
Number of options as of including options exercised during the period (in shares)										0	0
Number of options lapsed or cancelled (in shares)										0
Options lapsed or cancelled during the period (in shares)										0	0
OSA 2020
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Number of options granted (in shares)			407,972							0	407,972
Exercise price (euro per share) \| € / shares			€ 0
Exercise price (in euros per share) \| € / shares			€ 6.25
Number of share options outstanding in share-based payment arrangement (in shares)										387,456	400,709	0
Number of options, exercised (in shares)										0
Number of options as of including options exercised during the period (in shares)										0	0
Number of options lapsed or cancelled (in shares)										13,253
Options lapsed or cancelled during the period (in shares)										13,253	7,263
OSA 2021-04
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Number of options granted (in shares)		571,200								571,200
Exercise price (euro per share) \| € / shares		€ 0
Exercise price (in euros per share) \| € / shares		€ 13.74
Number of share options outstanding in share-based payment arrangement (in shares)										491,200	0
Number of options, exercised (in shares)										0
Number of options as of including options exercised during the period (in shares)										0
Number of options lapsed or cancelled (in shares)										80,000
Options lapsed or cancelled during the period (in shares)										80,000
OSA 2021-06
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Number of options granted (in shares)	120,000									120,000
Exercise price (euro per share) \| € / shares	€ 0
Exercise price (in euros per share) \| € / shares	€ 12.99
Number of share options outstanding in share-based payment arrangement (in shares)										120,000	0
Number of options, exercised (in shares)										0
Number of options as of including options exercised during the period (in shares)										0
Number of options lapsed or cancelled (in shares)										0
Options lapsed or cancelled during the period (in shares)										0

Share-based payments - Disclosure of Indirect Measurement of Fair Value of Goods or Services Received, Share Options Granted During Period (Details) € / shares in Units, € in Thousands										12 Months Ended
	Jun. 21, 2021 EUR (€) yr € / shares	Apr. 20, 2021 EUR (€) yr € / shares	Mar. 11, 2020 EUR (€) yr € / shares	Oct. 24, 2019 EUR (€) yr € / shares	Mar. 29, 2019 EUR (€) yr € / shares	Mar. 06, 2018 EUR (€) yr € / shares	Jan. 07, 2017 EUR (€) yr € / shares	Nov. 03, 2016 EUR (€) yr € / shares	Feb. 02, 2016 EUR (€) yr € / shares	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 EUR (€)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense for the year										€ 3,202	€ 2,924	€ 4,320
OSA
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense for the year										760	509	543
OSA 2016 Ordinary
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) \| € / shares									€ 13.05
Exercise price (in euros per share) \| € / shares									€ 13.05
Risk-free rate									0.32%
Yield									0.00%
Value of initial plan (in thousands of euros)									€ 117
Expense for the year										0	0	0
OSA 2016 Ordinary \| Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility									59.00%
OSA 2016 Ordinary \| Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility									62.00%
OSA 2016 Ordinary \| Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility									60.00%
OSA 2016 Ordinary \| Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) \| yr									5.5
OSA 2016 Ordinary \| Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) \| yr									6
OSA 2016 Ordinary \| Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) \| yr									6.5
OSA 2016-1 Performance
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) \| € / shares									€ 13.05
Exercise price (in euros per share) \| € / shares									€ 13.05
Volatility									59.00%
Maturity (in years) \| yr									5,000
Risk-free rate									0.19%
Yield									0.00%
Value of initial plan (in thousands of euros)									€ 69
Expense for the year										0	0	0
OSA 2016-2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) \| € / shares								€ 14.26
Exercise price (in euros per share) \| € / shares								€ 14.26
Risk-free rate								0.04%
Yield								0.00%
Value of initial plan (in thousands of euros)								€ 27
Expense for the year										0	0	3
OSA 2016-2 \| Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility								58.00%
OSA 2016-2 \| Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility								62.00%
OSA 2016-2 \| Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility								59.00%
OSA 2016-2 \| Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) \| yr								5.5
OSA 2016-2 \| Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) \| yr								6
OSA 2016-2 \| Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) \| yr								6.5
OSA 2017 Ordinary
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) \| € / shares							€ 15.93
Exercise price (in euros per share) \| € / shares							€ 14.97
Risk-free rate							0.23%
Yield							0.00%
Value of initial plan (in thousands of euros)							€ 31
Expense for the year										0	0	1
OSA 2017 Ordinary \| Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility							58.00%
OSA 2017 Ordinary \| Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility							61.00%
OSA 2017 Ordinary \| Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility							59.00%
OSA 2017 Ordinary \| Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) \| yr							5.5
OSA 2017 Ordinary \| Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) \| yr							6
OSA 2017 Ordinary \| Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) \| yr							6.5
OSA 2017 Performance
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) \| € / shares							€ 15.93
Exercise price (in euros per share) \| € / shares							€ 14.97
Volatility							59.00%
Maturity (in years) \| yr							5,000
Risk-free rate							0.11%
Yield							0.00%
Value of initial plan (in thousands of euros)							€ 35
Expense for the year										0	0	0
OSA 2018
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) \| € / shares						€ 12.87
Exercise price (in euros per share) \| € / shares						€ 12.87
Volatility						35.00%
Risk-free rate						0.00%
Yield						0.00%
Value of initial plan (in thousands of euros)						€ 252
Expense for the year										0	7	66
OSA 2018 \| Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) \| yr						5.5
OSA 2018 \| Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) \| yr						6
OSA 2018 \| Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) \| yr						6.5
OSA 2019-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) \| € / shares					€ 11.08
Exercise price (in euros per share) \| € / shares					€ 11.08
Yield					0.00%
Value of initial plan (in thousands of euros)					€ 140
Expense for the year										17	49	38
OSA 2019-1 \| Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility					38.10%
Risk-free rate					0.103%
OSA 2019-1 \| Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility					37.40%
Risk-free rate					0.149%
OSA 2019-1 \| Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) \| yr					6
OSA 2019-1 \| Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) \| yr					6.5
OSA LLY 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) \| € / shares				€ 6.41
Exercise price (in euros per share) \| € / shares				€ 6.41
Volatility				37.00%
Maturity (in years) \| yr				10,000
Risk-free rate				0.40%
Yield				0.00%
Value of initial plan (in thousands of euros)				€ 252
Expense for the year										0	0	436
OSA 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) \| € / shares			€ 6.25
Exercise price (in euros per share) \| € / shares			€ 6.25
Volatility			38.00%
Maturity (in years) \| yr			10,000
Risk-free rate			0.31%
Yield			0.00%
Value of initial plan (in thousands of euros)			€ 939
Expense for the year										329	453	0
OSA 2021-04 O
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) \| € / shares		€ 13.60
Exercise price (in euros per share) \| € / shares		€ 13.74
Yield		0.00%
Value of initial plan (in thousands of euros)		€ 684
Expense for the year										188	0	0
OSA 2021-04 O \| Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility		38.90%
OSA 2021-04 O \| Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility		37.80%
OSA 2021-04 O \| Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility		38.30%
OSA 2021-04 O \| Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) \| yr		5.5
OSA 2021-04 O \| Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) \| yr		6
OSA 2021-04 O \| Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) \| yr		6.5
OSA 2021-04 P
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) \| € / shares		€ 13.60
Exercise price (in euros per share) \| € / shares		€ 13.74
Volatility		39.10%
Maturity (in years) \| yr		10,000
Risk-free rate		0.03%
Yield		0.00%
Value of initial plan (in thousands of euros)		€ 1,816
Expense for the year										131	0
OSA 2021-06 O
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) \| € / shares	€ 12.20
Exercise price (in euros per share) \| € / shares	€ 12.99
Yield	0.00%
Value of initial plan (in thousands of euros)	€ 246
Expense for the year										79	0	0
OSA 2021-06 O \| Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility	39.20%
OSA 2021-06 O \| Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility	37.90%
OSA 2021-06 O \| Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility	38.10%
OSA 2021-06 O \| Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) \| yr	5.5
OSA 2021-06 O \| Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) \| yr	6
OSA 2021-06 O \| Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) \| yr	6.5
OSA 2021-06 P
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) \| € / shares	€ 12.20
Exercise price (in euros per share) \| € / shares	€ 12.99
Volatility	39.10%
Maturity (in years) \| yr	10,000
Risk-free rate	0.13%
Yield	0.00%
Value of initial plan (in thousands of euros)	€ 212
Expense for the year										€ 16	€ 0

Net financial income (loss) - Summary of Net Financial Income (Loss) (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income, expense, gains or losses of financial instruments [abstract]
Income from cash and cash equivalents	€ 0	€ 0	€ 105
Foreign exchange gains	6,347	104	599
Other financial income	13	97	133
Total financial income	6,360	201	837
Interest cost	(383)	4,676	(4,434)
IFRS 16 related interests	(288)	(333)	(359)
Foreign exchange losses	(109)	(1,697)	(176)
Total financial expenses	(780)	2,646	(4,970)
Financial income (loss)	€ 5,580	€ 2,847	€ (4,133)

Net financial income (loss) - Additional Information (Details) € in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 EUR (€)
Disclosure of financial instruments by type of interest rate [line items]
Interest cost	€ (383)	€ 4,676		€ (4,434)
Foreign exchange gains	6,347	104		€ 599
Foreign exchange losses		1,700
Proceeds from issuing shares \| $			$ 113.3
EIB fixed rate loan
Disclosure of financial instruments by type of interest rate [line items]
Accumulated variable interest expense accrual	4,200	4,800
Fixed interest rate \| EIB fixed rate loan
Disclosure of financial instruments by type of interest rate [line items]
Interest expense on borrowings	€ 1,800	€ 1,700

Income tax - Additional Information (Details) € in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 EUR (€)	Dec. 31, 2017	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax losses	€ 75.4	€ 60.2	€ 51.0
Deferred tax rate	25.80%	26.50%	25.49%
Unused tax losses
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax losses	€ 14.0	€ 59.6	€ 49.6
FRANCE \| Unused tax losses
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax liability (asset)	€ 284.0	€ 235.0	€ 184.3
UNITED STATES \| Unused tax losses
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax liability (asset) \| $					$ 3.4	$ 4.4	$ 4.8
Expiration period				20 years

Income tax - Schedule of Reconciliation Between Statutory and Effective Income Tax (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income taxes paid (refund) [abstract]
Net loss	€ (47,003)	€ (33,590)	€ (50,915)
Effective tax expense	5	9	3
Recurring loss before tax	€ (47,058)	€ (33,581)	€ (50,912)
Theoretical tax rate (statutory rate in France)	26.50%	28.00%	31.00%
Theoretical tax (benefit) expense	€ (12,470)	€ (9,403)	€ (15,782)
Share-based payment	848	819	1,339
Other temporary differences	117	(6)	(1)
Other non-taxable items	(644)	(540)	(736)
Unrecognized tax losses	12,154	9,138	15,177
Effective tax expense	€ (5)	€ (9)	€ (3)
Effective tax rate	0.00%	0.00%	0.00%

Loss per share - Schedule of Basic and Diluted Loss Per Share (Details) - EUR (€) € / shares in Units, € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Earnings per share [abstract]
Net loss for the period (in thousands of euros)	€ (47,063)	€ (33,590)	€ (50,915)
Weighted average number of shares (in shares)	34,733,418,000	24,385,827,000	21,631,514,000
Basic loss per share (in euro per share)	€ (1.35)	€ (1.38)	€ (2.35)
Diluted loss per share (in euro per share)	€ (1.35)	€ (1.38)	€ (2.35)

Loss per share - Additional Information (Details)	12 Months Ended
Loss per share - Additional Information (Details)	Dec. 31, 2021 shares
Earnings per share [abstract]
Potential additional ordinary shares that are considered antidilutive (in shares)	3,006,532

Commitments (Details) € in Thousands, $ in Thousands		1 Months Ended				3 Months Ended	6 Months Ended	10 Months Ended	12 Months Ended		36 Months Ended
Commitments (Details) € in Thousands, $ in Thousands	Feb. 03, 2020 USD ($)	May 31, 2021 USD ($)	Mar. 31, 2021 USD ($)	Jan. 31, 2019 USD ($) patient	Jul. 31, 2018	Mar. 31, 2021 USD ($)	Jun. 30, 2021 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€) lease_contract	Dec. 31, 2021 USD ($) lease_contract	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€)
Disclosure of contingent liabilities [line items]
Number of short term leases \| lease_contract									1	1
Annual short term lease expense \| €									€ 140
Annual lease expense \| €									10
Prepaid expenses \| €									2,213		€ 2,213	€ 2,217
MD Anderson Cancer Center, NBTXR3
Disclosure of contingent liabilities [line items]
Number of patients \| patient				340
Contractual capital commitments \| $				$ 11,000
Upfront payment \| $	$ 1,000			$ 1,000
Milestone payment, deferment period				6 months
Research expense since start of collaboration \| €											1,800
Prepaid expenses \| €									1,000		1,000	€ 1,600
MD Anderson Cancer Center, NBTXR3 \| Bottom of range
Disclosure of contingent liabilities [line items]
Milestone payment increase \| $										$ 2,200
MD Anderson Cancer Center, NBTXR3 \| Top of range
Disclosure of contingent liabilities [line items]
Milestone payment increase \| $										16,400
Termination of PharmaEngine License and Collaboration Agreement, NBTXR3
Disclosure of contingent liabilities [line items]
Upfront payment		$ 4,000	$ 2,500				€ 5,400	$ 6,500	5,400	$ 6,500
Milestone payment upon receipt of clinical study reports \| $			1,000			$ 1,000
Milestone payment upon second regulatory approval \| $			$ 5,000			$ 5,000
Royalties agreement, period			10 years			10 years
EIB fixed rate loan
Disclosure of contingent liabilities [line items]
Royalties agreement, period					6 years
Minimum \| EIB fixed rate loan
Disclosure of contingent liabilities [line items]
Estimated financial effect of contingent liabilities \| €									€ 35,000		€ 35,000

Related parties (Details) - EUR (€) € in Thousands	12 Months Ended
Related parties (Details) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Related party transactions [abstract]
Salaries, wages and benefits	€ 1,245	€ 1,073	€ 1,306
Share-based payments	2,018	1,723	2,066
Supervisory Board’s fees	375	70	70
Total compensation to related parties	€ 3,638	€ 2,866	€ 3,442

Subsequent events (Details) - EUR (€)							12 Months Ended
Subsequent events (Details) - EUR (€)	Mar. 11, 2022	Apr. 01, 2021	Mar. 17, 2021	Jul. 28, 2020	Jul. 27, 2020	Mar. 06, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of non-adjusting events after reporting period [line items]
Capital increase, net		€ 11,077.5	€ 735		€ 180		€ 0	€ 102,942,000	€ 28,079,000
Par value per share (euro per share)							€ 0.03	€ 0.03	€ 0.03
Equity							€ 26,790,000	€ 70,468,000	€ (1,908,000)	€ 14,243,000
Major ordinary share transactions
Disclosure of non-adjusting events after reporting period [line items]
Par value per share (euro per share)	€ 0.03
Share capital Ordinary shares
Disclosure of non-adjusting events after reporting period [line items]
Capital increase, net				€ 99,000		€ 9,000	€ 12,000	€ 361,000	€ 77,000
Capital increase, net (in shares)				3,300,000	6,000	316,083	393,750	12,017,083	2,566,666
Equity							€ 1,044,776.16	€ 1,032,963.66	€ 672,451.17	€ 589,000
Share capital Ordinary shares \| Major ordinary share transactions
Disclosure of non-adjusting events after reporting period [line items]
Capital increase, net	€ 1,500
Capital increase, net (in shares)	50,000
Equity	€ 1,046,276.16
Share capital Ordinary shares \| Major ordinary share transactions \| AGA 2020
Disclosure of non-adjusting events after reporting period [line items]
Capital increase, net (in shares)	50,000

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details